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Cell Cycle Regulatory Roles of Estrogen Receptor alpha (ERα) in Breast Cancer Cells 
 
 Sonia Javan Moghadam, M.S. 
 
Supervisory Advisor: Khandan Keyomarsi, Ph.D. 
 
 
Previous studies have shown that Estrogen Receptor alpha (ERα) is an important 
indicator for diagnosis, prognosis and treatment of breast cancers. However, the question 
remains as to the role of ERα in the cell in the presence versus absence of 17-β estradiol  In 
this dissertation the role of ERα in both its unliganded and liganded state, with respect to the 
cell cycle will be explored.  The cell line models used in this project are ER-positive MCF-7 
cells with and without siRNA to ERα and ER-positive MDA-MB-231 cells that have been 
engineered to express ERα. Cells were synchronized and the cell cycle progression was 
monitored by flow cytometric analysis. Using these methods, two specific questions were 
addressed: Does ERα modulate the cell cycle differently under liganded versus unliganded 
conditions?   And, does the presence of ERα regulate cell cycle phase transitions? 
 
         The results show for the first time that ERα is cell cycle regulated and modulates the 
progression of cells through S and G2/M phases of the cell cycle.  Ligand bound ERα 
increases progression through S and G2/M phases, whereas unliganded ERα acts as an 
inhibitor of cell cycle progression.  To further investigate the cell cycle regulated effects of 
liganded ERα, a luciferase assay was performed and showed that the transcription of target 
genes such as Progestrone Receptor (PgR) and Trefoil protein (pS2) increased duing S and 
G2/M phases when ERα is bound to ligand.  Additionally, complex formation between 
cyclin B and ER α was shown by immunoprecipitation and led to the discovery that anaphase 
promoting complex (APC) is the E3 ligase for both cyclin B and ERα at the termination of M 
phase. 
 
  v 
         Our findings suggest that unliganded ERα has an inhibitory effect on the progression of 
the cell cycle. Therefore, it is reasonable to speculate that the combination of drugs that 
lower estrogen level (such as aromatase inhibitors) and preserves ERα from degradation 
would provide better outcome for breast cancer treatment. We have shown that APC 
functions as the E3 ligase for ERα and thus might provide a target to design a specific 
inhibitor of ERα degradation. 
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Chapter I:  General Introduction 
 
         In this dissertation the role of Estrogen Receptor alpha (ERα) in both its unliganded 
and liganded (bound to 17-β estradiol) state, with respect to the cell cycle will be explored. 
The model system used in this project is composed of 4 different cell lines: 1) MCF-7 (ER-
positive) 2) MCF-7 siRNA-ER, 3) MDA-MB231 (ER-negative) and 4) MDA-MB231 ER 
(engineered to express ERα). These cell lines allow us to compare the effects of presence 
versus absence of ERα and also liganded versus unliganded ERα on the cell cycle duration 
and overall cell proliferation status of these cells. These cell lines were used to address two 
specific questions 1) Does ERα modulate the duration of the cell cycle differently under its 
liganded versus unliganded state. 2) Does the presence of ERα regulate cell cycle transitions.  
 
Estrogen Receptor 
        Estrogen receptor (ER) is a hormone activated transcription factor, which plays a 
significant role in the development of adenocarcinomas of reproductive organs 1. Steroid 
receptor expression and proliferation are strictly regulated in the normal mammary gland, but 
not in malignant tumors. In normal mammary gland there is a minimum expression of ERα 2 
3. ERα expression increases when normal mammary cells are proliferating such as the case of 
pregnancy or puberty period 4-6. However in breast cancer increased ERα expression appears 
to occur early in the premalignant to malignant progression, and these tumor cells will 
continue expressing ERα 7.  Additionally, ER-negative breast tumors are poorly 
differentiated and more aggressive 8. The difference in ER expression between normal (low 
ER expression) and tumor cells (variable ER expression) raises the question as to why ERα 
is absent both in the normal breast epithelial cells and in the worse prognostic breast cancers 
while ERα is present in the breast epithelial cells in luminal cancers? Should the presence of 
ERα be our only marker or there are other elements to determine the prognosis of the 
disease.  There are two possiblilites as to why lack of ER is associated with a poor prognosis 
1) An ER-positive tumor has the ability to lose ER expression and in doing so be transformed 
into a more aggressive ER-negative tumor or 2) ER-negative tumors originate from cells 
  2 
without expression of ERα.  There are active investigations in support of both of these 
possibilites 9-13 
 
BREAST CANCER 
        According to the reports of year 2010 from the American Cancer Society, in year 2010 
about 207,090 women will be diagnosed with breast cancer (new cases) and about 54,010 
women will be diagnosed with an in situ breast cancer in the US 14. The American cancer 
society also reported that the number of death due to breast cancer in 2010 will be about  
39,840 women in the US 15. It is expected to diagnose approximately 1,970 men with breast 
cancer in 2010 in the US, which is almost 1% of the total incidence of breast cancer cases. 
Abot 390 of these men expected to die from breast cancer in 2010 in the US. Lung cancer 
stands first for the number of the cancer deaths before breast cancer in women in the US 14, 16.  
The most recent National Cancer Institute report states that 12.5% of all US women will be 
diagnosed with breast cancer 17(©2009, American Cancer Society, Inc. (404) 320-3333). 
        Similar to other types of cancers, in breast cancer cells growth and proliferation increase 
and gets out of control, which then giving rise to malignant cells originating in the breast. 
Breast cancer may metastasize and spread through the body. The lymphatic system is the 
body's primary system in which the white blood cells and other immune system cells being 
produced and transported through out the body. However the lymphatic system is also known 
for being the primary route of cancer cells to metastastasize through the body. Cancer cells 
come off the primary tumor, which they attached to in order to penetrate into the flow of the 
lymph system and finaly exit the lumph sytem to settle in their secondary sites to form a new 
tumor and perpetuating the disease process. Tumor cells also can metastasize through the 
vascular system. Detached breast tumors cells from the primary tumors slip through the wall 
of capillary and enter the blood stream. These floating tumor cells journey ends either with 
their elimination through white blood cells in the blood stream or when they get immobilized 
in small blood vessels of an organ to give rise to a new (secondary) cancer in that organ, 
which this process also called metastasis in the area. The blood circulation in the body is in a 
way that mainly the first destination of the blood coming out of different organs is the lungs. 
The blood flow system makes the lungs an organ, which is highly at risk as a secondary 
  3 
organ to receive cancer cells through blood flow (metastasis). Liver is the second organ 
highly at risk for receiving the metastastatic growth of cancer cells 18.  
 
Breast cancer subtypes 
        An unanswered question is what kind of cellular abnormalities allows cancer to grow 
uncontrollably and spread throughout the body? The answer to this question is currently 
being investigated by unraveling the profile of cancer cells at both the genomic and 
proteomic levels. Cancer cells exhibit a number of properties that distinguish them from 
normal cells. Additionally cancer cells that develop in the same tissue/organ can give rise to 
different forms of the disease, due to the heterogeneity of the cancer cells. For example, in 
breast cancer, several groups have identified that biological features of tumors correlate with 
different clinical behavior 19 and  have identified multiple molecular subgroups 20, 21 22 23.  
There are five different subtypes of breast cancer called luminal A, luminal B, HER2 type, 
basal type and Claudin low subtype, which all have been described in Table 1 
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Table 1: Molecular characteristics and prognosis of breast cancer subtypes. 
 
Breast cancer risk factors 
        Extensive research over the last 30 years have shown different risk factors associated 
with higher incidence of women breast cancer (i.e. 24,000 papers listed in pubmed when the 
phrase “breast cancer risk factors” is interrogated). Some of the common risk factors include: 
age at diagnosis, genetic mutations, previous breast cancer, race, previous premalignant 
tumor biopsy, prior radiation treatment in the chest area, age  
of mensus onset, age of menopause, (earlier onset of menstruation and late menopause 
increases the breast cancer risk), use of oral contraceptives, pregnancy, hormone replacement 
therapy, obesity, poor diet, failing to exercise, fail to breast feed and excessive alcohol intake 
(more than one alcoholic drink a day) 24.    
  5 
 
Breast cancer therapy 
        Upon detection of breast cancer, which by The American Society of Cancer Research 
signs could be one or more of the listed symptoms such as: 1) Bloody discharge  2) 
Thickening of the skin and the underneath tissue that feels different from the surrounding 
area, 3) Breast lump , 4) Size or shape change of the breast, 5) Inverted nipple, 6) Peeling or 
flaking of the area around the nipple, 7) Redness of the skin over the breast (© American 
Cancer Society, Inc.)” it has a variety of treatment options available.  Choice of treatment is 
based on patient demographics such as age, previous treatments and currently known 
prognostic and predictive targets for therapy (ER, PgR, HER-2and lymph node status).   
These characteristics help the physicians to come up with the most beneficial therapy for the 
patient.  Surgery, to remove the primary tumor, can be followed (if necessary) by radiation, 
chemotherapy, hormonal therapy or any combination of these strategies.  
        Radiation therapy is used to destroy any remaining cancer cells that may reside after the 
surgery. Radiation kills dividing cells by causing severe chromosomal damage, which 
prevents cells from continuing to divide. Since tumor cells are frequently dividing, they are 
more sensitive to radiation therapy 25, 26. The other approach to treat breast cancer is 
chemotherapy, which involves the use of drugs that either kills cancer cells or interferes with 
their ability to proliferate 27.  
         The first-line therapy recommended for breast cancer patients has been chemotherapy  
for the past fifty years 28 and is currently used in three settings including neoadjuvant, 
adjuvant and palliative chemotherapy. In the neoadjuvant setting first the tumor size 
chemotherapy is given prior to surgery in order to shrink the tumor size. In the adjuvant 
setting chemotherapy is given post surgery to decrease the recurrence and in palliative setting 
chemotherapy is given to control metastatic breast cancer.  There are many choices for 
chemotherapy; for example the synthesis of DNA and RNA are being inhibited by  
anthracylcines (such as doxorubicin/adriamycin). Anthracylcines mechanism of DNA/RNA 
synthesis is through intercalating the strands. Anthracyclines also inhibit topoisomerase II 
enzyme, thus blocking DNA transcription and replication and create free oxygen radicals that 
damage the DNA 29.  Taxanes (such as docetaxel) function by freezing mitosis through 
disruption of microtubule function 30.   
  6 
        Modern systemic treatments continues to evolve, with use of different combination of 
cytotoxic chemotherapy plus endocrine therapy, or molecular targeted therapy. For example, 
trastuzumab is the only targeted therapy that is currently approved in combination with 
chemotherapy for adjuvant or neoadjuvant treatment of HER2-positive breast cancer patients. 
Lapatinib and bevacizumab, both are the approved drugs for treating metastatic breast cancer 
31. The preferred chemotherapeutic agent being used in these cases are anthracycline and 
taxane in combination 32. The overall treatment response has been increased by the use of 
chemotherapeutic agents in the adjuvant and neoadjuvant settings.  
        Although there are many choices of chemotherapies and the combinations can be 
tailored according to disease stage and health of the patient, they are not highly specific to 
tumor cells and result in toxicities to normal cells. To solve this issue there has been new 
approaches such as establishment of a genetic testing to identify the biological markers for 
which specific therapeutic strategy is available. In this setting, tailored neoadjuvant 
chemotherapy will be administered to the patient based on the biological markers 
identification. The early tailored neoadjuvant chemotherapy treatment response will help to 
set the strategy for the adjuvant treatments.  
 
Hormonal therapy 
        In addition to chemotherapeutic regimens, eligible patients receive endocrine therapy 
which falls into two treatment options 1) ER inhibitors (antiestrogens) and 2) Inhibitors of 
estrogen production (aromatase inhibitors). Patients will be categorized into ER-positive 
group versus ER-negative group based on the result of immunohistochemistry (IHC) test, 
which is a widely used test for assessing therapeutic biomarkers (such as ER) and has 
become a major part of practical diagnosis for various malignancies 33. Not all labs use the 
same criteria to analyze the results of the test. One method of IHC result reporting is based 
on the percentage of the cells that are positive for ER. The result will be between 0% (none 
of the cells are stained for ER) and 100% (all the cells are stained for ER) 34, 35. The second 
way to report the IHC result is based on a number between 0 and 3. Zero means that no 
receptors are present and 3 means that a large number of cells expressing ER 34, 35. The third 
method is called Allred score, which gives numerical values between 0 and 8 35. The system 
measures the percentage of cells testing positive for hormone receptors, along with the 
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intensity of the stain. This information is then combined to score the sample on a scale from 
0 to 8. The higher the score, the more receptors were found which were of higher intensity.  
An IHC score of 2 or greater (IHC of biopsy) is used to define ER positivity and as result 
eligibility for endocrine therapy 36. One additional marker that is also taken into account 
when considering endocrine therapy is the co-expression of the PgR, which is considered as a 
marker of ER functionality 37 and predicts a better likelihood of responsiveness to endocrine 
therapy 38. Since PgR is one of the ER’s target genes, its expression suggests that ER is 
functional and can transcribe it’s target genes 39.  
         The history of endocrine therapy dates back to 1896 40, with the advent of ovarian 
ablation (oophorectomy) as a mode of treatment, discovered by George Beatson 41. The 
rationale for oophorectomy comes from the initial observations of Dr. Beatson, who found 
that removal of the ovaries of the cow after calving allows for an indefinite production of 
milk. These observations also provided one of the first evidence of possible feed back 
between ovaries and mammary gland. He also found that changes (proliferation) in the 
mammary gland during the lactation are almost identical to those that occur in a cancerous 
mammary gland. He states that in both cases of lactation and breast cancer epithelial cells 
appears to proliferate faster to generate more cells, which the higher number of epithelial 
cells block the ducts and fills the acini in the gland. However the difference between the 
proliferation during lactation and the proliferation during breast tumor is that is that in the 
case of lactation cells vacuolated and then undergo fatty degeneration to form milk. In the 
breast cancer case epithelial cells do not go through the fattey degeneration so they grow 
continuesly and come short of space so the cells then start to penetrate the walls of the 
surrounding ducts and acini in order to make more room for hemselves, which basically 
during this process the tumor cells invade the surrounding tissues. 
        The first oopherectomy was performed by Dr. Beatson on a 33 year old breast cancer 
patient. He found that the cancerous tissue was reduced to a very thin layer of cells.  Since, 
ovaries are the main gland that secret estrogen into the body, by removing this organ, the 
cancerous mammary gland is devoid of estrogen required for its proliferation.  
        The next therapeutic approach was the estrogen administration in pharmacological doses 
followed by hypophysectomy and adrenalectomy followed by additive therapies such as 
androgens, glucocorticoids and progestins in high doses. The rationale behind the estrogen 
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administration was that high doses of estrogen (synthetic nonsteroidal) suppress pituitary 
gonadotropic secretion and endogenous estrogen secretion. In fact, the anterior hypophysis 
controls estrogen secretion through two different pathways 1) Pituitary adrenocorticotropic 
hormone (ACTH) which acts on the adrenal gland to induce the release of steroid and 
gonadotropic hormones and 2) ovarian gland. These early methods of breast caner treatment 
(oopherectomy and high dose estrogen) discontinued due to the high morbidity and toxicity 
to the patients 42-46.  These early treatments were replaced by modern anti-endocrine therapy: 
1) Selective ER Modulators (SERMs), which inhibit the activation of ER by inhibition of 
ER’s transcriptional activity, 2) Selective ER Down regulators (SERD), which function by 
down regulating the levels of ER protein in the cells, and 3) aromatase inhibitors, which 
function by inhibition of aromatase, the enzyme involved in the production of circulating 
estrogen.  
 
Selective ER Modulators (SERMs) 
        The SERM that is currently being used in the clinic is tamoxifen (TAM). Development 
of TAM as a mode of breast cancer therapy initiated in 1960s when scientists realized that 
oophorectomy, hypophysectomy and adrenalectomy are not viable solutions to treat breast 
cancer.  Additionally treatment with synthetic estrogen such as cortisone, distibestrol and 
other hormonal agent, MER25, is not a good option either due to concerns about long-term 
toxicities 47. In 1967, Dr Arthur L. Walpole who was an endocrinologists discovered the 
compound ICI46,474 (48). Dr Walpole discovered ICI46,474 while he was working at the 
Imperial Clinical Industries (ICI) Pharmaceuticals Division, which now is known as 
AstraZeneca 48 and performed the initial studies in rodents. This compound which was 
named TAM, tested on immature rat, which showed both estrogen agonist and antagonist 
effect while only showed a full estrogen agonist effect in the mouse.  A preliminary clinical 
study performed by Cole et. al. in 1971 and showed that ICI46,474 (TAM) may be a good 
agent to treat the postmenopausal breast cancer patients, since an improvement was observed 
in side effect profiles capmared to the standard high-dose estrogens or androgens treatments 
49. Due to the lower side effects of ICI46,474 (TAM) in compare to high dose estrogens 
treatment, ICI46,474 (TAM) was chosen as the vanguard medicine for treatment of all stages 
of breast cancer 48, 49. The intial lab based studies revealed that TAM blocks the binding of 
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E2 to ER, preventing the induction and proliferation of ER positive mammary carcinomas 50. 
However increase duration of TAM treatment also results in drug resistance. Another 
concern regarding the use of TAM as adjuvant treatment following the surgery was revealed 
by an evaluation of 5 versus 10 years of adjuvant TAM administration, which showed that 10 
years of adjuvant TAM treatment results in an increase in primary and secondary tumor 
recurrences (i.e. endometrial cancer) compared with 5 years of adjuvant therapy 51. The 
reason for increased incidences of endometrial cancer following TAM treatment is due to the 
selective estrogenic actions of TAM in the endometrium 52. Keoxifene, the compound that 
later became known as raloxifene replaced TAM since raloxifen does not show any 
estrogenic activity in endometrium and also enhances bone density 53.  
 
Selective ER Down regulators (SERD) 
        The next generation of ER modulators are called SERDs, which have a different 
mechanism of action from the SERMs 54. SERMs inhibit the activation of ER by inhibiting 
ER’s transcriptional activity while maitnating the integrity of the ER protein. On the other 
hand, treatment with SERDs result in a dramatic shortening of the ER protein’s half-life and 
down regulating the levels of ER protein in the cells 55. The next anti-estrogen discovered, 
Fulvestrant (ICI 182,780) is a “pure” anti-estrogen devoid of any agonistic activities 
compared to TAM, and therefore unlikely to lead to an increased risk of endometrial cancer 
56 57. At the molecular level, fulvestrant competes with estrogen for binding to the ER, and 
prevents ER dimerization, thereby disrupting its nuclear localization 58, 59. The mechanism of 
Fulvestrant’s action is also different than TAM as it accelerates degradation of ER protein 60, 
61. 
        Numerous clinical studies have been completed aimed at comparing the fulvestrant 
versus other agents used for endocrine therapy, such as  the antiestrogen TAM and estradiol 
inhibitors, aromatase inhibitors (see below). These comparison studies are done in order to 
evaluate the efficacy and tolerability of these drugs. A study with four trials each with 2125 
patients showed that there was no statistically significant difference in the overall survival 
and time to progression, between fulvestrant and other hormonal agents,.However in the arm 
of experiment with the patients receiving fulvestrant there was less incident of joint disorders 
compared to the patients in other arms of the trial who received hormonal agents other than 
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fulvestrant. 62, 63. In another study performed by Euler et. al. the efficacy and tolerability of 
anastrozole (an aromatase inhibitor-see below) was compared with TAM, which have been 
used as the first-line therapy in postmenopausal women. There were a total of 668 patients in 
the trial, which 340 of them were in the anastrozole treatment arm and 328 in the TAM 
treatment arm. The median follow up time after the treatment was 19 months. The median 
time to progression was 8.2 months in the anastrozole treatment arm and was 8.3 months in 
TAM treatment arm.  As the numbers reveal the time to progression and also overall survival 
were similar in both treatments. Overall patients treated with both anastrozole and TAM 
showed that both drugs were well tolerated however the only difference was that the 
incidences of thromboembolic events and vaginal bleeding were less in anastrozole treated 
patients compard to TAM treated patients. So Euler et. al. suggest that due to the lower 
observed incidence of side effects and the similar outcomes from anastrozole versus TAM, 
anastrozole is more beneficial to postmenopausal women with advanced breast cancer and 
should be considered as first-line therapy 64. 
        Another multinational, double-blind, randomized clinical trial aimed to compare TAM 
versus fulvestrant for the treatment of postmenopausal women with advanced breast cancer, 
who were not treated previously with any endocrine therapy was lead by Osborne et. al. In 
this study 587 patients were randomly assigned to each treatment (313 to fulvestrant and 274 
to TAM). The results, after a median follow-up of 14.5 months, showed that there was no 
significant difference between fulvestrant and TAM for the primary end point of time to 
progression. However the objective response rate (the sum of partial plus complete 
responses) for the overall population was 31.6% with fulvestrant and 33.9% with TAM. 
Based on the objective response advantage of TAM over fulvestrant, the study concluded that 
there is no advantage in using a SERD (fulvestrant) over a SERM (TAM) as a first-line 
breast cancer chemotherapeutic or chemopreventive agent 65. This finding suggests that with 
the complete elimination of ERα in the presence of SERDs, has a less favorable clinical 
outcome as compared to SERMs, which only inhibit the transcriptional activity of ERα 
without degradation of the ERα protein itself. 
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Aromatase inhibitors (AIs) 
        AIs represent an entirely different class of endocrine therapy.  These agents inhibit the 
production of estrogen by blocking the aromatase enzyme activity, which this enzymes 
activity converts androgens into estrogens in peripheral tissues, such as adipose tissue, and 
muscle in postmenopausal women 66. The reason that AI has shown a better result in 
postmenopausal women is that in postmenopausal women aromatase enzyme activity makes 
up the estrogen in the system rather than ovaries, which are the main estrogen producing 
orhan in premenopausal women. Since the circulating estrogens in premenopausal women 
are coming from ovaries and not from the aromatase activity so blocking the enzyme 
aromatase via AIs do not significantly decrease the level of circulating estrogen in 
premenopausal women while AIs decrease the circulating estrogens in postmenopausal 
women. As a matter of fact using AIs in premenopausal women not only is not beneficial but 
it seems that because of AI effect, which result in the decrease in peripheral estrogen a signal 
goes to the hypothalamus and the pituitary gland to increase gonadotropin secretion and 
stimulates the ovary to produce more androgen. This counteracts the effect of the AI 67. The 
first generation of AIs (i.e. Aminoglutethimide) were non-selective inhibitors of adrenal 
steroid synthesis 68, which lacked selectivity for aromatase and inhibited biosynthesis of 
cortisol, aldosterone and thyroid hormone as well as aromatase. The clinical experience with 
aminoglutethimide treatment in women with breast cancer reveals that similar to TAM, 1/3 
of women experience either complete or partial tumor regression 69. Despite the good 
response rate in breast cancer 70, 71, this generation of AIs had high toxicity, which resulted in 
the substitution of this group of AIs with the second generation of AIs, which were more 
selective inhibitors of aromatase. Examples of the second AI generation are non-steroidal 
inhibitor fadrozole and the steroidal inhibitor formestane 72, 73. In order to investigate the 
therapeutic effects of fadrozole (CGS 16949A) in women with prior treatment for metastatic 
breast cancer, 80 postmenopausal women with prior treatments were randomized to receive 
fadrozole. The overall response was 23% (10% complete response and 13% partial response), 
and frequent side effects (hot flashes, nausea and vomiting, fatigue and mild loss of appetite) 
were noted 72. In another trial with fomestane as the AI, 409 pateients with advanced 
metastatic breast cancer were randomized to receive either formesatan or TAM. Formestane 
and TAM showed comparable responses, which lead to the conclusion that formestane is an 
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effective treatment 73. However the selectivity of neither 2nd gernation AIs were complete 
either, and they were replaced with the third generation of AIs. These AIs, which are 
currently being used clinically, are more potent and selective inhibitors of aromatase and can 
be divided into irreversible steroidal activators (e.g., exemestane) and reversible non-
steroidal imidazole-based inhibitors (e.g., anastrozole, letrozole) 74. Disease-free survival 
have been noted upon exemestane treatments in postmenopausal women with ER-positive 
breast cancer. In this study, 4724 postmenopausal patients, who were on TAM for 2-3 years 
(disease-free), were randomly assigned in to two arms. Either these patients were in the arm 
of continue TAM (n=2372) or in the arm of switch to exemestane (n=2352) for the remainder 
of a 5-year endocrine treatment period. Upon a median of 55.7 months follow up on this trial 
the obtained results suggested that the patients in the exemestane arm showed more 
improvements in disease-free survival 75. A similar study with letrozole was conducted in 
4922 postmenopausal women with ER-positive early breast cancer 76. With a median follow-
up time of 71 months after randomization the results showed similar outcome in the overall 
survival in the women assigned in both arms of letrozole and TAM treatments. However, the 
studies for the   long-term effects of third generation AIs on the improvements lead to real 
gains in survival are ongoing and there are not much information on that yet. 
        One can attribute the overall outcome of the SERMs (i.e. TAM) and SERDs (i.e. 
fulvestrant) and AIs to the fact that upon inhibition of ER activity with SERMs and/or 
SERDs or upon inhibition of estrogen synthesis via AIs, there will be no estrogenic activity 
leading to the inhibition of estrogen signaling. Overall, all three class of agents block the 
estrogenic activity and result in an improvement on the patient’s disease free survival. 
However, even though the estrogenic activity resulting from the ERα binding to E2 is 
mitogenic and causes the tumor cell progression, the effects of liganded (with E2) versus 
unliganded (without E2) need to be differentiated to understand the liganded versus the 
unliganded activities of ERα, which does not initiate any estrogenic response.  One 
experimental approach to address this question is to examine the effect that TAM versus 
fulvestrant has on the progression of the cells through cell cycle.  Such an analysis will reveal 
if these two treatment strategies, which either results in inactivation of ER (TAM) or 
degredation of ER (fulvestrant) can alter cell cycle and cell proliferation of ER postive breast 
cancer cells differently.  
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THE CELL CYCLE 
        All cells that make up our body will eventually age and die. These cells must be 
replaced so that the body can continue functioning optimally. Cell cycle is the sequence of 
events between two cell divisions.  The cell cycle occurs as a sequential progression through 
different phases. These four stages - G1, S, G2 and M - are collectively known as the cell 
cycle phases. The S phase is defined as the phase of the cell cycle when DNA synthesis takes 
place and the genetic materials of the parent cell are faithfully copied and passed on to the 
daughter cells leading to a doubling of the amount of DNA per cell. The M phase (mitosis) is 
the phase in which the cells divide and receive the DNA content of the cell, which has been 
synthesized during the S phase. The G1 (i.e Gap 1) phase is defined as the interval between 
the M and S phases that prepares the cells for DNA replication (Figure 1).  During G1 in a 
diploid eukaryotic cell there are two sets of chromosomes present in the cell. If a cell does 
not need to divide it may enter quiescence, which, in this case it is when the cells are in the 
G0 phase. As shown in Figure 1, G2 is defined as the interval between the S and M phases 
that prepares the cells for mitosis 77.  At the end of mitosis, the cytoplasm of the cell will also 
be physically separated into two different cells.  Passage through the cell cycle is controlled 
by a variety of regulatory proteins (i.e.cyclins). As their name reveals and has been shown in 
the Figure 1 cyclins are synthesised at specific stages of the cell cycle. 
        Cyclin D and cyclin E are G1 phase cyclins while cyclin A and cyclin E are S phase 
cyclins and cyclin A expression continues till the end of G2 and cyclin B is an M phase 
cyclin. Cyclins have no catalytic activity on their own and require a kinase partner, called 
cyclin-dependent kinases (Cdks) 78. Cdks, which belong to a group of protein kinases 
(serine/threonine kinases) are activated by association with a cyclin, forming a cyclin 
dependent kinase complex 79. Most cdks are constitutively expressed in most eukaryotic cells 
79. Binding of Cdks to cyclins is necessary for the activation of Cdks function, which is to 
phosphorylate the target proteins (i.e. substrates) on their serine and threonine residues. 
Phosphorylation through cyclin-Cdk can activate or inactivate target proteins in order to 
coordinated the cell cycle progression through the phases and entry into the subsequent phase 
of the cell cycle 80. Cyclin-Cdk complexes phosphorylate specific downstream substrates 
(Figure 1). For example cyclin D upon binding to existing Cdk4 forms an active cyclin D-
Cdk4 complex, which in turn phosphorylates the retinoblastoma protein (Rb) 81. The Rb 
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protein dissociates from the E2F upon the phosphorylation. The E2F-Rb complex function by 
binding to the E2F responsive genes to block the transcriptions, which could results in 
activation of E2F. The dissociation of E2F and Rb causes the activation of E2F, which result 
in the transcription of various genes such as cyclin E, cyclin A and as the result progression 
of the cells from G1 phase to the susesuent S phase 82. The synthesized cyclin E then binds to 
Cdk2, forming the cyclin E-Cdk2 complex, which activates the transition of the the cell from 
G1 to S phase 81. During the G2/M phase cyclin B-Cdk1 complex formation initiates the 
breakdown of nuclear envelope and initiation of prophase, which results in the transition of 
cells from G2 into M phase 83.  
        The transition of each phase of the cell cycle to the next is governed by a specific set of 
cyclin/Cdk complexes.  These complexes are are depicted in Figure 1. 
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Figure 1: The cell cycle 
In the cell cycle, the cells pass through a series of discrete phases in order to divide in a way 
that the two new daughter cells receive a complete set of genetic materials. The phases are 
called the G1, S, G2 and M. All these phases are collectively called the cell cycle. The key 
cyclin/cdk complexes governing the transition of one phase of the cell cycle to the next is 
depicted in this figure. 
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Cyclins 
        As the name implies, cyclins are expressed during the cell cycle cyclically. The phase 
specific activation of Cdks is dependent on the presence of their related phase specific 
cyclins. Each phase of the cell cycle can be identified by the cyclin(s) specific to that phase. 
The cyclin that is expressed early in the G1 phase and takes part in early G1 phase 
progression is cyclin D, which forms a complex with either Cdk 4 or Cdk 6. Another G1 
cyclin is cyclin E and is first expressed in late G1 phase and degraded in mid S phase.  
During the G1 to S transition cyclin E forms a complex with Cdk2 and the cyclin E/CDK2 
complex regulated G1 to S transition.  Another cyclin that is also is associated with Cdk2 is 
cyclin A, but its association with Cdk2 occurs at S phase and continues to G2 phase when 
cyclin A switches partners from Cdk2 to Cdk1 81, 84.  The cyclin regulating M phase 
transition is cyclin B and forms a complex with Cdk1.  Cyclin B is synthesized and its 
expression gradually increases during the G1, S and G2 phase, reaching a peak at the end of 
G2 phase at which point it binds to Cdk1. The resulting Cdk1-cyclin B complex triggers the 
passage from G2 into M phase by regulating several events in mitosis such as 
phosphorylation and activation of 13S Condensin, which helps to condense chromosomes. 
Chromosome condensation is an important cellular process to ensure the faithful segregation 
of genetic information during M phase 85. Cyclin B-Cdk1 complex is also involved in the 
nuclear envelope break down and necessary for the initiation of cytokinesis. Cyclin B-Cdk1 
complex phosphorylate nuclear lamins, resulting in their dissociation 86. Cyclin B-Cdk1 
complex is inactive prior to mitosis because of the complex itself is phosphorylated by Wee1 
kinase 87. The complex is activated through dephosphorylation of Cdk1 by the Cdc25 
phosphatases 88. In contrast to Cdk1, which phosphorylation inactivates it, cyclin B’s 
activation is mediated by its phosphorylation by two kinases: Polo Like Kinase (PLK) and 
Cdk1 89. Inactivated  (unphosphorylated) cyclin B is abundant in the cytoplasm prior to 
prophase. However upon phosphorylation, cyclin B translocates into the nucleus 90. Cyclin B 
phosphorylation blocks the nuclear export signal so then cyclin B is unable to exit the 
nucleus 91. At the end of mitosis, cyclin B’s function is completed at which point its targeted 
for degradation by the Anaphase Promoting Complex (APC) 92. Once cyclin B is degraded, 
the cell exits mitosis.  
         Cdk1 is post-translationally modified by different phosphorylation and 
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dephosphorylation steps, rendering it active. Cdk activating Kinase (CAK)/Cdk7-cyclin H 
complex phosphorylates Cdk1 at a conserved threonine (activating threonine, Thr160) 
located on the activation segment (T loop) 93. In addition to the CAK mediated activating 
phosphorylation, Cdk is also subjected to dephosphorylation on residues Thr14 and Tyr15, 
which lie within the presumptive ATP-binding region of cyclin B-Cdk1 (p34cdc2) 94 by the 
Cd25c family of phosphatases. 93, 95. Cdc25 itself is activated through autophosphorylation of 
Ser 115 and Ser 320 residues by cyclin B/Cdk1 96. This cycle of phosphorylation of Cdc25 
via Cdk1 and then dephosphrylation of Cdk1 via Cdc25 creates a positive feedback loop, 
which results in the activation of Cdk1-cyclin B complexes more rapidly 97.  
        The proper timing of expression of these cell cycle regulators and their kinases is an 
important aspect of the cell cycle regulation. Cyclin synthesis is regulated transcriptionally 
and its degradation post-translationally, via the proteasome 98, 99. Several proteins in the cell 
cycle have temporally distinct positive and negative functions and are degraded accordingly 
at specific phases of the cell cycle 99-101. If their destruction through the proteasome pathway 
does not happen on time then they will impose negative barriers on cell division. For 
example, mitoic progression is controlled by the sequential degradation of different proteins 
through APC.  The signal for mitotic exit is cyclin B’s destruction 102. Similarly, destruction 
of cyclin D1 and cyclin E are also important in order to inhibit the premature and 
inappropriate transition of cells from G1 to S phase 100. The destruction of cyclin D involves 
Skp1-cullin-F-box-protein complex (SCF). SCF only ubiquitinates and degrades a 
phosphorylated protein.  Accordingly, cyclin D1’s turnover is dependent on its 
phosphorylation on threonine 286 (T286), which is mediated by Glycogen synthase kinase 3β 
(GSK3β) 103-105. Accumulation of the cyclins due to their aberrant proteasomal degradation is 
associated with a variety of malignancies 106-109.  For example the elevated levels, of cyclin E 
has been linked to poor prognosis in breast cancer. Normally, the decrease in Cdk2 activity at 
the G1/S transition is controlled by proteasome- mediated degradation of cyclin E, the 
turnover of which also depends on SCF 110. SCF consists of four subunits: Skp1, Cdc53/Cul-
1, Roc1 and an F-box protein, which determine substrate specificity 111. The elevated level of 
cyclin E in the breast cancer cell line SUM149PT, is thought to be associated with the 
mutated gene encoding the cyclin E specific F-box protein, FBW-7 110.  
        Cyclin D1 over-expression gives a growth advantage to cells, and has been associated 
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with numerous malignancies 112. In ovarian cancer, over expression of cyclin D1 has been 
associated with decreased survival in patients. Under normal conditions, cyclin D1 levels are 
elevated only during the G1 phase to prepare for DNA synthesis, but then it needs to be 
degraded to allow for regulated transition to S phase 113. Phosphorylation of cyclin D through 
GSK3β results in the export of cyclin D1 from nucleus to the cytoplasm, which follows by 
the cyclin D1degradation via the proteasome machinery 104, 114. However, in rat skeletal-
muscle cell line L6 and A431 (human epithelial carcinoma cell line) Ras- 
phosphatidylinositol 3 kinase (Akt pathway) negatively regulates GSK3β, resulting in the 
stabilization of cyclin D1 and a rapid G1 to S phase transition, which is a mitogenic 
stimulation 115, 116. However, cyclin E, another G1 cyclin, can compensate for the cyclin D 
functions under conditions where cyclin D is no longer expressed 117-119. For example, Chen 
et al used cyclin D knock out (KO) mice in order to study the brain development. They 
suggest despite the high level cyclin D expression in the embryonic brain of WT mice there 
is no difference between the morphology of the central nervous system (CNS) in cyclin D 
KO and control wild-type (WT) mice at 1, 4 and 12 months of age. These studies have shown 
that interestingly cyclin E expression level has increased 13.5 days post coitum in KO mice, 
which suggest  that cyclin E may compensate for the absence of cyclin D in KO mice 118. In a 
pharmacological study, it was revealed that phosphatidylinositol 3-OH-kinase (PI3K) 
inhibitor LY294002 can block both cyclin D1 accumulation and Cdk4 activity, resulting in 
inhibition of the G1 phase progression in Chinese hamster embryonic fibroblast cells (alpha-
thrombin-stimulated IIC9 cells) 120. However overexpression of cyclin E in IIC9 cells can 
rescure cell progression in the presence of LY294002, which suggest that cyclin E renders 
Cdk4 activity dispensable for G1 progression 117. 
        Human cyclin A degradation process during the cell cycle begins at the early pro 
metaphase and completes by the end of metaphase 121, 122. However, unlike cyclin B, the 
protein(s) that targets cyclin A for proteolysis are still not identified. The destruction box (D-
box), which is a short sequence near the N-terminus site of cyclin B is necessary for the 
degradation of cyclin B. D-box is involved in the ubiquitin-dependent proteolysis 123, 124. 
Using affinity chromatography with immobilized D-box matrixes to identify the factors that 
specifically bind to the D-box in cyclin B, Yamano et al found that the APC purified from 
Xenopus egg extracts can bind to the D-box of cyclin B in a cell cycle-dependent manner, 
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whereas Fizzy (Cdc20) does not. To confirm their observations they also have performed this 
same experiment using mutated forms of cyclin B D-box and reveal that mutations in D-box 
abolished this interaction 125. In another study Suzumori et. al. found that several proteins 
identified through either yeast two hybrid screening or other protein complementation assays 
to bind to the D box of cyclin B.  These proteins included RING finger-like protein RFPL4, 
HR6A, which is an ubiquitin-conjugating enzyme (E2), proteasome subunit ? type 1, and 
ubiquitin all interact with the D-box domain of cyclin B facilitating its proteasomal 
degradation 126. Cyclin A also contains a D-box domain in its N-terminus region 127-129. 
However, it seems that only the D-box is not sufficient for the destruction of  cyclin A in 
human. An additional short sequence (KEN box) following the D-box has been shown to be 
required for cyclin A proteolysis in Drosophila 121, 122, 130. The D-box of cyclin A is 10-20 
residues longer than that of cyclin B 122. Another difference between the mechanisms of 
degradation of cyclin A versus cyclin B, is their times of degradation in the cell cycle. Cyclin 
A degradation timing corresponds to the period when metaphase transit to anaphase, while 
cyclin B degradation time is right after anaphase. Geley et. al. have used microinjection of 
antibodies against subunits of the APC (or against human Cdc20 (fizzy) and observed that 
APC elimination arrested cells at metaphase and stabilized both cyclins A and B. APC is 
activated as cells enter mitosis. Upon APC activity during mitosis phase cyclin A is being 
targeted for degradation around the metaphase to anaphase transition.  The cyclin B1 
degradation delayed due to its role in spindle assembly checkpoint. 
        The degradation of cyclin B via anaphase promoting comples (APC) is necessary and 
occurs right after the spindle assembly checkpoint, resulting in the metaphase to anaphase 
passage and then exit from the mitosis 131. APC also needs to be activated by phosphorylation 
via polo-like kinase (PLK) and presence of activator proteins, called Cdc20/Fizzy and 
Cdh1/Fizzy-related 132. In fact mutations in fizzy have shown to block sister chromosome 
separation, indicating that it plays a crucial role in the metaphase/anaphase transition 102, 122, 
132. Once cyclin B is targeted for degradation it is ubiquitinated on Lys-48 in the destruction 
box 133, 134.  Ubiquitylated cyclin B is degraded by a constitutively active 26S proteasome, 
and leaving behind an inactive monomeric Cdk1 131, 135, 136.  
        There are several check points in the cell cycle that keep the regulated progression of 
the cells from one phase to the next and help to halt the passage of the cells in a specific 
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phase upon damage or deregulation signals. The spindle checkpoint, which is between 
metaphase and anaphase, occurs before chromosome movements begin via the attached 
microtubules to the chromosomes, to ensure that all the chromosomes are completely lined 
up and will be evenly distributed in to each daughter cell 137. DNA replication checkpoint 
may occur before the onset of M phase (at late G1, S and G2) to ensure that DNA synthesis 
has been completed successfully prior to proceeding into M phase where cell division occurs 
138. This checkpoint occurs frequently during the cell cycle in order to ensure that no DNA 
damage can accumulate in the process of cell division 138.  
        Several check point sensors have been identified, however the most established check 
point molecule is p53. Upon damage, the cell cycle will halt temporarily to allow the cell to 
repair the damage. If the damage is repaired, the cell will continue to progress through the 
cell cycle.  However, if the damage is too severe, apoptosis can be triggered-all three events 
are governed by p53 97.  Another checkpoint event (e.g. protein) is activated at the restriction 
point, which occurs at the end of G1 phase preventing S phase entry in the absence of 
mitogenic stimuli 139. pRb, which is a key protein in the restriction point,  prevents the cell 
from replicating a damaged DNA when it is hypophosphorylated 140. Hypophosphorylated 
pRb has a tumor suppressor role and can bind and inhibit the transcription factor, E2F 141. 
When E2F has not been sequestered by pRb, it activates the transition of cells from G1 into S 
phase. However, pRb binding to E2F and DP proteins keeps E2F-DP inactive as a 
transcription factor and stalls the cells in the G1 phase 142.  When E2F is inactivated, it also 
suppresses the next step in DNA synthesis by attracting a histone deacetylase (HDAC) 
protein to the chromatin to reduce the transcription of S phase promoting factors 143-145. 
        pRb in it’s hyperphosphorylated state is inactive (147). pRb is phosphorylayed 
sequentially by cyclin D-Cdk4/6 and  cyclin E/Cdk2 complexes through out the G1 phase 140, 
146. pRb remains phosphorylated throughout S, G2 and M phases by other cyclin/Cdk 
complexes active at each phase 147. Hyperphosphorylated pRb results in the release of E2F, 
which can then result in transcriptional activation of proteins necessary for G1 to S transition. 
These proteins include cyclins E and A, and proliferating cell nuclear antigen (PCNA), 
among many others 140, 146, 148, 149.  
        Another class of cell cycle regulators are the inhibitors of cyclin dependent kinases 
which are generally termed as the brakes of the cell cycle and are encoded by two gene 
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families the cip/kip family and the INK4a/ARF family. The cip/kip family include the 
proteins p21, p27 and p57 and they mediate their inhibitory activities by binding to the 
catalytic cleft of the cdks, mimicking ATP, resulting in the inhibition of phosphorylation of 
substrates such as pRb and G1 arrest 150-152. The INK4a family includes p16INK4a and 
p14arf proteins, which act by binding to Cdk4 and inhibiting its binding to cyclin D. The 
mutation on Cdk4-Arg24Cys site specifically affects the ability of Cdk4 binding with p16 
wihout effecting its binding to cyclin D 153. As such, the INK family of inhibitors antagonize 
the formation and activation of cyclin D-Cdk4 complexes 154.  P16 induces a G1 phase arrest 
by inhibition of cdk4 and cdk6 mediated Rb phosphorylation 155, 156.  
        Aberrant expression of proteins regulating the cell cycle checkpoints is common in 
cancer.   For example, loss of pRb function leads to malignant phenotype due to cell cycle 
deregulation 157, 158. Rb function could be abrogated via: 1) phosphorylation through cyclin D 
overexpression, which happens in several types of tumors such as parathyroid adenomas, B-
cell lymphomas and squamous cell 159, 160, 2) viral oncoprotein binding.  
        In tumor cells (such as cervical cancer, mesothelioma), it has been shown that E2F gets 
inactivated through pRb binding to DNA tumor virus oncoprotein 161-163. Faulty checkpoints 
have the same downstream effects as increased growth factor production (another 
characteristic of cancer cells).  An excess of growth factor results in the over- production of 
Cdk-cyclin D complex and results in unabated G1 phase to S phase transition of the cells 164. 
Ectopic expression of cyclin D in the Rb-negative osteosarcoma cells, following introduction 
of a function Rb, results in reversal of Rb mediated cytostatic affect.  As such Hinds et. al. 
suggest that the cyclin D gene can function as an oncogene 165.  Additionally overexpression 
of cyclin D into BRK cells (rat embryo fibroblasts) resulted to increased foci formation, an 
indicator of oncogenic cell transformation (166). Therefore, both excessive growth factors 
and nonfunctioning restriction point result in untimely progression through the cell cycle. 
 
ERα  & ERβ  SIGNALING  
        The human ER belongs to the nuclear hormone receptor family. ER is a transcription 
factors, which its activation is hormone dependent. Hormone (17βestradiol (E2)) upon 
diffuse through the membrane binds to ER, which then can initiate the transcription of genes 
containing ER response elements (ERE) 166. To date, two ER have been identified, ERα and 
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ERβ which are differentially expressed in various tissues and thought to have different 
functions. The structure of the ER protein is depicted in Figure 2, which shows the known 
domains within the protein.  These domains include the E domain. Ligand Binding Domain 
(LBD) or AF2 region is located in the E domain of ERα. AF2 region is an important region 
in initiation and activation of ER-target genes 167. It contains the binding domains (cavities) 
for ligand and also coactivator or corepressor bindings 168. Upon ligand binding to LBD at 
AF2 ERα forms dimers, which followed by the phosphorylation of ER (see Figure 2). The 
phosphorylation of ER initiates gene transcription (168,169, 170. The A/B domain is located at 
the N-terminal of ERα protein. A/B domain contains the AF-1. Similar to AF2, the AF1 
region also can initiate gene transcription, however the gere transcription initiated from the 
AF1 region is a ligand independent phenomenon 171. There is another difference between the 
gene transcriptions initiated from AF2 region compared to AF-1 region other than the Ligand 
dependency. The number of the genes being transcriptionaly activated through AF1 region 
are not as vast as genes being activated via AF2 region and also the transcriptional activity 
initiated from AF1 is weak 172. The binding of ERα protein to the ERE site on DNA is done 
via the C domain on the ER protein. The C domain also called DNA-binding domain (DBD) 
(Figure 2) 173.  The domain that connects the E domain (AF-2) and C domain (DBD) is called 
the hinge region 171.   
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Figure 2: ERα  protein structure 
 A schematic ERα protein, which depicts all the identified domains on the ER protein such as 
A/B domain (AF1) and C domain (hinge region) and D domain (DBD) which followed by E 
region (AF2/LBD) and last F domain. The known phosphorylation sites on each domain are 
marked.  
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         Unliganded ERα is found in the cytoplasm binding to the heat shock protein of 90 kDa 
(hsp90) in a large molecular complex (Figure 3) 174. The molecular chaperones binding to 
target protein (ie. ER) causes the maintenance of proper protein folding within the cytoplasm, 
which is necessary for different intracellular processes such as 1) stabilizing the nascent 
polypeptide chains, 2) prevention of protein aggregation 3) chaperoning and transportation of 
the proteins across the cellular membranes 175, 176. E2 binding of ER follows by the 
dissociation of ER from the HSP90, which allows a conformation change in ER protein, and 
result in ERs homodimerization (Figure 3). These events trigger an estrogenic (i.e. ligand 
dependent) response in the cell 166, consisting  of an increase (3x to 4x) in the basal level of 
ER phosphorylation upon treatment with estrogen as compared to un-liganded conditions 177. 
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Figure 3: Estrogenic response 
ERα upon binding to Estrogen (E2) dissociates from the heat shock proteins and forms 
homodimer and internalizes into the nucleus so it can initiate transcription from the ERE sites 
of the ER-target genes.  
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Phosphorylation of ERα is an important regulatory mechanism, which also changes, 
the conformation of ER exposing the protein to allow further rounds of phosphorylations, 
resulting in 178-182 the activation of ER and transcription of the target gene based on the 
specific phosphorylation 169, 183-185.  
 ER can also be activated by non-classical, non-genomic and/or ligand-independent 
manners (Figure 4) 186.  In the non-classical pathway, ligand bounded ERα forms a complex 
with the transcription factors (ie. SP-1 and AP-1), which are bound directly to the DNA. 
Through ER binding to AP-1 and SP-1 ERα is able to activates the transcription of genes that 
do not contain classical ERE elements 187. Examples of non-ERE containing promoters are 
the ovalbumin proximal promoter, collagenase and IGF-1 genes 188-194. In all three cases ER 
initiates the transcription through binding to AP-1 sites through recruitment by Jun/Fos. 
Under these non-ERE transcriptional activation, ER is part of the coactivator complex for 
Jun/Fos 195.  
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                                            Figure 4: Non-genomic path of ERα  
 ERα upon stimulation of growth factors is able to initiate a signaling cascade involving the 
cytoplasmic pathways (i.e. MAPK and PI3K). ERα is phosphorylated in the non-genomic 
pathway independent of ligand and ligand binding and can result in the unregulated 
transcription of the downstream genes.  
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The non-genomic functions of ER seem to be mediated via the membrane-associated 
ERα. The non-genomic function of ER gives rise to the intracellular signal transduction 
pathways in order to generate rapid cytoplasmic signaling (Figure 4) 196-199. Simoncini et. al. 
showed that “nuclear” ER also resides outside the nucleus. He mentioned that the 
cytoplasmic ER could have a different role in the cell compared to the nuclear ER. This 
group showed that ERα binds to p85-alpha subunit of the phosphatidylinositol-3-hydroxy 
kinase ( the regulatory subunit of PI3K) in a ligand dependent manner 200. They showed that 
in human vascular endothelial cells, physiological concentrations of E2 increased endothelial 
nitric oxide synthase (eNOS) activity. The eNOS activity upon E2 exposure is being 
mediated via mitogen-activated protein kinase (MAPK). Nitric oxide (NO) (a pleiotropic 
regulator,) functions by regulating different biological processes such as vasodilatation, 
neurotransmission and macrophage-mediated immunity. The NO connection with cancer has 
been well established 201. ENOS activity is completely blocked using either wortmannin 
(PI3K inhibitor) and ER antagonist ICI 182,780 and the inactive E2 stereoisomer 200, 202. In 
this non-genomic pathway, ER initiates a rapid and transient cascade of signaling originating 
from the cytoplasm via direct association with signal transduction proteins such as MAPKs, 
PKC and guanosine triphosphate-binding proteins (G proteins) 203, 204. In fact, treatment of 
human granulosa-luteal cells (hGLCs) with agents known to enhance CAMP levels, results in 
downregulation of ERα mRNA levels. Additional studies using adenosine 3',5'-cyclic 
monophosphorothioate (a PKA inhibitor), Rp-isomer, triethylammonium salt and an 
adenylate cyclase inhibitor (SQ 22536) also could modulate ER levels suggesting that the ER 
and the signal transduction pathways such as PKA or PKC are infact linked 205.   
        Another example is the non-genomic action of ERα is through MAPK. Treatment of 
MCF-7 cells with E2 results in the activation of MAPK, which is preceded by a rapid 
increase in cytosolic calcium. Subsequent treatment of MCF-7 cells with E2 upon treatment 
or no treatment with ICI 182,780 abrogates the activation of MAPK 206. It has been suggested 
that the cytoplasmic or cell membrane ER is only a small subset of the classic ER, or perhaps 
is of a short form/spliced variant of full length ER 207, 208. Support for this hypothesis came 
about when a spliced variant of ERα, with a molecular weight of 46-kDa  (ERα46), was 
identified in human endothelial cells 208.   Confocal microscopy revealed that a proportion of 
both full length ERα (ERα66) and ERα46 was localized outside the nucleus capable of 
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binding to E2 (Figure 5). However, E2 mediated transcriptional activation by ERα46 was 
much less than with ERα66 and ERα46 could inhibit classical ERα66-mediated 
transcriptional activation (209). In other studies, the membrane ERα and the intracellular 
ERα were found to be closely related and originate from the same coding sequence 209-211. 
Using immunohistochemical methods Watson et al found that eight distinct antibodies 
against full length ERα could also recognize membrane ERα, suggesting that the membrane 
and nuclear ERα proteins are highly related 211. 
        ER’s activation through the ligand independent pathway is mediated by growth factor 
signaling which results in the phosphorylation of ER 212, 213. Examples of ligand independent 
activation of ER have been documented with Epidermal Growth Factor Receptor (EGFR) 
and Insulin Like Growth Factor Receptor (IGFR) 214.   Signaling from EGFR activates 
cytoplasmic nonreceptor kinases (i.e. -Src) that can phosphorylate ERα and some of its 
coactivators 213. A direct interaction between ERα and IGFR results in the activation of IGFR 
and downstream MAPK signaling. Specifically, upon E2 stimulation ERα binds to IGF-1R 
and forms a heterodimer, which results in the activation of downstream MAPK signaling 215.  
In these studies, ERα was overexpressed in COS7 and HEK293 cells, which have high levels 
of endogenous IGFR. Treatment of these cells with E2 resulted in ERα binding to IGFR, 
followed by a rapid phosphorylation of IGFR, which inturn induced the phosphorylation and 
activation of cytoplasmic kinases extracellular signal-regulated kinases 1/2 (ERK1/2). These 
sequential events, triggered by ERα, were required to induce the activation of ERE-LUC in 
IGFR stimulated cells. Taken together, this data suggests that the ligand binding of ERα is a 
necessary step toward a rapid cascade of cytoplasmic signaling via IGFR (Figure 4) 215. 
        The cell-membrane-localized-ERα also interacts directly with Her2/neu. Yen et al. have 
suggested a novel mechanism by which Her2/neu coupled to the cell membrane ERα is 
involved in TAM resistance of breast cancer cells 216. They have shown colocalization of 
membrane ERα and Her2/neu in BT-474 cells in which results in the abrogation of TAM 
initiated apoptosis. However, when Her2/neu was dissocated from cell membrane ER, TAM-
induced apoptosis was activated 217.  
        E2 stimulated ERα that is G protein-coupled can also initiate signal transduction from 
plasma membrane through the transactivation of the EGFR/IGFR which in turn result in the 
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activation of c-Src and matrix metalloproteinases 218. Briefly, E2 bound cell membrane ER 
has the ability to activate matrix metalloproteinase-2 (MMP-2) and MMP-9 via Src. MMP-2 
and MMP-9 are type IV collagenase/gelatinase, which in mammals, degrade the collagens of 
the extracellular matrix and facilitate the ability of cancer cells to invade induce the ability of 
cancer cells to invade through basement membranes. The tyrosine kinase c-Src, leads to the 
activation of downstream cascades such as MAPK, PI3K, PKC. C-Src activates these 
cytoplasmic cascades via interactions with ion channels, G proteins, which are the 
membrane-associated signaling molecules. The downstream effects of c-Src via the 
membrane signaling molecules can elicit a number of physiological effects such as 
proliferation, metastasis and survival 219. Caveolae is the plasma membrane cavity in which 
the signaling molecules such as ER and G-protein are enriched in and can interact 220. Other 
signaling molecules, which are needed for the initiation of cytoplasmic cascades will also 
move to the caveolae 219. The interaction of ERα with G protein in the caveolae can recruit c-
Src, 221, Shc (Src homology complex) and p85α subunit of PI3K 222. As a result of ERα 
activation, MMP-2 and MMP-9 can then activate multiple kinase cascade of signaling 
through the EGFR transactivation 223. Additionally, c-Src, Shc and p85α subunit of PI3K can 
lead to activation of secondary signaling messengers and downstream kinase pathways such 
as ERK, MAPK and PDK1/AKT216, 224-226.  
 
COACTIVATORS & COREPRESSORS OF ERα   
        It is clear that ER-mediated transcriptional activity plays a significant role in 
proliferation of both normal and cancer cells. There are also numerous studies suggesting that 
ER is able to transfer extracellular signals intracellularally through it’s non-genomic activity 
213. One approach that has been used to elucidate the mechanisms of E2 action is the 
identification of the protein partners of ER. These studies were initiated by Onate et. al. who 
identified a protein that interacts with human steroid receptors to enhance the transcriptional 
activity. Since the identified proteins stimulated transactivation of the steroid receptors such 
as; ER, PgR, Glucocorticoid receptor, Thyroid hormon receptor, retinoid X receptor, it has 
been named as steroid receptor coactivator-1 (SRC-1) 227.  Upon many different studies it is 
now known that there are a large number of proteins interacting with ER to regulate it’s 
transcription. These proteins are called coactivators and or corepressors based on their effect 
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on the downstream transcription activity of ER at ERE 228. Coactivators function as adaptors 
in a signaling pathway that transmit transcriptional responses from the DNA bound receptor 
to the basal transcriptional machinery 229. For example, E2 binding to the LBD of ER induces 
a conformational change in the AF-2 domain (Figure 2) creating a new protein interaction 
site that is recognized by coactivators 179. Alternatively, when TAM binds the conformational 
change at AF-2 domain is obstructed resulting in the recruitment of corepressors that can 
actively silence ER responsive genes (180, 229. The presence of coactivators is essential for 
ER transcriptional activity 230-232.  Another co-activator of ER is p300 in which in complex 
with ERα has an intrinsic histone acetylase activity, resulting in the acetylation of lysine 
residue histone proteins 233, 234.  Like p300, other coactivators such as CBP, SRC1, GRIP1 
and AIB1 bind through the coactivators’ LXXLL domains and the ER’s AF-2 domain 
(Figure 2) 235-239. The roles of cofactors are still under investigation but so far it is believed 
that cofactors can either directly regulate chromatin remodeling or they can recruit factors 
with chromatin remodeling properties.  
        Another family of ERα cofactors is the p160 family of proteins, which includes SRC1, 
GRIP1 (SRC2) and AIB1 (SRC3), all of which have a basic helix-loop-helix (bHLH) 
domain. The bHLH motif, consist of two α-helices connected by a loop. One helix, which is 
bigger in size contains the basic amino acid residues that facilitate DNA binding and the 
other helix is smaller, and, due to the flexibility of the loop, allows dimerization in the form 
of protein-protein interaction by folding and packing against another helix 240. bHLH domain 
on ER coactivator, p160, mediates the initiation of ERα’s transcriptional activity 234, 241-244. 
E2-bound ERα recruits HATs (p300, pCAF and CBP coactivators) to the ERα 
transcriptional complex via SRC1 (103, 245, 246. CBP and p300 coactivators possess intrinsic 
HAT activity and can interact with all p160 family members 247-249. P300 can also directly 
interact with the AF2 domain, which can further promote the transcriptional activity of ERα 
236, 250-252. P300 has not only been shown to be involved in the transcriptional initiation in 
breast cancer but also in the direct regulation of the acetylation state of AR leading to 
increased cell proliferation in prostate cancer cells 253, 254.  The increase in expression level of  
p300 and CBP in invasive ductal carcinoma cases 255 and in prostate cancer 256, coupled with 
their recruitment to the promoter of target genes underscores the role of HAT activity in 
regulating hormone response in these diseases 253, 254, 256-258.  
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        Another category of ERα cofactors has histone methyltransferases function and include 
CARM1 (PRMT4) and PRMT1 259, 260. The histone tails get methylated via CARM1 and 
PRMT1 facilitates subsequent histone acetylation, which results in transcriptional activity 261-
264. CARM1 and PRMT1 interact with ERα indirectly through p160 or p300 cofactors 202, 265, 
266.  As with p300 and CBP, the interaction between ERα and CARM1, PRMT1 could 
happen in the absence of E2, which might be another explanation for the role of cofactors of 
ERα in overcoming the transcriptional inhibition in the absence of ligand 257, 267. CBP/p300 
acetylase activity and the CARM1 methyltransferase activity can positively regulate the 
expression of estrogen-responsive genes (i.e. pS2) in MCF-7 cells through arginine 
methylation followed by acetylation of H3. CARM1 methyltransferase activity follows upon 
overexpression of CBP in the absence of E2 stimulation, suggesting that the acetylase 
function of CBP is downstream of E2 stimulation and upstream of CARM1 
methyltransferase activity. Additionally the step-wise activation of CARM1 and CBP reveal 
how the cooperation between these two ERα cofactors can initiate the transcriptional activity 
without the ligand stimulation 268.  
        The other fairly new transcription factor, which have been introduced for estrogen 
receptor is FOXO3a. FOXO3a is a member of forkhead transcription factors, which are 
categorized in class O (FOXO). FOXO3a have been shown to have a tumor suppressor 
function in breast cancer269. FOXO3a interacts with ERα in MCF-7 cells. The new data on 
this group of transcription factors suggesting a crosstalk, which connects FOXO3a and ER 
pathways breast cancer cells expressing ERα269. 
 
COREPRESSORS of ERα 
         While HAT activity can acetylate the histone tails and mediate decondensation of 
chromatin and initiation of transcription, Histone deacetylases (HDACs) can deacetylate and 
reverse the effect of HATs on the chromatin, resulting in the condensation of the chromatin 
and inhibition of transcription 270 TAM-bound ERα recruits NCOR1 and SMRT, which act 
as adaptors for binding to proteins with HDAC activity and repress the ER transcriptional 
activity (HDAC3 and HDAC1) 237, 271, 272. Corepressors were first identified in association 
with PgR in both yeasts and HeLa cells using wild-type and mutant PgR. This study revealed 
the conformational changes of PgR is different upon whether progesterone agonists or to 
  33 
progesterone antagonists bind to the amino acida at the ligand binding domain of PgR 273, 274. 
Hence a co-activator and a co-repressor not only bind to different regions of the receptor, but 
the resulting conformational change is also distinct.  
         NCOR1 protein levels are decreased in invasive breast cancer and in TAM-resistant 
mouse models. Using MCF-7 as the ER positive breast cncer cell line, investigators found 
resistance to TAM is associated decreased levels of NCOR1 and sequesteration of NCOR1 
and SMRT into the cytoplasm 260, 275, 276. Specifically, the investigators serum starved MCF-
7 cells, in the presence of TAM followed by stimulation with insulin. Upon insulin 
stimulation the NCOR-ERα association was significantly decreased while the insulin 
treatment conversely increased the association of two coactivators, SRC-1 and p/CIP with 
ERα. Additionally, TAM treatment of MCF-7 cells results in the association of ERα with 
NCOR and SMRT while with pure antiestrogen (ICI 182780 and ICI 164384) treatment did 
not induce detectable association of ERα with either of the corepressors 276.  
         In advanced breast cancers, which have developed resistance to TAM, E2 initiation of 
NCOR1 degradation through proteasomal pathway could be the mechanism of NCOR 
suppression 277. Perissi et. al. used embryonic stem cells to show that the two F box related 
proteins, which are also identified as one of the components in the NCOR complex, TBL1 
and TBLR1, are involved in the recruiting the ubiquitin conjugating (19S proteasome 
complex) to the NCOR 277. Table 2 has a list of ERα related cofactors and their function and 
activity. 
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Table 2: ERα coactivators and their type of activity and function-part I 
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Table 2: ERα coactivators and their type of activity and function-part II 
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ESTROGEN RECEPTOR BETA (ERβ) 
        A second ER isoform, ERβ, has been identified recently. The two ER isoforms have a 
similar domain structure as shown in Figure 5 (5). The central DNA binding domain (DBD-C 
region in the figure) is highly (97%) 278, 279 conserved between ERα and ERβ (Figure 5). The 
C-terminal ligand binding domain, which is responsible for high affinity ligand binding, 
dimerization, and hormone-dependent activation (AF-2- E region in the figure), is 
moderately conserved (59%) (283, 284). The N-terminal region contains hormone-
independent activation function1 (AF-1- A/B region in the figure) and its poorly conserved in 
ERβ  (18%) (283, 284, 23). 
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                                    Figure 5: ERα  and ERβ  protein structure 
 ERα and ERβ show significant overall sequence homology. Both are composed of five 
domains (A/B=AF-1, C= DNA binding region, D= Hinge region, E +AF-2 and F domain 
function is not entirely clear). The 46 kDa, ERα isoform lacks 173 amino acids at the N-
terminal compared to the full length 66 kDa ERα. ERα-46 is encoded by a new class of ERα 
transcript that lacks the first coding exon (exon 1A) of the ERα gene 280. 
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    The current paradigm of estrogen signaling in breast cancer is that ERβ can function   
a repressor of ERα gene transcriptional activity 281 282. For example, ERβ inhibits 
proliferation of  T47D in the presence of E2. The inhibitory effect of ERβ on the 
proloferation in T47D cells is concomitant with a decrease in some of the main regulators of 
cell cycle including; cyclin E (both mRNA and protein), Cdc25A mRNA, p45 (Skp2) 
protein. P45 regulates p27 proteolysis. In addition the inhibitory effect of ERβ also causes a  
reduced Cdk2 activity.  Similarly, the expression level of the brakes of the cell sysle, such as 
p27 (Kip1) were increased 282. Further evidence for the opposing action of ERα and ERß was 
observed when cyclin D levels were decreased in response to ERβ over expression in T47D 
and HC11 cells 282-285. HC11 is derived from mouse mammary epithelial cells (282). Upon 
ERβ overexpression, pS2 and PgR transcription could be suppressed via binding of ERβ to 
the promoters of these genes in a repressive manner 286. In this study, T47D cell line with an 
inducible tet-off FLAG-ERβ was generated to examine the kinetics of expression of pS2 and 
PgR, which were downregulated in response to ERβ induction 286. The differences in the ERs 
were also evaluated in the mouse knock out models.  When ERß knock out (BERKO) mice 
(ERα+/+β-/-), which were generated by crossing male double-heterozygous (ER+/-ß+/-) mice 
with female double-heterozygous (ER+/-ß+/-) mice 287, were examined for bone loss the results 
revealed that female mice with ERβ knockout were partly protected against age-related 
trabecular bone loss. Peripheral Quantitative Computed Tomography (pQCT, a test to 
measure bone density) was used to measure trabecular volumetric BMD (Bone Mineral 
Density) in the metaphysis of the distal femur and in the proximal tibia in both the ERα 
knock out mice (ERKO) and BERKO. The pQCT results showed that BERKO mice do not 
show any significance change in the BMD, while ERKO mice showed decreased BMD as 
well as radial skeletal growth. Thus, ERα but not ERβ is essential for the maintenance of 
bone mass in female mouse 288.  
        One possible mechanism by which ERβ represses ERα activity could be through 
preventing of the recruitment of particular cofactors of ERα. For example, a CHIP assay 
targeting ERß depicted a marked reduction in the recruitment of AP-1 factors to both the pS2 
and PgR promoters. Additionally, upon ERβ expression the recruitment of c-Fos to the PgR 
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promoter is abrogated in part due to abrogation of E2-dependent induction of c-Fos mRNA 
286.  
        The function of ERβ in breast cancer remains unclear as current data suggests different 
function and pattern of expression of ERß as compared to ERα. ERβ is expressed in 
surrounding stromal cells rather than in epithelial tissue of the mammary gland, which is the 
case for ERα (145). The comparison between the distribution of ERα and ERß mRNA levels 
in different tissues of a normal rat revealed that ERβ mRNA is expressed in organs such as: 
1) Prostate, 2) Ovary, 3) Lung, 4) Bladder, 5) Brain, 6) Uterus, 7) Testis. However they 
showed that ERα mRNA, is mainly expressed in 1) Uterus, 2) Testis, 3) Pituitary, 4) Ovary, 
5) Kidney, 6) Epididymis, 7) Adrenal 289.  The lack of ERβ protein affects tissues such as 
ovaries, uterus, bladder and lung, while mammary glands have minimal functional defects as 
a result of ERβ deficiency 287, 290, 291.   
        The ability of ligand binding and activity have been compared between the two 
receptors based on different levels of homology of DBD and LBD found in each receptor 
(see Figure 5). For these analysis, the binding affinity of diethylstilbestrol, TAM,17ß-E2 and 
ICI-164384 to each receptor was measured using radioligand upon treatment with different 
doses of unlabeled competitors. These studies revealed that the ligand binding (set as 
arbituary values with that for E2 being 100 for each receptor) was different for each receptor. 
For example, the ligand binding values for diethylstilbestrol is 468 and 295, for TAM is at 6 
and 7, for ICI-164384 is 85 and 166 for ERα and ERβ respectively 289. Hence, these results 
reveal that in addition to the differences enumerated above, there are also significant 
differences in ligand binding affinities between ERα and ERβ.  It is thought that the reason 
patients with the same ERα levels respond differently to endocrine therapy may be due to 
differences in the level and activity of ERβ. 
 
ERα  IN NORMAL MAMMARY TISSUE 
        The female mammary gland is in a state of quesante until puberty, which at that point 
the cells division increases substantially. Upon onset of puberty during the adult life some 
cyclical changes (estrous cycles) are observeable in female’s mammary gland cells. These 
cyclical changes contain the proliferation of the cells, which followed by the involution 292. 
The expression pattern of hormones during estrous cycle is depicted in Figure 6.  In  
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                                  Figure 6: Menstrual cycle in humans 
The menstrual cycle is a recurring cycle of hormonal fluctuation, which begins at menarche 
and ends at menopause. During each cycle a series of physiological changes occurs in order 
to prepare the female body for the purpose of fertilization and ovulation. Unless pregnancy 
occurs, the cycle will repeat. 
 
 
 
 
 
 
 
  41 
the adult breast, the luteal phase marks the phase of the estrous cycle that the proliferation of 
breast epithelial cells are maximal, which the exact timing is a week after ovulation.  Both 
hormones, E2 and progesterone, are being secreted through corpus luteum during luteal 
phase while during follicular phase only the E2 level is high 293-300. 
However, normal human breast tissue proliferation appears to be solely dependent on 
E2 with no obvious effects of progesterone 301. To examine the specific function of E2 versus 
progesterone in the normal mammary gland proliferation, pieces of normal human breast 
tissue were implanted into athymic nude mice (subcutaneously) 301. Slow-release E2 and/or 
progesterone pellets were also inserted subcutaneously into these mice and the rate of 
proliferation of the implanted tissues was assessed by thymidine uptake. The results revealed 
that E2 pellet increased the thymidine labeling index from a median of 0.4% to 2.1% after 7 
days while progestrone pellet had no effect on the thymidine labeling index (306). Additional 
evidence for the importance of E2 in maintenance of a healthy breast is the association of the 
breast cancer risk with the longer duration of E2 exposure.  
         For example early onset of menarche and late menopause are both associated with 
greater cancer incident risk 302. During the proliferative stages of a normal breast, which are 
both puberty and the estrous cycle (Figure 6), the majority of proliferating cells do not 
express ER or express ER in a very low level in terminal end buds and ducts 303. The level of 
differentiation of mammary parenchyma determines the mammary epithelium proliferative 
activity 302. In post-pubertal women the lobule type 1 (Lob 1) is the most undifferentiated 
structure. Lob 1 is also known as Terminal Ductal Lobular Unit (TDLU). Lob 1 progresses to 
Lob 2, which are more morphologically complex morphology and are more differentiated 
when compared to Lob 1.  Lob 1 and Lob 2 progress to Lob 3 and Lob 4 during pregnancy 
under hormonal influence 304. Upon the full differentiation of Lob 1, Lob 2 and Lob 3 into 
Lob 4 during pregnancy, the proliferative activity of mammary epithelium is reduced 292.  
        The content of ERα and PgR in the lobular structure are directly proportional to the rate 
of cell proliferation. The ERα/PgR content of epithelial cells in Lob1 is much higher (14%) 
than Lob 3 (0.5 %) due to the higher proliferation activity of cells in Lob 1, which could 
explain the higher susceptibility of Lob 1 to transform and become the site of origin for 
ductal carcinomas 4-6. Lob 1 contains at least 3 different cell types based on their ER and 
proliferative ability as masured by Ki67 expression: A) ER-/Ki67+, B) ER+/Ki67-, C) 
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ER+/Ki67+.  These three cell types are also regulated by positive and negative feed back loop 
mediated by estrogen signaling.  For example, E2 stimulation of group B could release 
certain growth factors, which through paracrine pathways can increase the proliferation of 
group A. The group C cells could be the precursor of ER-positive tumors. The groupings into 
the three different cell types is dependent on two proteins, Ki-67 and ER. Ki-67 is a potent 
tool for evaluating the proliferation index of cells in the three different goups. The antibody 
against ki-67 recognize the nucleare antigen ki-67, which is only expressed in cycling and 
not G0 cells 305. Using an antibody to ER to determine the precise level of expression of ER 
is critical since, the ER content of the tumor cell dictates if a patient will respond to 
endocrine therapy. Additinally, there is some controversary regarding the possibility that ER-
negative cells maybe capable of reverting to ER-positive cells 306, 307. To address this 
question, a study was initiated to examine whether cellular expression of ER occurrs on a 
clonal basis or as a function of the differentiation process.  For these studies MCF-7 cells 
were subjected to soft agar colony assay in the presence or a TAM followed by 
immunoperoxidase staining with monoclonal ER antibody.  The results revealed that there 
was heterogeneity in ER expression among cells within the same clone or different clones in 
agar cultures. TAM significantly reduced clonal growth. The ERexpression was so low in the 
proliferating clones , which were unresponsive to the antiestrogen (TAM). Based on these 
results, some investigators propose that change of ER expression occurs concommitantly 
with differentiation of cells within clones 306. They suggest that ER-positive colonies may 
arise from ER-negative progenitors. There is also evidence that the proliferation state of the 
cells can be independent of the ER/PgR content of the cell. Knabbe et. al. suggest that 
adjacent cells can control the proliferation of adjacent cells through autocrine/paracrine 
function. 308-310. To this end they co-cultured MCF-7 cells with MDA-MB231 cells and found 
that secretion of biologically active Transforming Growth Factor-β (TGF-β) from MCF-7 
cells can result ininhibition of cell proliferation in MDA-MB231 cells 308-310.  
        40% of the epithelial cells in the prepubertal rats express ER in the nucleus. The level of 
ER expression in these cells decreased to 30% upon puberty. The level of ER expression 
decreased even more to 5% upon pregnancy to only 5%. However there was a huge induction 
in the nuclear ER protein level during lactation, which was up to 70%. Studies show that 
about 90% of ERβ expressing cells do not proliferate (2). Also studies have shown that 55-
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70% of thecells, which are dividing express neither ERα nor ERβ (2). These data shows that 
none of these receptors are a prerequisite for estrogen-mediated proliferation 2. Similarly in 
proliferating MCF-7 cells treatment with any of the SERMs (i.e. TAM) results in increase of 
ERα levels. The increase in ERα results in the increase in p27, which is a marker of non-
proliferative cells 276.  
        In another model system, which is done in the cells from the rat mammary gland, the 
stage of mammary gland development is dependent on the percentage of ERα expressin in 
the nuclei Shyamala, 1990 #706}.  ERα is expressed in 30% of the cells during puberty. The 
ERα expression level goes down to 5% at day 14 of pregnancy. The ERα expression in the 
nuclei increase during lactation till the expression level reaches to 70% by day 21. Through 
out pregnancy cells do not express ERα or express a very low level of ERα , which no or low 
level of ERα has been shown (discussed in my current study) to be a marker of proliferative 
phenotype. However, ERα reexpress during lactation in 60% of breast epithelial cells. These 
cells are non-proliferative and E2-insensitive 311. These studies, using normal mammary 
gland, highlight the paradoxical role of ER has on cell proliferation. 
        Unlike normal mammary epithelial cells containing ER/PgR, which do not proliferate in 
response to estrogens, human preadipocytes are stimulated to proliferate by estrogens.  When 
human preadipose cells are treated with estrogens, c-myc and cyclin D1 expression are 
induced, suggesting that they may be mediators of estrogen stimulated proliferation in these 
cells 312. The pathway that seems to be activated in these cells is the autocrine/paracrine 
pathway. Proliferating cells are often located adjacent or in close proximity to non-dividing 
cells that contain ER/PgR 292, 303, 313, 314. ER/PgR positive cells can stimulate proliferation in 
adjacent ER/PgR negative cells via paracrine signals through E2-induced genes such as PgR, 
pS2 and genes that encode the growth factor amphiregulin.   Amphiregulin binds to EGFR 
and mediates signaling through intracellular pathways such as MAPK, JAK and STAT to 
stimulate proliferation through Myc, Myb and ETS and cyclin D1 315.  
        Another example of the paracrine/autocrine cross talk was revealed upon examination of 
proliferation rate of lobules in non-tumor bearing women throughout the menstrual cycle. 
The proliferation rate in these women showed a correlation with different satges of the 
menstrual cycle, which the details of this study have been explained below. This study started 
by enrolement of 83 women to this study. Breast tissue samples were collected from these 
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women at different stages of menstrual cycle. Samples were analyzed for the proliferation 
and apoptosis rates. Interestingly there was a sequential cell multiplication (mitosis) and cell 
deletion (apoptosis) during each menstrual cycle (Figure 6). There was a  higher levels of 
mitosis and apoptosis in the second half of menstrual cycle 295. The higher level of mitosis 
and apoptosis at the second half could be due to higher E2 and progesterone level at this half 
of the menstrual cycle (Figure 6). There was a cyclical changes between the mitosis and 
apoptosis throughout the 28-day menstrual cycle. The peak for apoptosis was 3 days after the 
peak for mitosis. Breast, is a target tissue for E2 and progesterone, so the abundance of these 
hormones at the second half of menstrual cycle cause the higher proliferation rate which is 
followed by apoptosis to control the cell number and homeostasis of the tissue. 
 
ERα  AND ITS INTERACTION WITH CELL CYCLE MEMBERS 
        Dearegulated expression of key cell cycle regulators can trigger a cascade of events 
leading to mammary tumorigenesis 312. Both ER receptors have been shown to influence cell 
proliferation and cell cycle. A well established example linking the ERα with the cell cycle is 
through its interaction with cyclin D1 312. Cyclin D1, a key cell cycle regulator, binds to the 
Retinoblastoma protein (Rb), which directs Cdk4 and Cdk6 to Rb, allowing for its efficient 
phosphorylation and resulting in the passage of cells from G1 to the S phase of the cell cycle 
164 (Figure 7). Cyclin D1 is required for normal breast cell proliferation and differentiation 
associated with pregnancy. However, cyclin D1 also have shown to be an important factor in 
the breast cancer development (Figure 7) 316. To evaluate the oncogenic potential of cyclin 
D1, Schmidt et al. generated transgenic mice over expressing cyclin D1, which 
overexpression of cyclin D1 gave rise to the  malignant mammary cell proliferation, which 
end up to the development of mammary adenocarcinomas 317. Additionally, cyclin D1 highly 
express in majority of human breast adenocarcinomas 318, 319. Estrogens can induce the 
expression of cyclin D1 via the binding of the liganded ERα to the cyclin D1 gene promoter 
to activate its transcription 320, 321. When MCF-7 cells were cultured in an E2-free condition 
about 72 hours and restiumulated with E2 and subjected to ChIP assays, results reveated that 
ERα protein binds to a site downstream from the cyclin D gene, important for its 
transactivation 272. Moreover, E2 increased p300 and Forkhead box protein A1 (FoxA1, an 
ERα transcription factor) recruitment to the cyclin D regulatory regions, which prepares the 
  45 
site for transcriptional activation of cyclin D (Figure 7). Furthermore, cyclin D mRNA and 
protein expression levels increase upon ERα, FoxA1 and P300 binding to the promoter while 
cyclin D transcription is disrupted upon downregulation of each of these factors 321.  
        Cyclin A is another key cell cycle regulator, which has been linked to the ER pathway. 
Cyclin A shares several features with cyclin D, such as phosphorylating Rb protein upon 
binding to it. Due to its function in phosphorylating Rb it is normal to expect that the 
modulation in cyclin A expression results in the irregulation of the G1 to S progression 82, 322. 
The phosphorylation of serine residues located at amino acids 104 and 106 of ERα protein 
via cyclin A-Cdk2 complex causes the increase in the transcriptional activity of ER 323. 
Additionally cyclin A over expression leads to increased ER transcriptional activiation 
independent of E2 or TAM treatment 323. 
        Additionally, as shown in Figure 7 ER may influence cell proliferation by direct protein-
protein interactions with regulatory proteins such as p27. p27 is the main inhibitor of the 
cyclin A-Cdk2 complex resulting in the arrest of cells at S phase and activation of apoptosis 
(221).  
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                                     Figure 7: ERα  involvement in cell cycle 
 Role of ERα during different phases of the cell cycle, and identification of interactions 
between ERα and cell cycle elements, such as FoxA1 and Rb during G1 phase and ER 
interaction with p27 during S phase.  
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        ERα is capable of binding to the C terminal region of p27 to sequester it to the 
cytoplasm, which interrupt p27’s inhibitory activity in the cell cycle (Figure 7) 324.  
        Other members of the cell cycle regulatory pathway are also indirectly involved in ER 
function or its regulation. For example, when MCF-7 cells are serum starved and stimulated 
by E2 to reneter the cell cycle, cyclin E-Cdk2 is activated which leads to the phosphorylation 
of the Rb and the progression of the cell cycle from G1 to S phase (Figure 7) 325.  E2 (1nM) 
was sufficient to induce Cdk2-associated histone kinase activity and Rb kinase activity 8 and 
5 fold respectively higher than that in growth-arrested cultures 326. Additionally, levels of 
cyclin D and E, proteins were increased sequentially post E2 treatment of growth-arrested 
MCF-7 cells 325. 
        It has been reported that the E2 mediated transactivation of cyclin D which results in 
overexpression of cyclin D also results in the shift of p21 complexing with cyclin E-Cdk2 to 
cyclin D-Cdk4. The dissociation of p21 from cyclin E-Cdk2, results in the activation of 
cyclin E-Cdk2 complex.  Additionally, association of p21 with cyclin D-Cdk4 has been 
shown to activate this complex as well 325. These results support the notion that E2 can 
manipulate the cell cycle progression and in a bigger picture the proliferation rate of the 
breast cancer cells by modulating the G1 phase cyclin, cyclin D and also regulating the 
activities of G1 cyclin-dependent kinases 325.  
        Another way that E2 can modulate the transition of cells from one phase of the cell 
cycle to the next is by the inhibition of the negative regulators of the cell cycle.   For 
example, E2 can repress Reprimo (RPRM), a cell cycle inhibitor  (Figure 7) 327. RPRM is a 
protein known to be induced following irradiation in a p53-dependent manner. RPRM was 
first identified following a screen of genes induced by x-ray irradiation in wild-type as 
compared to p53-/- MEF cells. RPRM mRNA levels were induced in wild-type MEFs and 
not in p53-/- MEFs following x-ray irradiation 328. Over expression of RPRM in various cell 
lines, including HeLa, MCF7 and mouse NIH3T3 cells resulted in G2 arrest of the cell cycle 
by inhibition of Cdk1 activity and also interfering with the nuclear translocation of the Cdk1-
cyclin B1 complex. In double thymidine synchronized HeLa cells, transduced with RPRM 
adenovirus, resulted in the cytoplasmic accumulation of cyclin B and inhibition of key M 
phase events such as chromosomal condensation. (333, 329-331. Formation of a complex 
between ERα and histone deacetylase 7 and FOXA1 is the necessary first step to inhibit 
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RPRM 327 (Figure7).  FOXA1, protein expression (IHC score greater than 3) in breast 
cancers has been associated with ERα positivity, luminal A subtype and better predictor of 
survival compared to PgR 332. 
        While the examples listed up to this point underscore the importance of E2 in activating 
cell cycle progression, there are also examples of how modulation of E2 leads to inhibitory 
affects on cell cycle.  The genes that are repressed by E2 include genes encoding proteins 
such as CD24, E-cadherin, Breast Cancer And Salivary gland Expressed Gene (BASE), 
Interleukin-6, Insulin Receptor (IR), pRb, ERBB2, vascular endothelial growth factor 
(VEGF), tumor necrosis factor alpha (TNF-α), and CD36 333-340.  Below I have highlighted 
the repressive action of E2 onRb and IL-6. 
        There have been studies that link increased risk for breast cancer in the mothers of 
children suffering from retinoblastoma and osteosarcoma 341. In fact, MCF-7 cells treated 
with 10-9 M E2 for 48 hours lead to decreased expression of Rb protein by 70%, and its 
mRNA by 50% 336.  
        Cytokine interleukin-6 (IL-6), is a key mediator of immune system, and acts as both a 
pro-inflammatory and anti-inflammatory cytokine 342. The role of estrogens on the activity of 
IL-6 were examined in endometrial adenocarcinoma cell line Ishikawa which were treated 
with phorbol esters to induce the activation of the IL-6 promoter 339.  In these experiments 
Ishikawa cells were transfected with IL-6/luciferase in the presence or absence of ER. 
Eighteen-hours post-transfection cells were treated with E2 in the presence or absence of 
phorbol ester. E2 treatment showed an ER-dependent inhibitory effect on IL-6 promoter, an 
affect that was abrogated when mutant ER transcripts were used. These experiments suggest 
that ER requires both its DBD and HBD to repress IL-6 while residing on the IL-6 promoter 
region. Similarly, the direct interaction of ER with the transcription factors NF-IL6 and NF-
kappa B results in their inability to bind DNA, and provides a plausible mechanism by which 
estrogens lead to repression of IL-6 gene expression (344). 
         Another cell cycle related gene that is repressed by E2 is the G1 cyclin called cyclin 
G2. Similar to cyclin E, cyclin G2 expression site is in highly differentiated tissues, such as 
heart, muscle, and brain 343. The function of these cyclins despite the other “established” 
cyclins, which are mainly involved in progression of the cells through cell cycle phases, is 
associated with the inhibition of the cell cycle progression by negatively controlling the cell 
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cycle progression and maintaining the cells in a quiescent state 344. In fact, cyclin G2 was 
identified in microarray analysis as an E2 down-regulated gene in MCF-7 345. Cyclin G2 
mRNA levels are repressed in response to E2 treatment with very rapid kinetics. ChIP assays 
also revealed that E2 treatment results in the recruitment of ER to the cyclin G2 promoter 
region, followed by detachment of the RNA polymerase II detaches, and formation of a 
complex containing N-CoR (Nuclear Receptor Corepressor), and histone deacetylases (i.e. 
HDAC1).  These steps act coordinately to repress the cyclin G2 transcription 346.  Due to 
inhibitory effect of cyclin G on the cell cycle it’s repression, augments the proliferation and 
survival of the tumor 346. The one common modality in transcription repression is the 
recruitment of repressive complexes such as NCoR SMRT (Silencing Mediator of RAR and 
TR), HDAC1 and CtBP1 (C-terminal-binding protein 1) to the promoter region of the target 
gene. 
        TAM-bound ERα associates with the corepressors, NCOR and SMRT, which result in 
the repression of transcription 345. However, silencing of both corepressors (NCOR and 
SMRT) led to TAM induced stimulation of the cell cycle 271. Silencing of NCOR and SMRT 
in MCF-7 cells treated with with E2 or TAM did not alter the activation of the ER target 
genes such as c-myc, cyclin D1 or stromal cell-derived factor 1, however, XBP1 was 
markedly elevated in these cells 271.  Additionally, in MCF-7-derived TAM-resistant cells 
XBP-1 expression was elevated 3 fold compared to the parental cell line 347. What is missing 
from these studies is role for XBP-1 in E2- or TAM-mediated cell proliferation. These 
examples suggest that in breast cancer cells NCOR and SMRT prevent TAM from 
stimulating proliferation through repression of XBP-1.  
        The role of ER in the G2/M phase of the cell cycle has not been explored as thoroughly 
as its role in G1 phase, which as discussed is the mediator of cell proliferation.  However, 
there are several studies, which show that there might be link between the ER-E2 pathway 
and G2/M phase.  The key regulator of the G2/M transition is the cyclin B-Cdk1 complex, 
which resides as an active complex until initiation of metaphase. In order for proliferating 
cells to enter into anaphase, cyclin B needs to be degraded via the APC 202. Mitotic Arrest 
Deficient 2 (MAD2) protein, which interacts with APC, is one of the kinetochore proteins 
present on the chromosomes during cell division and is involved in the attachment of the  
chromosomes to the mitotic spindle upon anaphase onset. MAD2 inhibits the activity of 
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APC, which results in the blockade of anaphase. ERβ interacts directly with MAD2 and 
increases MAD2’s activity.  Moreover, the ERβ/MAD2 complex helps to correct 
chromosome orientation in the mitotic spindle through binding of MAD2 to the kinetochores 
348.  These studies suggest that ERβ possesses an ability to delay cell division and activate 
apoptosis. So based on the ERβ and MAD2 relationship and the opposite activities of ERα 
and ERβ, one can conclude that ERβ could have an inhibitory effect on the cell cycle during 
G2/M, by regulation of chromosomes attachment to the mitotic spindle prior to anaphase 
entery. The studies described in the following chapters of my thesis have interrogated the 
effects of ERα on G2/M phase and reveal that ERα hastens the passage of cells from S and 
G2/M by upregulating ER target genes, which result in increased proliferation. Based on the 
disparate roles of ERα and ERß, one can predict that while ERα leads to the rapid 
progression of cells from S and G2/M, that ERß may result in the slowing down of the G2/M 
transition.  
        There have been also been reports providing evidence for cross talk between ERα and 
cyclin B.  In one study aimed at examining how RanBP-type and C3HC4-type zinc finger-
containing protein 1 (RBCK1), a protein kinase C1 (PKC1) interacting protein, result in the 
progression of cell cycle by driving the transcription of both ERα and cyclin B1 in ER-
positive breast cancer cells 349, ChIP analysis on parental MCF-7 cells revealed that RBCK1 
is recruited to the major ERα promoter region, which results in induction of ERα mRNA 
levels. No RBCK1 was detected on the cyclin B promoter.  However, when RBCK1 was 
silenced, both both ERα and cyclin B mRNA and protein levels were reduced and cells were 
arrested in the G2 phase.  Addition of cyclin B, but not ERα, released the cells from G2 
arrest. This study connects both ERα and cyclin B to the progression of cell cycle. The 
importance of cyclin B for the cell cycle progression is not a new concept while the 
connection of ERα to the cell cycle progression is new and supports our observation in this 
study. 
 
ERα  LOCALIZATION  
        ERs are classically viewed as nuclear receptors, and reside in the cytoplasm in the 
absence of ligand. Heat shock protein 90 (HSP90) is the chaperone protein binding to 
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unliganded ER in the cytoplasm (54). Ligand binding triggers a conformational change and 
the subsequent translocation of the receptor into the nucleus where it functions 
transcriptionally. There have been reports suggesting that ERα is also localized to the 
cytoplasm and cell plasma membrane 223, 350. The studies were initiated by 
immunofluorescence staining which detected ER in the cytoplasm 350. Others have shown 
that the cytoplasmic ER has non-genomic functions  (Figure 4) 186, 351. ER localization to the 
nucleus versus cytoplasm could explain, at least in part, the possibility of existence of 
multiple complimentary and overlapping mechanisms that might be working to influence 
ERα interactions in the cell. Membrane-associated ERα is G-protein linked and E2 binding 
to ER has been shown to activate many signal transduction pathways that emanate from G-
protein activation, such as MAPK and PI3K pathways as shown in Figure 4 352. Although the 
ERα that resides in the cell is localized to different regions and mechanistically be different 
(signaling versus transcriptional transactivation), the cell biological roles are likely to overlap 
or be complementary 225, 353-355. For example E2 bound ERα can rapidly activate MAPK in 
breast cancer cells. MAPK activation involves the phosphorylation of Shc (Src-homology 
and collagen homology), which in turn results in Shc-Grb2 (growth factor receotor protein-
2)-Sos (son of sevenless) complex formation in MCF-7. The biological consequence of the 
activation of the down stream proteins in the MAPK pathway is the transcriptional activation 
of ERE (Estrogen Response Element) and SRE (Serum Response Element), which results in 
a higher proliferation rate of the cells 225.  
        Even though these studies support the presence of a functional ERα in the plasma 
membrane, other groups, suggest that the ERα present in the cell membrane is not the full 
length protein, but the amino-terminal truncated product (ER46) of full length ERα (ER66), 
which is detectable by the ERα antibody and capable of transducing E2-triggered signaling 
(Figure 4,5) 207. For these studies ER46 was stably overexpressed in immortalized human 
endothelial cells (EA.hy926), cells were separated into subcellular fractions, and the 
expression of ER was monitored in each cytosolic fraction. The results revealed that ER46 is 
found in the plasma membranes, and the components (Figure 8) 207.  ER46 is devoid of the 
N-terminus, which contains the A and B domain (AF-1) of ERα protein. ER46 is capable of 
binding to ER66 and forming heterodimers in order to activate the estrogenic response. 
Additionally, upon binding to ER66, ER46 serves as a competitive inhibitor of ER66 for 
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DNA binding. However since ER46 is missing the AF-1 domain it can only function as a 
competitive inhibitor when transactivation is mediated through the AF-1 domain 280, 356, 357.                 
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                                       Figure 8: ERα  localization in the cell   
ERα is primarily located in the nucleus. However, a fraction of the ERα is localized to the 
plasma membrane region, which mediates signal transduction in a non-genomic manner. 
There are other studies showing the presence of functional ERα in the cytoplasm, 
endoplasmic reticulum, mitochondria and microsomes. The precise structural features and 
different actions of ERα that result from the different localization of this protein have not 
been determined. 
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To this end a a series of cotransfection experiments of ERα66 and ERα46 with 
different ratios were performed in HeLa and the HepG2.  These cell lines were ideal for these 
experiments since they are very specific in the manner in which ER transactiation occurs. In 
Hela cells the ERα transactivation is mainly through the AF-2 domian while in HepG2 ERα 
signaling is dominant through the AF-1 domain 358-360. The results revealed that while ERα46 
is a potent competitive inhibitor of ERα66 in HEPG2 cells resulting in the complete 
suppression of ERα66 activity, that in HeLa cells ERα46 did not inhibit the transactivation 
of ERα66 280.  
        The differential localization of ERα could also be organ and gender dependent. For 
example in uterine Syrian hamster myometrium (SHM) cells ER is mainly perinuclear 361. 
SHM cells are primary uterine leiomyosarcoma cells, which are stimulated by both chronic 
E2 and androgen treatment. In lung adenocarcinomas, whether the cells are derived from a 
female (H1793) or a male patient (A549), the localization of ER is changed 362. Both cell 
types have equal ER expression howover the H1793 and not the A549 cells respond to E2 by 
transcriptionally activating proliferative genes. When both cell lines are cultured in the 
presence of E2, only in H1793 but not A549 cells, the phospho-serine-118-ERα is increased 
concommitatnly with cyclin D-both in the nucleus as measured by dual-label 
immunofluorescence staining and fractionation. These experiments, in just one pair of cell 
lines do provide evidence supporting the gender dependent localization of ER. It is important 
to note that the addition of E2 in H1793 activates the non-genomic activities of ER through 
MAPK signaling, which could be responsible for the sex-dependent differences in the 
incidence of lung adenocarcinoma. Additionally, since there is a two fold higher risk of lung 
cancer in females as compared to males, one can propose that there may be ER mediated sex-
dependent factors, which could cause the differences in the etiology of lung cancer 363. 
        In addition to the nuclear, perinuclear, cytoplasmic and memberane localization of ER, 
there is evidence ERα also localizes to the nuclear matrix complex 364. These studies show 
that 16α-hydroxyestrone, a natural metabolite of E2, is able to interact with ERα covalently 
sequestering to the complex to the nuclear matrix as performed by frationiation, which 
followed by the analysis of the samples via western blot on treated MCF-7 cells (Figure 9). 
The levels of 16α-hydroxyestrone metabolite of E2 was also measured in 10 normal and 33 
breast cancer patients and the results revealed that the level is higher in breast cancer 
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patients, which is statistically significant (14.9%) compared to normal women (9%) 365, 366. 
Additionally in patients with breast cancer and the high-risk women, the enzyme involved in 
formation of 16α-hydroxyestrone from E2 (estrogen 16 alpha-hydroxylase) is shown to be at 
higher level compared to normal women.   
        The translocation of ER by pharmacological agents has also been examined to assess if 
the signaling of ER either through its genomic or non-genomic pathways is altered. To this 
end, several different cell lines from different tissues, COS-7 (monkey kidney-derived cell 
line), Mouse osteoblastic cell line, which is called MC3T3-E1 and MCF-7 cells all were 
transfected with ERα-GFP. Upon ERα-GFP transfection cells were treated with either E2 or 
Raloxifene (RLX), a SERM and ER localization was monitored microscopically. The results 
showed that in 80% of both E2 and RLX-treated MCF-7 cells there was nucleolar 
translocation of ERα. The transcriptional activity of ERα was also examined under E2 and 
RLX treated conditions in ERE-Luciferase and ERα transfected cells.  The results revealed 
that in contrast to E2 treated MCF-7 cells, RLX treated cells show an inhibition of the ERα 
mediated transcriptional activity 367. Overall the results here show that RLX induces its 
inhibitory effect on the growth of mammary gland cells by inducing the nucleoli 
translocation of ERα. 
        ERß is also subject to multiple cellular localization. ERß is localized to the 
mitochondria and co-localizes almost exclusively with a mitochondrial marker (MitoTracker 
Red) in rat primary neurons, primary cardiomyocytes, and a murine hippocampal cell line. 
Microscopically, the ERβ staining was distributed predominantly in the cytosol in a 
punctuate form similar to that of the MitoTracker Red staining. To examine the response of 
ERß to ligand, the primary cardiomyocytes were cultured in an E2 containing media 
followed by western blot analysis with ERß and MnSOD (mitochondrial marker) and Histone 
H1 (a nuclear marker).  The results revealed that in response to the ligand, ERß did not 
translocate to the nucleus 368.  
        ERß has also been detected in mitochondria as a protection against apoptosis.  When 
C2C12 cells (murine skeletal muscle cell line) were treated with E2 (10–8 M) for 45 minutes 
prior to the apoptotic stimulus of H2O2, apoptosis (as measured by staining for nuclear and 
DNA fragmention) was decreased significantly as compared to non E2 treated cells-from 
73% in the absence of E2 to 8% apoptosis in the presence of E2 369. Analysis of the apoptotic 
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pathways revealed that the phosphorylation of BAD and PI3K/AKT signaling activation has 
been modulated in response to E2.  Western blot analysis revealed that while there was no 
change in phosphorylation of Akt upon treatment with only H2O2 that the E2 pre-treated cells 
showed an increase in AKT phosphorylation. Additionally in the presence of H2O2 
phosphorylation of BAD was not observed, while E2 pre-treated group showed 
phosphorylation of BAD (376). Collectively, this data suggests that the mitogenic effect of 
E2 is partly due to the anti-apoptotic action of ERβ-E2 in the mitochondria 370. 
        Studies on the binding affinities of estrogens in different normal tissues and tumor cell 
lines have revealed that a population of estrogen-binding sites have been observed in the 
microsomes in the uterine and anterior pituitary cells of rat 371 372. When purified microsomal 
portions of the anterior pituitary as well as the uterine were compared to MCF-7 cells, the 
results showed that the normal tissues had equivalent high affinity binding estrogen sites as 
those in breast tumor cells 371 372. Other tissues, such as lung and diaphragm from adult 
female rats showed that these organs were devoid of specific microsomal E2 binding sites. 
The nature of the microsomal binding moieties with high affinity for E2 was examined by 
treating the microsomes with different detergents that can degrade either DNA, RNA or 
protein. These studies revealed that the E2 binding to these moieties is sensitive to pronase 
(proteinase), but not to ribonuclease or deoxyribonuclease, suggesting that neither RNA nor 
DNA are involved in the microsomal E2 binding. The main macro-molecules that are 
involved in the E2 binding affinity in the microsomes are proteins 371 372.  The function of the 
microsomal-protein with high affinity for E2 has not been examined, however one can 
speculate that microsome binding to E2 can provide another pathway for the activation of the 
non-genomic functions of ER in the cytoplasm.  
        The localization of the different male and female sex steroid hormone receptors have 
also been examined in the normal human mammary gland. The localization of ERα, ERβ, 
Progesterone Receptor A (PgRA), Progesterone Receptor B (PgRB) and Androgen Receptor 
(AR) on samples derived from reduction mammoplasty tissue of 17 premenopausal women 
have been determined by IHC 373. The results revealed that all steroid receptors examined 
were mainly localized in: 1) The inner layer acini lining (epithelial cells) 2) Intra lobular 
ducts (epithelial cells) 3) The external layer of interlobular ducts (myoepithelial cells) 4) 
Stromal cells. However, ERβ is the most widespread steroid receptor and was also detected 
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in epithelial cells and myoepithelial cells of acini and ducts as well as stromal cells. It is 
highly possible that the direct or indirect interaction of steroid hormones on epithelial and 
stromal cells in human mammary gland affects both the normal function and/or malignant 
function of the steroid receptors in the breast.  
 
E2 METABOLISM, STRUCTURE AND FUNCTION 
        In addition to ovaries, which are the main source for estrogen production, there are other 
tissues in the body such as: 1) Ovarian granulose cells, 2) Brain ,3) Adipose/skin fibroblasts, 
4) Bone 5) Placental syncytiotrophoblast,, that can synthesize estrogens from androgens. 374. 
What all these tissues/organs have in common is the enzyme (aromatase), which is involved 
in androgen conversion to estrogen. Aromatase is an estrogen synthase, which is categorized 
as a cytochrome P450 enzyme (CYP19). The C18 estrogens synthesizes from C19 androgens 
via the activity of CYP19 enzyme 375. Follicle-stimulating hormone (FSH) induces the 
formation of P450-aromatase through formation of cyclic AMP and its regulation is 
transcriptional 376 377.  
        It is thought that differential pattern of distribution of fat in men versus women is due to 
the different concentrations of CYP19 enzyme distribution in different organs. Measurement 
of the aromatase activity by [1β-3H]-androstenedione in abdominal subcutaneous (Sc) 
adipose tissue from male and female patients revealed that, aromatase activity increases in 
females from 11.5 to 28.0 pmol/mg·h by 10-6 M cortisol. However aromatase activity is 
inhibited in males from 19.4 pmol/mg·h to 7.5 by 10-6 M cortisol. Western blot analysis using 
an antibody against the aromatase enzyme (CYP19) confirmed the enzymatic results. Since 
the level and activity of CYP19 in tissues generates estrogen which can induce preadipocyte 
cell proliferation, it suggests that, CYP19 can regulate adipose tissue mass and its 
distribution differently in men and women 378.  
        To understand the role of CYP19 in generating estrogen, one needs to understand the 
estrogen metabolic pathway, schematically presented in Figure 9. There are three  
metabolites of estrogens - E1, E2 and E3.  E1 (estron) is the least powerful and most 
abundant, which accounts for 80-90% of human estrogen in the body. E2 (estradiol) is the 
most powerful and most carcinogenic (17-ß estradiol and 4-hydroxy-17-ß estradiol induce 
oxidative damage and are carcinogenic). E2 is mainly produced by the ovaries in non-
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pregnant females, and breaks down to estrone in the liver 374. E3 (estriol) has similar 
properties to E2 but is considerably less biologically active. Estriol is also the primary 
estrogen during pregnancy (week 20 to 40) 379.           
        First through a17ß oxidation activity E2 converts to estrone, which this conversion is 
reversible. Then the next step is the irreversible conversion of estrone to 2-hydroxyestrone or 
16alpha-hydroxyestrone through an oxidation process. As the figure 9 shows 2-
hydroxyestrone and 16alpha-hydroxyestrone are the initial metabolites formed 380.  
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Figure 9: Estrogen Metabolism380     
 2-hydroxyestrone and 16alpha-hydroxyestrone are the two starting products that initiate the 
two dominant pathways for estrogen metabolism. The ratio of estriol to estrone, which gives 
rise to these metabolites, varies in women.  It is thought that the imbalance between their 
ratios is associated with an increased risk for breast cancer. 
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        The balance between the two converted metabolites from E2 is a very important 
phenomenon. Alteration of the balance between 2-hydroxyestrone and 16alpha-
hydroxyestrone could be the reason for the proposed risks of certain pesticides, herbicides, 
plastics, and other xenoestrogens (foreign estrogens) for breast cancer incidence 365, 381. In 
fact, 16alpha-hydroxyestrone is elevated in C3H mouse strain, assoicated with high tumor 
incidence, while its levels are lower in   C57BL mice, associated with low tumor incidence.  
Cross-breeding between the two mice results in progeny who had inherited estradiol 16 
alpha-hydroxylase as an autosomal dominant resulting in tumor incidence similar ot the C3H 
mice 382. 
        Unlike 16alpha-hydroxyestrone ,2-hydroxyestrone is a very weak estrogen. The affinity 
of 2-hydroxyestrone to 2-hydroxyestradiol for binding to cytosolic ER is also different.  2-
hydroxyestradiol has twice the affinity for tumor cytosol receptors in 
dimethylbenzanthracene (DMBA)-induced rat mammary tumors as compared to 2-
hydroxyestrone. Additionally, 2-hydroxyestradiol, but not 2-hydroxyestrone, can translocate 
tumor cytosol ER to the nucleus 383. The levels of these two estrogen metabolites are also 
different in human breast tumors. 16alpha-hydroxyestrone is five times more active in urine 
of patients with breast cancer compared to women without cancer 380.  
        Early on, it was discovered that the disruption of the aromatase gene could have dire 
consequences on disease development including cancer. The generation of the aromatase 
knockout mouse (ArKO) revealed that the resultant female mice had pubertal failure, cystic 
ovaries, hypergonadotropic hypogonadism, virilization (the development of male physical 
characteristics), , delayed bone age, which could be the reason behind tall stature phenotype 
384.   Female ArKO mice showed an undeveloped external genitalia and uteri at 9 weeks. 
ArKO mice also showed numerous follicles with abundant granulosa cells in the ovaries due 
to the arrested antrum formation. However, aromatase deficiency in male mice does not have 
any remarkable effect in childhood development except that aromatase deficient male mice 
show a tall staure due to the continued linear bone growth throughout puberty, which is due 
to the failure of epiphyseal closure in these mice. Aromatase deficient male mice also show 
osteopenia (delayed bone age). In the male ArKO mice there was evidence of enlarged male 
accessory sex glands wihtout affecting their fertility (391). 
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        A very limited number of human cases (six females and three males) with aromatase 
deficiency have been reported, which these cases show mutations in the CYP19 gene. The 
mutations observed include: 1) two single base changes in the coding region of the P450 
gene [C to T mutation at the base pair 1303 and G to A mutation at the base pair 1310], 
resulting in codon changes of R435C and C437Y, respectively; 2) insertion of 87 base pairs, 
which the insertion encodes the aminoacids which are located from exon 6 to intron 6 of the 
normal aromatase gene with no termination codon 385-387. These mutations highlighted the 
importance that estrogen effect has on the height (due to its role in epiphyses) and male bone 
density 388-390. The absence of aromatase activity also causes androgen accumulation, which 
inturn results in virilization of the female at birth (males are not affected) 386 and if the 
deficiency occurs in in the placenta of pregnant mother it can result in the virilization of 
mother 385. Absence of aromatase activity in female causes amenorrhea 391. Both female and 
male individuals lacking estrogen show a tall stature due to the failure of estrogen function to 
close the distal ends of the bones 388.  
 
E2 IN BRAIN 
        E2 is not only involved in the regulation of function of reproductive tissues but is also 
important in other organs such as the brain. E2 is critical for neuronal plasticity and 
protection of neurons in the hippocampus and prefrontal cortex, both of which are involved 
in the explicit and working memory 392. The role of E2 in female brain has been the topic of 
several studies and the implication is that E2 increases the functioning of this major organ.  
The studies examining the role of E2 included post menopaual women (46) who were treated 
with E2 (2 rounds) over a 3 weak period, at which point brain activation patterns using MRI 
were performed and showed that treatment with E2 increased activation in the inferior 
parietal lobule, the area in the brain critical for storage of verbal material 393.   Other studies 
concluded that E2 is a key element for learning and memory in women, and that the 
cognitive decline and age-related dementia in women could be due to the decline of E2 
synthesis 394. One key unanswered question is what are the brain specific consequences of 
endocrine therapy in breast cancer patients. One could speculate that endocrine therapy could 
result in the lack of E2 availibility to the nervous system resulting in lethargy, a common side 
affect of this therapy.  
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ENVIRONMENTAL E2 
        During the last several years, scientists have learned that new synthetic products and 
materials not only have brought more convenience to our lives but have also been a detriment 
to the environment by releasing of chemicals with hormone-like effects. For example, 
nonylphenol, used in plastics manufacturing, which can be released from plastic  has 
estrogenic activity. To examine the carcinogenic functions of nonylphenol, it was extracted 
from plastic products, purified by HPLC and used to treat MCF-7 cells. Nonylphenol treated 
MCF-7 cells resulted in higher rate of cell proliferation and an increase in ERE 
transcriptional activity, which upregulated PgR. Nonylphenol also triggered endometrial 
mitotic activity in the rat endometrium 395.  Bisphenol-A (BPA) is another compound with 
estrogenic activity released from plastic in high temperatures 396.  MCF-7 treated with BPA 
had increased PgR expression higher rate of prolifearation. 
        Pesticides also release metabolites with estrogenic activity including 
 dichloodiphenyltrichloroethane (DDT) and dichlorodiphenyldichloroethylene (DDE). 
Exposure to DDT early in life increases breast cancer risk. A prospective study of young 
women who were exposed to DDT and DDE using using blood samples obtained during 
1959-1967 revelaed that women who were heavily exposed to DTT in young age contained a 
high levels of serum DDT, which the high DTT serum level predicted a 5 fold higher breast 
cancer risk 397-399.  
        The impact of the environmental contamination with these man-made products (i.e. 
plastic, DDT, pestisides) is vast and affects both men and women. For example, low sperm 
counts were found in workers in a plant producing Kepone containing DDT 400 and feminized 
male fish were found near sewage outlets which contain Alkyls phenols, a product of 
degradation of detergents during sewage treatments 401. The use of DDT was banned in 
the1970s and 1980s in most of the developed countries. However there are different products 
in our daily use at the present time that has been found to be a health hazard such as BPA in 
plastic products. BPA has been found in the content of canned food due to the polycarbonate 
lining in the can placed to isolate the food content of the can from the aluminium 402.  
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ERα  TURN OVER 
        The ubiquitin-proteasome pathway is the major route for the degradation of the short- 
lived regulatory proteins in eukaryotes. Protein degradation through the proteasome pathway 
requires the ubiquitination of the targeted protein for degradation. The binding is covalent. 
Ubiquitin is a highly conserved 8.6 kDa protein, which binds to the lysine residue of the 
targeted protein for degradation 403, 404.   
        Ubiquitination involves three classes of enzymes, E1, E2 and E3. E1 (UBA) is the 
ubiquitin activating enzyme. E1 activity requires ATP. The ATP dependent function of E1 
results in a thioester bond between the cysteine residue of E1 with the carboxyl-terminal 
(glycine residue) of UBC.  E2 (UBC) is the ubiquitin conjugating enzyme, which receives the 
ubiquitin from the UBA. Unlike E1, there are several E2 enzymes, which are all involved in 
the transfer of ubiquitin from E1 to E3.  E3 is the ubiquitin protein ligase, which is 
specifically is involved in the transfer of the ubiquitin (from E2) to the specified target 
protein 403-408. More than 35 UBCs and more than 100 E3 ligase enzymes have been 
identified to date 409, 410.  
        One example of how a cell cycle protein is degraded through the ubiquitin pathway is 
cyclin B. Proteasomal degradation of cyclin B at the end of mitosis requires the formation of 
ubiquitin-cyclin B conjugates as a sequential action of E1, E2 and E3 411. The initial studies 
used the clam oocyte system 412, where M phase extracts  were fractioniateded and separated 
by high speed centrifugation. One band was the result of fusion of cyclin B to  E1 enzyme. 
The other fraction was the n-terminal portion of cyclin B bound to ubiquitin. This fragment 
was only found in the extracts harvested from the M phase of the cell cycle and not found in 
The G2 extracts. They also found a novel species of E2, which they called it E2-C. E2-C is 
“specifically” involved in the ligation of ubiquitin to cyclin B (419). The E3 ligase that is 
involved in the cyclin B degradation is APC, consisting of a group of subunits such as Cdc20 
and Cdh1 413, 414.  
        Ubiquitination of proteins prepares them for degradation. However, the protein 
degradation is not the only fate of the ubiquitinated proteins. In some cases, ubiquitination 
may serve a regulatory function by redirecting the sub cellular localization of the 
ubiquitinated protein 405, 415.  
        For example, IκBα activates the transcription factor NF-κB by phosphorylation, at 
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which point IκBα is targeted for degradation. The degradation of IκBα is depends on the 
phosphorylation of IκBα on serine residues 32 and 36, which then targets this protein to the 
proteasome pathway. The kinase that phosphorylates IκBα requires ubiquitination too and is 
a pre-requisite for specific phosphorylation of IκBα. Thus, ubiquitination serves a novel 
regulatory function that does not always result in proteolysis.  
        The degradation of ERα is also through the ubiquitin-proteasome pathway and occurs in 
an E2-dependent fashion 416. Following transcriptional activation of ERα by E2 it is targeted 
for degrades through proteasome pathway. In the original study documenting ER mediated 
proteasome degradation, HeLa cells were transfected with both ERα and an ERE-luciferase 
reporter construct. Following transfections the cells were treated with E2 and and MG132 
(proteasome inhibitor), at which point they were subjected to luciferase assay.  The results 
revealed that ERα protein levels were decreased (i.e. degraded) upon E2-stimulated 
transactiovation while in control (not treated with E2) ERα remained intact. Additionally 
MG132 treatment attenuated luciferase activity while in untreated cells (with E2 present) 
luciferase activity was high. This study provided the first evidence that the ubiquitin-
proteasome dependent degradation of ERα requires ligand binding and regulates 
transcription at ERE sites (423, 311). Additionally, ERα coactivators (SRC-1, SRC-2 or 
CBP) are also subject to degradation through the proteasome pathway, contributing to ERα 
transcriptional activity 416.  
        Other groups have also shown that SRC3, one of the most well studied coactivators of 
ERα, degrades through proteosome pathway 417. They suggest that the basic helix-loop-helix 
(bHLH) domain on SRC3 contains a bipartite nuclear localization signal domain. These 
residues (K17 and R18) are required for the turn over (proteasome dependent) and nuclear 
localization and also regulation of SRC3 transcriptional coactivator capacity 417.  
        The studies showing the importance of E2 in the stability of ER dates back to the 1970s 
when Gorski et al. revealed that the half-life of the mammalian ER in the absence of 
hormone is almost five days. However, in the presence of E2, the half life of ER dramatically 
declines to one hour 418. For these studies cells (which ones) were treated with cycloheximide 
for different time intervals to block protein synthesis and an E2 binding assay was used to 
estimate the turnover of ER.  In other studies E2 treatment of ovariectomized rats resulted in 
a 60% drop in the ER levels in uterine tissue 419. While these studies all show that ligand 
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binding to ERα is a requirement for the turn over of ERα, others provide evidence that 
unliganded ERα is also capable of degradation through proteasome pathway. To this end, 
Hela cells were used to purify the ubiquitin ligase complex for unliganded ERα, by using the 
(GST)-fused LBD domain of ERα in the presence or absence of E2 as the bait. The protein 
products were then subjected to SDS–PAGE, and peptide mass fingerprinting which 
identified a 35 kDa protein, carboxyl terminus of Hsc70-interacting protein (CHIP). 
Hsp/Hsc70 itself, is a 70 kDa chaperone protein 420. CHIP is an E3 ubiquitin ligase, which 
can specifically bind to unliganded ERα and conjugate it to ubiquitin 421-424. The ability of 
CHIP to degrade wild-type ERα was compared to ERα (HE82), which has no ability to bind 
to DNA due to three amino-acid substitutions in the DNA-binding region 425. These studies 
revealed that ERα (HE82) gets degraded by CHIP, while ligand binding of wild-type ERα 
causes the dissociation of CHIP from ERα.  These results suggested that the CHIP-dependent 
degradation is specific for unliganded and misfolded ER proteins 426.  These results also 
highlight that the turnover of ERα is regulated by two independent ubiquitin-proteasome 
pathways. One pathway is necessary for the transactivation of ERα and the other pathway is 
involved in the quality control of ERα (433).  
        Even though many studies suggest that ERα down regulation is essential to ERα 
transcriptional activity 416, 433, 434), there are other studies, which provide an alternate view. 
For example, in studies aimed to examine the dependency of ERα transcriptional activity to 
its degradation revealed that proteasomal degradation of ERα is not always necessary for its 
transcriptional activity. In this study HeLa cells were transfected with ERα and ERE-pS2-
Luc and then blocked either ubiquitination (cotransfection of Hela cells with construct 
expressing the mutant Ubc12 (pcDNA-Ubc12C111S) or proteasomal degradation (addition 
of MG132). The results show that both ways of inhibition of ER degradation markedly 
increased E2-induced ER transactivation at ERE. When this experiment was repeated in 
MCF-7 cells with endogenous ERα, similar conclusions were reached since an increase in 
PgR (an endogenous target of ER transactivation at ERE) levels were observed 427. 
        There are several signaling pathways that can affect the faith of ERα in the cell either 
through proteasomal degradation or stabilizing the ER protein 380.   One example is the 
Glycogen Synthase Kinase-3 (GSK3) which phosphorylates ERα on Ser-118 in an E2-
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induced fashion and results in increased ERα transcriptional activity and also stabilizes ERα 
by protecting it from proteasomal degradation 428. When GSK-3α and GSK-3β were silenced 
in MCF-7 cells it resulted in a modest (35%) of ER protein in the absence of E2, while E2 
treatment of the GSK-3/ß silenced cells resulted in a pronounced downregulation of ER 
protein (90%).  In control MCF-7 cells, E2 treatment resulted in only a 50% decrease of ER 
protein level. GSK-3 silencing results in the increased proteasomal degradation of ER. as 
analyzed by CHX treatment. Collectively, these results suggest that GSK-3 phosphorylates 
ERα, protecting it from from degradation through proteasome, allowing enough stable ERα 
in the cells to continiously initiate the transcriptional activation at ERE 429-432.  
 
ERα  AND BREAST CANCER 
        Steroid receptor expression is strictly regulated in the normal mammary gland, but not 
in malignant tumors. Increased ERα expression appears early in the pre-malignant to 
malignant progression, as it is detectable in ductal hyperplasia 7. Elevated levels of ERα are 
detected in two thirds of all breast cancers as compared to the normal adjacent tissue. Tumor 
formation and metastasis rise due to imbalance between mammary epithelial proliferation 
and death (apoptosis)  433.  ER participates in different stages of tumorigenesis and is 
associated with uncontrolled cell proliferation and low apoptotic potential of the cells (176). 
ERα is therefore a positive prognostic marker in breast cancer, and consequently breast 
cancers that are positive for ER are generally well differentiated, have low rates of 
proliferation and respond well to anti-estrogens.  ER-negative breast tumors on the other 
hand are poorly differentiated, have a deregulated signaling pathway, higher proliferation 
rate and do not respond to anti-estrogens. 8.   
        ERα knock down (ERKO) mice have helped to shed light on mammary gland 
development and tumorigenesis. The mammary glands in ERKO mice can form tumors 
despite the absence of ER following the introduction of oncogene, wnt-1. Wnt-1 MMTV 
transgenic (TG) mice were engineered to produce the secretory glycoprotein, Wnt-1, 
resulting in the development of mammary hyperplasia and neoplasia. ERKO mice were then 
crossed with Wnt-1 TG mice to examine the oncogenic potential of Wnt-1 transgene in the 
absence of ERα. The results revealed that Wnt-1 TG/ERKO mice were capable of forming 
tumors, suggesting that at least in this mouse model system, ERα is not required for 
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oncogenesis 434. Addition of E2 to this system results in an accelerated tumor formation. E2 
was administered using the “Clamp” method which consists of small silastic tubes filled with 
E2/cholesterol mixtures at various levels: those representing postmenopausal level of E2 in 
women (5 and 10 pg/mL), representing E2 at early follicular phase in women (80 pg/mL) and 
representing E2 at midluteal phase in women (240 pg/mL). The implants containing the 
hormones surgically placed under skin of the back of the mice. The implants were changed 
every other months. The results showed that E2 at the levels of follicular and midluteal phase 
levels accelerated tumor formation ERKO/Wnt-1 animals. Consequently, when 
oophorectomy was performed or when these mice were treated by an aromatase inhibitor 
(Letrozole) delayed tumor development occurred 435.  
        The results of both in vivo studies suggest an ER-independent action of E2, which can 
influence breast tumor development in mice. Additionally, based on the results of my own 
project, described in subsequent chapters of this thesis, I suggest that even though ER has a 
key role in the development of reproductive tissue that it is not a strong driver of mammary 
hyperplasia-instead E2 is more effective. As such, I suggest that the blocking of E2 synthesis 
would be a more effective approach to prevent breast cancer rather than the current 
treatments such as antiestrogens, which only block ER-mediated effects. There are several 
epidemiological studies that also illustrate the importance of E2 as a key contributing factor 
to initiation and progression of breast cancer. E2 administration in various animal models 
results in breast cancer. The key study was performed in a DMBA treated rat model.  In this 
experiment 63 female Sprague-Dawley rats were randomized into the following groups 1) no 
treatment 2) oophorectomy and 3) TAM, 10 mg/kg/week 2 weeks prior DMBA treatment. 
All animals received 20 mg DMBA. At the end of the 16 weeks post treatment, 78% of the 
untreated rats developed tumors, while only 22% of TAM treated rats developed tumors. 
However, none of the rats in the oophorectomy group developed tumors 436, 437.  
        The role of E2 in human cancer development has also been investigatod. For example, 
exogenous E2 in the form of contraceptive pills and hormone replacement therapy have been 
linked to higher cancer incidence in women 438. Alternatively, oophorectomy before age 35 
reduces the risk of breast cancer by 75% 439, 440. Additionally, high levels of circulating E2 
due to obesity and long-term hormone replacement therapy are also factors associated with a 
higher risk of breast cancer incidence. A prospective cohort study within 11,508 women, who 
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had a hysterectomy and reported information on E2 use at baseline in 1980 and follwed for 
22 years (cohort 28,835) revealed a high incidence (30% increase) of invasive breast cancer 
in women being exposed to E2 versus those who did not take E2 in any form 441-444. 
        The mechanisms by which E2 acts as a driver of oncogenesis, while studied extensively, 
still remains controversial. The most commonly proposed hypothesis is that cell proliferation 
is being stimulated upon ligand (E2) binding of ERα 445. During each round of cell cycle 
despite the tight checkpoint and restriction points there are still chances of error. These errors 
could result in point mutations, which accumulate over time and give rise to neoplastic 
transformation 446, 447. These sequential events rush the cell through transcriptions in which 
the DNA fidality has not been preserved due to the mutations during the replication, coupled 
with the inability of the DNA repair mechanism to repair mutation due to the rapid passage 
of the cells through cell cycle mediated by E2. The incidence of both ER-positive and ER-
negative breast cancers abolish upon ovarectomyThis observation suggest that ovarian 
hormones are also important for the initiation and progression of the ER-negative breast 
cancers 448.  
        The model system used to examine the role of E2 in tumor formation was the human 
xenograft HMLE-Rashi cells which were injected in both pregnant and nulliparous female 
mice 449, 450. HMLE-Rashi mammary tumors formed with high efficiency in mice injected 
following pregnancy and also in nulliparous mice. However the difference between these two 
groups was that the tumors developed in pregnant mice 2 to 4 weeks before their nulliparous 
counterparts. When a weaker version of the oncogenic cells, the HMLE-Raslo cells were 
injected in both pregnant and nulliparous mice they found that preganat mice formed 
palpable mammary tumors within 8 weeks while nulliparous mice did not form any 
mammary gland tumors and only formed benign epithelial structures in their mammary 
glands 448. Examination of the stromalization of the tumors formed in HMLE-Rashi and 
HMLE-Raslo pregnant and nulliparous mice revealed that tumors in mice injected with both 
HMLE-Raslo and HMLE-Rashi following pregnancy included a large proportion (44%) of 
stromal cells within the tumor tissue while this percentage was 9% in the nulliparous mice 
448.  
        E2 has also been implicated as a ligand for other receptors besides ER. The G protein-
coupled receptor (GPR30) is a candidate receptor, which binds to E2 yet differs from classic 
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ERs. The role of GPR30 in ER-positive breast cancer remains unclear; however, it is known 
that GPR30 can mediate nongenomic signaling. GPR30 is involved in early response to E2, 
which results in transactivation of EGFR, activation of MAPK and PI3K signaling pathways 
(Figure 4) 352, 451. GPR30 can also modulate proliferation and tumor progression in hormone-
dependent tumors such as endometrial, ovarian and breast cancer tumors. For example, the 
ability of E2 and G-1 (GPR30 ligand) to activate transcriptional activity of c-fos by ERE was 
examined in BG-1 cells. BG-1 cells, derived from a patient with stage III ovarian 
adenocarcinoma express ERα and GPR30 but lack ERβ.  The results revealed that E2 
induced transcriptional activity at the ERE site while G-1 induced the transcription of c-fos 
promoter but not the ERE site. They also found that both G-1 and E2, were able to result in 
up-regulation of c-fos protein levels, likely through transcriptional activation of c-fos.  
Consequently, the c-fos protein induction was abrogated by the inhibitors specific for EGFR 
kinase (tyrphostin AG 1478), MAPK (PD 98059), of the Src family tyrosine kinase (PP2). 
However the inhibitor to PI3K (wortmannin) did not alter c-fos protein level. These results 
suggest that both G-1 and E2 signal through the EGFR/ERK signaling pathway but not 
through PI3K to induce the expression of downstream transcriptional effectors such as c-fos 
452-459. GPR30 can also induce the expression of ERα46, variant of ERα (ERα66) that is 
responsible for the non-genomic activities and can also be expressed in ERα66 negative 
breast cancer (see Figure 4) 460. GPR30 knockdown in SKBR-3 breast cancer cells results in 
down regulation of ERα46 while the ectopic expression of GPR30 into results in the increase 
of endogenous ERα46 expression by transcriptional activiationof GPR30.  The activation of 
ERK1/2 in response to E2 and G-1 were also examined and the results revealed that .E2 
induced phosphorylation of the MAPK/ERK1/2 in both ERα46 and ERα66 cell lines but not 
in the control cells transfected with the empty expression vector 461. These results suggest that 
E2 can exert its mitogenic activity through ERα46 and ERα66 and also through GPR30. E2 
effects through ERα46 and GPR30 result in the activation of non-genomic pathway of ERα, 
which inturn initiates the mitogenic cytoplasmic pathways such as MAPK/ERK1/2, resulting 
in deregulated proliferation (Figure 4).   
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GAP OF KNOWLEDGE: 
        Previous studies have shown that the presence or absence of ER in breast cancers is an 
important indicator for diagnosis, prognosis and treatment. Expression of ERα is necessary 
for response to endocrine therapy. However, not all ER-positive cancer cells respond to 
endocrine therapy. Some ER- positive cells keep their sensitivity to therapy while some 
others develop resistance.  
        There are controversial reports regarding the advantages versus disadvantages of the 
presence of ERα in breast cancer cells. The important question that these studies raise, is 
what is the function of ERα in the presence versus absence of E2? Does unliganded ERα 
have an inhibitory effect on the cell proliferation and, as a result, on the cell cycle? If so, 
could modulation of ERα activity provide new opportunities to exert influence on 
proliferation and cell cycle progression? Could unliganded ERα be utilized as an inhibitor of 
the cell proliferation in cancer cells?  
        The goal of this study is to determine the differential effects of liganded ERα versus 
unliganded ERα on cell cycle progression and ERα transcriptional activity.  Our findings 
thus far suggest that unliganded ERα has an inhibitory effect on the progression of the cell 
cycle. However, the liganded ERα (bound to E2) could cause a rapid progression of the cell 
through the cell cycle. Increased knowledge of ERα activity during the cell cycle will 
enhance our understanding of the causes, potential treatments, and mechanisms to prevent 
breast cancers via new approaches.  
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Chapter II:   Estrogen Receptor Alpha is a Cell-Cycle Regulated Protein and has different 
effects on the cell cycle depending on its ligand status (liganded versus unliganded ER). 
 
INTRODUCTION 
        The function and involvement of estrogen and ER have been extensively studied 
through the years both in the normal mammary gland development as well as in the 
malignant transformations, which have been described in Chapter 1 of this dissertation 5. 
Cumulativly the data suggests an important role for ERα in proliferative state of the breast 
epithelial cells both in normal (during puberty and pregnancy) and also in breast tumor cells. 
However the mechanism of function of ERα in regulation of cell proliferation under both  
normal and cancer remains unclear. To address the role of ERα in cell cycle, I have 
examined the following in this chapter:  (1) The pattern of ERα expression in relation to the 
cell cycle and (2) the role of liganded versus unliganded ERα on the progression of the cells 
through cell cycle.  These investigations will help elucidate the role of ERα on the 
progression of the cells through different phases of the cell cycle in the presence versus 
absence of the ligand, estradiol.  The results of these studies show the novel findings that:  
(1) ERα is cell cycle regulated and modulates the progression of cells through the cell cycle 
by affecting S and G2/M phases of the cell cycle and (2) ligand bound ERα functions to 
increase cell cycle progresion, whereas unliganded ERα acts as a cell cycle inhibitor. 
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MATERIALS & METHODS:  
 
Chemicals  
        Lovastatin (Mevinolin/Lovastatin), FW:  404.25, LKT Laboratories, Inc. 
To make a 10mM stock solution of lovastatin in 70% ethanol, 0404g of lovastatin was added 
to 7mL of 100% ethanol (EtOH) in a tube. The solution was vortexed to dissolve the powder 
completely and 3mL of filtered dd H20 was added to the tube and 1mL aliquots of the 10mM 
solution were stored at -20°C for several month. 
Mevalonate (DL-Mevalonic Acid Lactone), FW: 130.1, Sigma. 
       To make a 0.5M solution of mevalonate, 1 gram of mevalonate was added to 7.7mL of 
1M NaOH and incubated overnight at room temperature. Next day, the pH of the solution 
was adjusted to 7.0 with HCl and the volume was adjusted to 15mL with H20, making a final 
concentration of 0.5M mevalonate.  The solution was filtered through a 0.22 micron filter to 
sterilize and then aliquotted in 1mL cryovials and stored at -20°C for couple months. 
        Nocodazole (Methyl N- (5-thenoyl-2-benzimidazolyl) carbamate, FW: 301.32, Sigma. A 
stock solution of 3.3mM nocodazole is made by dissolving 10mg of Nocodazole per mL of 
DMSO (nocodazole is not H2O soluble) and aliquotted in cryovials and stored at -20°C for 
up to two months. 
        Aphidicolin from Nigrospora sphaerica, FW: 338.48, Sigma.  
Aphidicolin was solubilized in EtOH at a concentration of 1mg/mL and is stable for 1 week 
in ethanol in 4°C. Solublized aphidicolin is stable for six weeks at -20°C.  
        Thymidine (1-(2-Deoxy-?-D-ribofuranosyl)-5-methyluracil, 1-(2-Deoxy-?-D-
ribofuranosyl) thymine, 2?-Deoxythymidine, dT, Thymine deoxyriboside), FW: 242.23, 
Sigma. A 0.2 M stock solution of thymidine was generated by adding 2.42g of thymidine to 
50 mL H2O. To facilitate solubilization, the solution was incubated at 37°C for 10 minutes 
followed by vortexing and the solubilized mixture was sterilized using a 0.2 micron filter and 
aliquotted for storage in -20°C for up to 2 weeks.  
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Cell Culture Conditions 
        The cell lines (MCF-7, MDA-MB231, ZR75-T, ZR75-1, MDA-MB468, 293T) were 
acquired from the depository of American Type Culture Collection (ATCC) (Manassas, VA, 
USA). All cells were authenticized using the short tandam repeat (STR) method. Prior to 
authentication, 40 vials of each cell line were stroed in liquid nitrogen.  Once the cells were 
authenticized, each vial would remain in culture for only 6-7 passages to ensure that the same 
cell population is used in all experiments. To examine the effect of E2 on MCF-7 cells, 
MCF-7 cells were kept in E2-free media for three weeks to clear estrogen completely from 
the cells.  E2-free media is supplemented with 10% charcoal dextran-treated FBS (Hyclone, 
South Logan, Utah), which is stripped of estradiol. In order to prevent the slight estrogenic 
activity of phenol red in the media, phenol red-free IMEM (Biosource, Carlsbad, CA) was 
used to culture the MCF- 7 cells as described 462. The phenol red-free, E2 free media, with 
10% charcoal dextran treated FBS was also supplemented with 1M Hepes, 200mM 
Glutamine, 10mg/mL cipro (Ciprofloxacin), 1mg/mL Insulin from bovine pancreas (Sigma, 
15500), 1mg/mL hydrocortisone (Sigma, H4001), 25µg/mL EGF (Recombinant human 
epidermal growth factor, Millipore, Bedford, Massachusetts), 1% of nonessential amino acids 
and 1% sodium pyruvate.   
        Early passage (from ATCC) MCF-7 cells were cultured in 37°C in a humidified 
incubator containing 6.5% CO2.  The MCF-7 cells were passaged at a 1:10 when 70-80% 
confluency was reached and harvested by incubating with 0.25% trypsin-EDTA (Sigma) for 
5 minutes, followed by inhibition of trypsin using 3.8 g/L of trypsin inhibitor (Sigma). The 
cells were then pelleted and plated as the next passage at a 1:10 ratio. 
        Following three weeks of E2 starvation, MCF-7 cells were seeded at a density of 1×106 
mL in 100mm plates.  For all experiments, cells were plated in duplicates to compare the 
effects of the presence versus the absence of estradiol (10nM) on MCF-7 cells.  Therefore, 
the experiments testing the E2 positive and negative conditions were always run parallel to 
each other.  
To culture cells in non-E2 free conditions, (MCF-7, MDA-MB231, ZR75-T, ZR75-1, MDA-
MB468, 293T) cells were cultured in complete alpha medium supplemented with [1% of 1M 
HEPES (Sigma, St. Louis, MO), 10% of FBS (Atlanta Biologicals, Atlanta, GA), 1% of non-
essential amino acids (Sigma, St. Louis, MO), 1% of 200mM Glutamine (Sigma, St. Louis, 
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MO), 1% of Sodium pyruvate (Sigma, St. Louis, MO), 0.1% of 1mg/mL Insulin (Sigma, St. 
Louis, MO), 0.1% of 1mg/mL Hydrocortisone (Sigma, St. Louis, MO), 0.05% of 25µg/mL of 
EGF (Invitrogen, Carlsbad, CA), 1% of 10mg/mL Cipro]  and incubated as before in 37°C in 
a humidified incubator containing 6.5% CO2 
 
Plasmids 
        ERα plasmid was subcloned into a pcDNA3.1 backbone and used in all transfection 
studies described with MDA-MB231 and MCF-7 cells .  For some experiments I also used 
HA tagged ERα, also in pcDNA3.1 backbone, which was kindly provided by Dr. Susan 
Fuqua. HA-ERα was expressed through CMV promoter in this plasmid. HA-ERα was used 
to transfect MCF-7 cells in order for us to be able to differentiate the endogenous ERα from 
the expressing exogenous ERα. pERE-tk Luciferase (containing the estrogen-regulated 
element) was on pcDNA3 back bone. 
        ERE-Luc plasmid used in order to transfect MCF-7 cells and measure the ERE 
transcriptional activity. Myc tagged Ubiquitin (myc-Ub) was used for an invitro 
ubiquitination assay in order to measure the ubiquitination of ERα.  
 
Synchronization of cells 
 Four different arresting agents were used to synchronize cells in different phases of the 
cell cycle (Figure 10). These include Lovastatin, which arrests cells at early G1 phase 
through inhibition of the proteasome.  As a result of proteasome inhibiton, p21 and p27 
levels increase and inhibit Cdk2, which halts the cell cycle at G1 Phase463. Double 
thymidine block which results in the inhibition of DNA synthesis by inhibiting nucleotide 
synthesis caused by an imbalance of the nucleotide pool 464, 465, therefore inhibiting cells in 
early S phase. Aphidicholin arrests cells in late G1 phase by inhibiting DNA polymerase 
of eukaryotic cells (i.e. DNA polymerase α) 466.  Nocodazole causes microtubule 
stabilization inhibiting cells from pulling away from the metaphase plate and arresting the 
cells in mitosis 467, 468.   
     Lovastatin (Fgure 11A):  1×106 cells from each cell line (MCF-7, MDA-MB231, ZR75-T, 
ZR75-1, MDA-MB468, 293T) were plated on 100mm tissue culture dishes in E2-free media.  
Twenty-four hours post plating, the media was changed to fresh E2-free media containing 
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10µM lovastatin (2) for 36 hours, at which media was changed to E2-free media containing 
1mM mevalonate (to release the cells from lovastatin arrest). At the point of mevalonate 
addition (considered time zero), cells were harvested every 4 hours thereafter for 44 hours 
and prepared for western blot and FACS analysis. For the group of cells that were to be given 
E2 (10nM), it was added at the same time as mevalonate (at the release from arrest). 
Double Thymidine (Figure 11B): A double treatment of thymidine provides a method 
for synchronizing cells at the G1/S border 469. 1x 106 exponentially growing MCF-7 cells 
were plated in 100mm plates.  Twenty-four hours post plaing media was removed and 
replaced with media containing 2mM thymidine and incubated for 24 hours. The thymidine-
containing media was removed from the cells by washing three times with thymidine free 
media and cells were cultured for an additional 12 hours in thymidine free medium (E2-free 
medium, supplemented with 10% charcoal dextran treated FBS and growth factors). At the 
end of the 12 hours, cells were cultured for an additional 24 hours with a second dose of 
thymidine at a final concentration of 2mM.  The cells were washed three times before adding 
normal growth media to the cells, at which point cells were harvested every 4 hours 
thereafter for 44 hours and prepared for western blot and FACS analysis.  
Aphidicholin (Figure 11C) MCF-7 cells were maintained in E2-free media for three 
weeks before they were treated with 4 µg/mL of aphidicholin for 24 hours. Cells were 
released from arrest by washing with drug free media at which point cells were harvested 
every 4 hours thereafter for 44 hours and prepared for western blot and FACS analysis. As 
with other synchronization methods, E2 (10nM) was added to the E2-positive group at the 
time of release from arrest.  
 
Nocodazole (Figure 11D) Nocodazole is widely used to arrest cells at the M phase of the 
cell cycle because of its ability to induce mitotic arrest through stabilizing microtubules468. 
       To arrest MCF-7 cells with nocodazole, cells were maintained in E2-free media for  
three weeks and were then treated with increasing concentration of nocodazole (0 - 0.4  
µg/mL) for 24 hours.  The goal of treating the cells with various concentrations of drug was  
to optimize the percentage of cells arrested in the G2/M phase with the least amount  
of toxicity. After optimizing the nocodazole concentration, MCF-7 cells were treated with  
the selected concentration of nocodazole for 24 hours. Cells were then released from arrest  
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by three repeat washes with drug free media. E2 was added (10nM) to the cells in the E2-
positive group at the time of release. Cells were collected at regular intervals to be analyzed 
by both flow cytometry and western blot analysis to examine the ERα expression and the cell 
cycle status in the presence or absence of the ligand E2. 
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Figure10: Arresting agents used to synchronize cells in different phases of the cell 
cycle.  
 
 
 
 
 
 
 
 
 
  78 
 
Figure 11: Flow chart of different synchronization schedules (A) Lovastatin, (B) Double 
Thymidine, (C) Aphidicolin, (D) Nocodazole   
 
 
A 
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D 
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Transient transfections in combination with lovastatin synchronization 
        MDA-MB231 cells were cultured in E2-free media for 3 weeks, then synchronized with 
lovastatin as described above with the following modifications. Briefly, 1x106 MDA-MB231 
cells were plated in 100mm. The next day, 10µM of lovastatin was added to the cells. 
Lovastatin remained on cells for 36 hours. After 24 hours of cell exposure to lovasatin (12 
hours before taking off the lovastatin), cells were transfected with the vector of interest (HA-
ER, ERE-Luc or Ub-myc). The media on the cells was not changed at the time of 
transfection, however, 12 hours following the transfection (36 hours after lovastatin 
treatment), fresh media containing 1mM mevalonate was added. Depending on the 
conditions being tested, E2 was added (or not) at the time of mevalonate addition. Twelve 
hours of transfection proved to be enough time to take up the introduced DNA and start 
expressing the protein. Samples were harvested and prepared for further experiments. 
 
Generation of Stable Pools and Clones 
Generation of stable clones of MCF-7 cells with shERα: The ERα shRNA was inserted into 
pSilencer 2.0-U6 vector according to the protocols provided by the manufacturer. The DNA 
oligos for ERα shRNA vector construction were synthesized by SigmaGenosys (Houston, 
TX). The sense oligo sequence for ERα shRNA is: sense 
5’GATCCCGCGCTCTAAGAAGAACAGCCTTCAA 
GAGA GGCTGTTCTTC TTAGAGCGTT TTTTGGAA-3’, and the antisense oligo is:  
5’AGCTTTTCCAAA 
AAACGCTCT AAGAAG AACA GCCTCTCTTGAAG GCTG TTCTTCTTAG AGCGCG 
G-3’. 
For ERα knockdown using the ERα shRNA, MCF7 cells were cultured on a 100mm 
culture dish (for immunocytochemical staining, one cover slip was put in each dish) and 
grown to 70% confluency in DMEM medium with 10% FBS. Premixed with 15µL of 
FuGene6 (Roche, Switzerland) and ERα shRNA/or negative control vector (Ambion, USA) 
at 10µg/dish were added to each well. Cells were harvested at 24, 36, and 48 hours after ERα 
shRNA transfection. Western blot analysis and immunocytochemical staining was performed 
to ensure the down regulation of ERα. 
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        For stable down regulation of ERα, 1x106 MCF-7 cells were plated in 100 mm plates 
and then transfected with fugene6 (Roche, 1 814 443) and 5µg of the vector per plate. The 
next day, the transfected cells were selected by culturing with medium supplemented with 
1µg/mL of puromycin for 14 days. At the end of 14 days, colonies were picked 
microscopically and individual colonies were transferred into each well of a 96 well plate 
already containing media with 1µg/mL of puromycin.  After the cells reached 70%  
confluency in 96 well plates, they were sequentially transferred to 6 well plates and 100mm 
plates upon reaching 70% confluency. The puromycin was kept in the media as cells were 
sequentially passaged. Some cells were harvested upon each passage to assess the ER 
expression 
        Immunocytochemical staining:  5x104 cells were plated on sterilized cover slips that had 
been placed inside each well of a 6 well plate. At the time of harvest cells on the coverslips 
were fixed using 4% paraformaldehyde for five minutes at room temperature (RT), then 
washed with PBS for 3x 5minutes, followed by blocking (3% BSA containing 0.1% NP-40 in 
PBS) for 1 hour at RT. Primary antibodies were added at a dilution of 1:200 in blocking 
solution and were incubated on the slides at 4°C overnight. The next day, the slides were 
washed for 3 X 10 minutes with PBS and were incubated with fluorescent labeled secondary 
antibodies for three hours at RT. Slides were washed again with PBS for 3 X10 minutes and 
covered with 4',6-diamidino-2-phenylindole (DAPI) containing anti-fade solution (Vector, 
Burlingame, CA).   Slides were then analyzed using an Olympus DSU spinning disc confocal 
microscope fluorescent microscope. 
 
Irradiation of MCF-7 cells 
        MCF-7 cells were plated at a density of 5x105 cells per 100mm plate.  This density 
allowed cells to be about 50% confluent the next day when the media was changed and cells 
were irradiated using increasing grays of raditation:  0, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 grays.  
Cells recovered in the incubator for 24 hours after the irradiation, at which point the cells 
were harvested and prepared for FACS and western blot analysis.  
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Cell Cycle Analysis 
        The DNA content of cells was determined by flow cytometry.  For each preparation,  
1×106 cells were harvested,washed with cold PBS and centrifuged to pellet the cells.  The 
cell pellets were then fixed overnight with 60% ethanol. The next day, the cells were washed 
twice with PBS and then stained with a solution containing propidiom iodide (PI) 
(10µg/mL), RnaseA (20µg/mL), 0.5% Tween-20 and 0.5% bovine serum albumin (BSA). 
The solution to PI staining made in PBS. All staining reagents were from Sigma-Aldrich (St. 
Louis, MO). Cells were filtered 24 hours after the staining and then subjected to analysis 
using a fluorescent activated cell sorter (FACS) machine, FACscalibur (Becton Dickinson, 
Franklin Lakes, NJ). Events (2×104) were acquired within a cellular region of forward scatter 
versus side scatter plot using Cell Quest software (Becton Dickinson). These events were 
then statistically analysed for the percentage of cells residing within different phases of the 
cell cycle using Modfit software (Verity Software House, Topsham, ME). A diploid model 
was selected and the position and range of the marker placement was assessed. The 
program’s “fit” option was selected to calculate the relative cell cycle distribution of the 
acquired cells.  
 
Growth Curve and Doubling Time Analysis 
        To examine the doubling time of MCF-7 and MDA-MB231 cells in alpha media and in 
E2-free media, 1x104 cells were plated in each well of a six-well plate.  Enough wells were 
plated to analyze triplicate wells every other day for two weeks. The media was changed 
every other day. Doubling time was calculated using the cell counts from the exponential 
growth phase using the following formula:    
Doubling time =[(0.301 Δt)] : [Log10 (N/N0)] 
 
Western Blot Analysis 
        Protein samples were obtained from cells that had been harvested and resuspended in 1x 
protease/phosphatase inhibitor (ppi) [ 250µg/mL of Leupeptin, 25µg/mL of Aprotinin, 
10µg/mL of Pepstatin, 1mM Benzamidine, 10µg/mL of soybean trypsin inhibitor, 0.5mM 
phenylmethylsulphonyl fluoride (PMSF) made in dimethyl sulfoxide (DMSO), 50mM 
sodium floride (Naf), 0.5mM sodium ortho-vanadate] and kept in -80°C. To this end the cells 
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were lysed by sonication with a sonicator fit with a horn adaptor for three rounds of six 
minutes. After the sonication, samples were centrifuged at 45,000rpm for 45 minutes in a 
table top ultracentruge (100,000 x g). The supernatant was removed from the pelleted cell 
debri and was ready for storage in -80°C and protein assay. BioRad protein assay was 
performed to determine the concentration of the protein extracted from the cells using optical 
density at 595nm.  
        Expression of different proteins using samples from synchronized cells was determined 
by subjecting cells to western blot analysis.  To this end 50µg of protein lysate diluted in 
0.4µg/µL in PBS and 10µL of sample buffer (500µL 20% SDS, 106µL β-mercapthoethanol, 
208µL crystal violet, 207µL 80% glycerol) were denatured by boiling for 10 minutes, kept 
on ice for 5 minutes and then put in a 37°C H2O bath for five minutes.  The samples were 
vortexed and centrufuged briefly to bring the tubes content down and then loaded on each 
well of different percent SDS-PAGE gels.  Following electrophersis, the protein content of 
the gels were transferred into pre-soaked PVDF in the cold room for 90-120 minutes using 
100 volts. The blots were incubated in to a bloking solution, blotto (5% nonfat dry milk in 
20mM tris, 137mM Nacl, 0.25% Tween, PH 7.6) overnight. The next day the blots were 
washed in TBST (20mM tris, 137mM Nacl, 0.25% Tween, PH 7.6) and incubated in primary 
antibody for 2.5 hours.  The monoclonal antibodies used were: ERα (NCL-ER-6F11, 
Novocastra Laboratories, UK), cyclin A, cyclin B, cyclin E, cyclin D1 (all from Santa Cruz 
Biotechnology, Santa Cruz, CA), Cdk1 (POH1, cell signaling Technology) and the 
polyclonal antibodies used were ERα and cyclin B both from Santa Cruz Biotechnology, 
Santa Cruz, CA. All primary antibodies made in blotto at a concentration of 1µg/mL. After 
the incubation with the primary antibody, blots were washed with TBST for 10 minutes for a 
total of 5 washes, then incubated for 60 minutes with secondary antibody in blotto. 
Secondary antibodies (horseradish peroxidase conjugate, Pierce biotechnology, Rockford 
IL.) were used at the dulution of 1:5000. After an hour in secondary antibody, blots were 
washed with TBST for 10 minutes 6 times and then developed in chemoiluminescence 
reagent (NEN Life Science Products, Boston, MA) as directed by the manufacturer.   
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RESULTS 
Lovastatin mediated synchronization of breast cancer cells arrests them reversibly in 
the G1 phase of the cell cycle.  
        To study the role of ERα during each phase of the cell cycle, a system was devised to 
evaluate the percentage of cells in each phase of the cell cycle and the duration of the cell 
cycle phases under various conditions.  To this end, cells were synchronized in their cell 
cycle be arresting the cells at a specific point of the cell cycle.  Once most of the cells were 
arrested at the same point, the cells were released from arrest in order for cells to enter the 
cell cycle phases sycnhronously. The cell cycle phase duration and the pattern of regulatory 
proteins in each phase were examined. Lovastatin was used to arrest the cells in the G1 phase 
470. Synchronization by lovastatin arrests many cell types, including human breast cancer 
cells MCF-7 and MDA-MB231 cells, reversibly in the G1 phase of the cell cycle. Lovastatin 
(10µM) mediates an 85% accumulation of MCF-7 and MDA-MB231cells in the G1 phase of 
the cell cycle (Figure 12). The cells were released from the G1 arrest and entered into late 
G1, S and G2/M phases of the cell cycle synchronously by addition of mevalonate (at 100X 
the lovastatin concentration). Western blot analysis was performed to detect the expression of 
key cell cycle proteins. Cyclins A and B were used as markers specific to the S and M 
phases, respectively, to indicate the synchronous transition through phases of the cell cycle 
following the release from G1 arrest by lovastatin.   As Figure 12 shows, at time zero (release 
from arrest) 85% of the MCF-7 cells were coming out of a G1 phase arrest. As the MCF-7 
cells exited G1 phase around 15 hours after the release, the percentage of cells in S phase 
increased. Similarly, as the cells exited from S phase 24 hours after the release, the 
population of the cells in the G2/M phases of the cell cycle increased.   
 The percentage of cells in G2/M phase was the highest 31 hours after release from 
lovastatin induced arrest (Figure 12).  At approximately 33 hours after relase, cells exited 
G2/M phase, and entered G1 phase of the subsequent cell cycle, shown by an increased 
percentage of cells in G1 phase again. Within the 44 hours that samples were collected, one 
complete cell cycle plus the G1 phase of the subsequent cell cycle was observed. A high 
reproducibility of data was seen in the triplicate lovastatin arrest experiments shown in 
Figure 12 and labeled as I, II and III depicting three different experimental replicates.  
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        Similar to what was observed with MCF-7 cells, lovastatin resulted in a high percentage 
of MDA-MB231 cells (an ER-negative cell type) to be arrested at G1 phase.  Upon the 
release of cells with mevalonate, MDA-MB231 cells progressed through the cell cycle 
synchronously. In experiment one (shown as I in Figure 12) of lovastatin induced 
synchronization on MDA-MB231 cells, 85% of the cells arrested in G1 phase.  MDA-
MB231 cells exited G1 phase 17 hours after release from arrest, at which point the 
population of cells in S phase increased and peaked at 28 hours after release. After 29 hours, 
cells exited S phase and entered G2/M phase.   The peak of the percentage of cells in G2/M 
phase occurred at the 36 hour time point.  By 38 hours, cells exited G2/M phase and entered 
the G1 phase of the next cell cycle. Similar results were observed in experiments II and III of 
lovastatin synchronized MDA-MB231 cells (Figure 12).  As shown, the cells progressed 
through the cell cycle synchronously after release from lovastatin induced arrest and the 
lengths of G1, S, and G2/M phases can be extrapolated from the FACS data (Figure 12). The 
increasing slopes of the graph as the cells enter each cycle phase represent the start of each 
phase, and the declining slopes represent the end of each phase (Figure 12).  Due to the high 
level of synchrony of the cells, this method of extrapolation was used throughout this study 
to determine the length of the cell cycle phases.  
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Figure 12: Lovastatin arrests MCF-7 and MDA-MB231 cells in G1 phase of the cell 
cycle. FACS analysis of MCF-7 (top row) and MDA-MB231 (bottom row) cells 
synchronized with lovastatin from three separate experiments (I, II and III) for each cell line.   
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ERα  expression is cell cycle regulated in synchronized MCF-7 cells. 
        To investigate whether ERα  is a cell cycle regulated protein and whether the presence 
or absence of estradiol affects the cell cycle distribution pattern of ERα, we studied the 
expression pattern of endogenous ERα using MCF-7 cells.  MCF-7 cells, which were 
maintained in E2-free media, were synchronized with lovastatin as described above. In this 
experiment there were two parallel groups, one group in which lovastatin synchronized cells 
did not receive 17β estradiol (E2) at the time of release and the other group which did receive 
17β estradiol (10nM). Cells were harvested at 4-6 hour time points after the release and then 
prepared for western blot and FACS analysis. When exposed to E2 at the time of release 
from arrest, the level of ERα protein increased at the 24 hour time point, peaked at 28 hours 
and then decreased at 40 hours after release (Figure 13, left panel).  A similar pattern of 
expression was observed for cyclin B. Cyclin B protein expression also increased at 24 hours, 
peaked at 28 hours and was down regulated at 40 hours after release from lovastatin arrest. 
The levels of cyclin A protein showed an increase at 20 hours, peaked at 28 and was also 
down regulated at 40 hours after release. Therefore, ERα and the cell cycle markers cyclin A 
and cyclin B showed a similar pattern of cell cycle expression.  This data suggests that in the 
presence of E2, ERα expression coincides with the expression of cyclin A and B, 
concomitant with entrance of cells into late S and G2/M phases of the cell cycle.  
The expression pattern of ER was different under E2-negative conditions.  When cells 
were synchronized in the absence of E2, the expression of ERα protein increased at 28 hours 
after release and peaked at the 40 through 46 hour time points. However, no decreases were 
observed in the ERα protein level even at the last taken time point. A similar pattern was 
observed for cyclin B levels. Cyclin B was up regulated at 24 hours, peaked at 32 hours, but 
did not decrease within the time points observed. The levels of cyclin A had increased by 28 
hours and stayed up through the 46 hour time point.  These results suggest that the 
endogenous ERα is subject to cell cycle regulation with its expression level peaking at the S-
G2/M phase of the cell cycle (Figure 13). It was also evident from the western blot and 
densitometric analysis that E2 free conditions caused a slower down regulation of cyclins A 
and B and ERα compared to the sharp decline in their expression at the end of G2/M phase 
in E2-positive (liganded ERα) conditions. 
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Figure 13: ERα  is a cell cycle regulated protein in MCF-7 cells. The upper panels show 
western blots of endogenous ERα, cyclin A and cyclin B expression at 4-6 hour timepoints 
after release from lovastatin induced arrest in the presence (left panel) and absence (right 
panel) of E2.  The densitometric values of the ERα, cyclin A and cyclin B western blot 
data were then graphed (lower panel).  
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Liganded ERα  modulates cell cycle progression by decreasing the time that MCF-7 
cells spend in S and G2/M phases of the cell cycle. 
        The data so far shows that ERα expression is cell cycle regulated under both E2-
positive and E2-negative conditions and is predominanty expressed during the G2/M phases 
of the cell cycle.  The question arises as to the role of liganded and unliganded ERα during S 
and G2/M phases. To address this question, the cell cycle profile of ERα expression was 
examined in MCF-7 cells in the presence and absence of ligand (17β estradiol) to allow for a 
quantitative analysis of cell cycle progression.  MCF-7 cells were maintained in E2-free 
media and then synchronized with lovastatin; meanwhile, 17β estradiol (10nM) was added to 
one group of cells while another group remained E2-free.  
        Cells were harvested at four-hour intervals after release from arrest and were subjected 
to flow cytometry. As shown in Figure 14, 88% of MCF-7 cells were arrested in G1 phase 
and then released synchronously into the cell cycle phases and the experiment was repeated 
three different times and labeled as I, II and III.  In experiment I, the cell cycle profiles of the 
two groups of MCF-7 cells (presence and absence of E2) were compared. Synchronized 
MCF-7 cells exited from G1 phase 17 hours post release in both conditions.  By the time 
cells entered the proceeding G1 phase, the cells in the presence of E2 had altered cell cycle 
profiles compared to the cells in the absence of E2.  Specifically, MCF-7 cells in the E2 
negative conditions showed a delayed entrance to the subsequent G1 phase of the next cell 
cycle compared to cells under E2-positive conditions. The comparison of S phases between 
the E2-positive and E2-negative conditions of experiment I showed that cells entered S phase 
approximatley 4 hours earlier under E2-positive conditions compared to E2-negative 
condition, with 17 and 21 hour entry times respectively.  
        The decline of the S phase population of MCF-7 cells was much faster and sharper in 
E2-positive compare to E2-negative conditions. It follows that the entrance of the cells to the 
subsequent S phase of the cycle was earlier under E2-positive compared to ER-negative 
conditions.  MCF-7 cells entered G2/M phase 7 hours earlier in E2-positive conditions (20 
hours post release) compared to E2-negative conditions (27 hours post release).  Also, the 
population of cells in G2/M peaked at 29 hours in E2-positive condition compared to the 
cells in E2-negative conditions, which was at 31 hours. The exit of the cells out of G2/M was 
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again faster in E2-positive conditions compared to E2-negative conditions. The entrance of 
cells in to the subsequent G2/M phase of the next cell cycle was detectable under E2-positive 
conditions, but not seen in the E2-negative condition due to the slow cell cycle progression of 
the cells (Figure 14).  
        In experiment II, there was not as much of a difference in the timing of the G1 phases 
between the two conditions as there had been in experiment I, however the effect of E2 was 
seen later in S phase.   Cells exited S phase faster under E2-positive conditions (at 31 hours 
post release) compared to E2-negative conditions (35 hours post release).  The cells in E2 
media that exited S phase faster also entered G2/M faster (24 hours post release) compared to 
those in E2-negative conditions (29 hours). Again the G2/M phase of the subsequent cell 
cycle was not observed in E2-negative conditions; while in E2-positive conditions, the entry 
of cells in to the next G2/M was observed (Figure 14). In experiment III, the profile of cells 
in G1 phase did not differ much between the two conditions.  There was a sharp increase in 
the percentage of S phase cells at 17 hours after release from lovastatin arrest under E2-
positive conditions compared to the broader peak of S phase cells at 20 hours after release in 
the E2-negative conditions.  The effect of E2 was more pronounced in G2/M phases. Cells 
sharply entered into G2/M phase at 25 hours in E2-positive conditions, compared to E2-
negative condition where the incline started at 29 hours. The cells in G2/M under E2-positive 
conditions peaked at 30 hours, while the percentage of cells in G2/M phase did not peak until 
37 hours under E2-negative conditions (Figure 14).   
        Overall, the results of the second and third independently performed experiments 
support the results from experiment I. Flow cytometric analysis clearly revealed that liganded 
ERα in MCF-7 cells modulated cell cycle progression by shortening S and G2/M phases of 
the cell cycle (Figure 14).  
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Figure 14: Liganded ERα  hastens the passage through S and G2/M in MCF-7 cells.  
The percentage of cells in each phase of the cell cycle as determined by FACS analysis of 
lovastatin synchronized MCF-7 in the presence (E2+) or absence (E2-) of estradiol.  Three 
separate repeats of the experiment are shown (I, II and III).  The arrows indicate the peak 
percentage of cells in each phase and the point at which cells start to exit the phase of the cell 
cycle. The time spent by MCF-7 cells in each phase of the cell cycle under E2-positive 
versus E2-negative conditions can be extrapolated from the graphs.  The hatched vertical 
lines in each panel depict the start of the specific phase of the cell cycle. 
Data used for experiment III are the data used in experiment III in figure 12.  
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Table 3 shows the results of analysis of the duration of S and G2/M phases of the MCF-7 cell 
cycle in the presence versus absence of estradiol.   Treatment of the MCF-7 cells with 
estradiol resulted in a shortening of S phase by 3.3 and of G2/M phase by 2.3 hours in the in 
the presence of the ERα ligand (E2). The total time for the cell cycle of MCF-7 cells in E2-
free condition is 36.5 hours while the total cell cycle time of MCF-7 cells in the presence of 
E2 is 32 hours making the difference between E2-positive and E2-negative conditions 4.8 
hours, which is significantly different (p<0.05). The differences between the duration of each 
cell cycle phase was measured by calculating the hours that cells spent between the times that 
the percentage of cells started to increase in that phase (ascending line) until the time that the 
percentage of cells started to decrease in that particular phase (descending line) (Figure 14). 
The measurment of each phase of the cell cycle was done on three different replicates of the 
experiment and then averaged. The significance of the difference between each cell cycle 
phase in E2-positive and E2-negative conditions were measured using two-tailed t-test. The 
results are depicted in table 3. 
 
 
 
 
 
 
 
Table 3 -Analysis of the duration of G1, S and G2/M phases (in hours) of MCF-7 cell cycles 
in the presence versus absence of E2 as determined by FACS. Data shown is the average 
from three different experiments (Figure 14).   
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Regulation of endogenous ERα  expression is observed in MCF-7 cells synchronized 
with aphidicolin.   
        We have shown that ERα expression is cell cycle regulated upon synchronization of 
cells in the G1 phase of the cell cycle by lovastatin.  To confirm that these results are not 
unique to the method of synchronization used, cells were also synchronized using aphidicolin 
(Figure 15). Aphidicolin arrests the cells in G1/S phase through inhibition of DNA 
replication by selectively inhibiting the cellular replicative DNA polymerase alpha 471. MCF-
7 cells, which had been maintained in E2-free media, were used for aphidicolin 
synchronization. As with the lovastatin synchronization experiments, two parallel groups 
(one receiving 10nM 17β estradiol at the time of release and the other group not receiving 
any ligand) were used for aphidicolin experiments.  Cells were harvested in three hours time 
intervals and the samples were then prepared for FACS and western blot analysis. 
        Aphidicolin synchronized 78% of MCF-7 cells at the border of G1/S phase (Figure 15, 
bottom panel). The synchronized cells were all arrested at the end of G1 phase, therefore the 
cells synchronously progressed through S and G2/M phases and also the G1, S and partially 
through G2/M phase of the subsequent cell cycle quickly (by about 12 hours) upon release 
from aphidicolin release.  It was immediately clear by examining the FACS data that MCF-7 
cells exit the S and G2/M phases faster in the presence of E2 compared to the absence of E2 
(Figure15, bottom panel).  
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Figure 15: Aphidicolin synchronized MCF-7 cells confirm that ERα  is cell cycle 
regulated. Top panel shows the western blot analysis of aphidicolin synchronized MCF-7 
cells. Arrows indicate the times where ERα expression is increased.  The bottom panel 
shows the FACS data graphed as the percentage of aphidicolin synchronized MCF-7 cells in 
each phase of the cell cycle. The dotted lines correspond to timing of ERα protein expression 
determine by the above western blots.   
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        The faster progression of cells through S and G2/M phases in E2-positive condition 
compared to E2-negative condition possibly could explain why there were two cell cycles in 
the E2 treated cells within the time frame studied while in E2-negative conditions only one 
cell cycle was observed  (note the 2 S phase peaks in E2-positive conditions and only one S 
phase peak in E2-negative conditions in figure 15), In E2-positive conditions, the cells had 
progressed through one entire cell cycle, and the G1, S and part of G2/M of the second cell 
cycle.  Meanwhile, in E2-negative conditions, only a prolonged G1 phase of the second 
consequent cell cycle was observed (Figure 15). The western blot analysis of MCF-7 cells 
synchronized with aphidicolin and released under E2-positive conditions (top left) showed 
that there were two peaks of ERα expression, as shown by arrows in Figure 15. The first 
peak of ERα expression started at 6 hours and ended by 12 hours after release from arrest.  
The second peak was between the 22 and 24 hour time points. Interestingly, the duration of 
both of these peaks correlated with the peaks of cell populations in S-G2/M phases in two 
consecutive cell cycles. Similar to the observed peaks of ERα, there are two peaks in the 
protein expression of cyclin A in the E2-positive condition. The first peak of cyclin A 
expression starts from time point 0 and continues until time point 8. The second peak starts at 
time point 18 and continues until time point 22.  The timing of the increases in cyclin A 
expression corresponds to S phase. In the cells released from aphidicolin arrest under E2-
negative conditions (Figure 15, right side), there were again two peaks for the level of ERα 
protein.  The first peak started at the four hour time point and declined at 8 hours.  The 
timing of this peak coincided with the S and G/M phases of the first cell cycle. The second 
peak of ERα level started at 14 hours after release and remained to the end of the experiment. 
Similarly, there were two observed peaks for the protein expression of cyclin A. The first 
peak started at time point 0 and continued until time point 6, which corresponded to the S 
phase. The second peak of cyclin A expression, which is not as strong as the first peak, 
started at time point 14 and declined at time point 18. Both peaks of cyclin A corresponded to 
the S phase, however because the population of cells in the second S phase is not as high as 
the first S phase in the E2-negative condition, the amount of cyclin A protein expression is 
lower.  
        The FACS data was analyzed to explore what the effects were on the progression of the 
cell cycle as the ERα levels remained elevated.  The FACS data showed no observable 
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incline, peak or decline in the percentage of cells entering S and G2/M phases of the second 
subsequent cell cycle. From 14 hours after release from arrest (when ERα expression peaked 
the second time) through to the end of the experiment (30 hours) there were still 40% to 50% 
of the cells residing in the S and G2/M phases.  In summary, in the absence of E2, 
progression through the cell cycle was abrogated compared to the presence of E2. 
Collectively, the results to this point show that ERα is cell cycle regulated in MCF-7 cells 
that have been synchronized by arresting cells with lovastatin (Figure 13) and aphidicolin 
(Figure 15). The increase in ERα protein expression level correlates with the time points at 
which the cells are in S-G2/M phase of the cell cycle.   
        To better quantitate the effects of liganded versus unliganded ERα in MCF-7 cells 
synchronized with aphidicolin, three independent replicates of the experiment were 
performed (Figure 16).  As shown in the left panel of Figure 16 (experiment I), 78% of MCF-
7 cells were arrested in G1 phase by aphidicolin and released synchronously into the cell 
cycle phases.  Aphidicolin synchronized MCF-7 cells exited G1 phase at the 4 hour time 
point in both conditions, and entered the subsequent G1 phase at 11 hours after their release. 
The percentage of cells in the second G1 phase peaked at 14 hours after release in the 
presence of E2, while the peak percentage of cells in G1 in the absence of E2 was not until 
the 20 hour time point. In addition, the exit from the second G1 phase appears much faster in 
E2-positive conditions compared to E2-negative conditions (Figure 16).   
        When comparing the percentage of MCF-7 cells in the S phase between the E2-positive 
and E2-negative conditions, the results from experiment I showed that cells entered and 
exited the S phase of the first cell cycle at the same time after release from arrest.  In both the 
presence and absence of E2, the MCF-7 cells entered S phase at 2 hours and exited 8 hours 
after relase from aphidicolin arrest.   Despite this synchronous S phase progression, the 
pattern of cells progressing through the S phase of the subsequential cell cycle is different 
when E2 is present compared to when it is not. In E2-positive conditions, cells entered the S 
phase of the subsequent cell cycle at 15 hours, peaked at 18 hours and exited 20 hour post 
release.  
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Figure 16: 17β  estradiol hastens the passage through S and G2/M phases in aphidicolin 
synchronized MCF-7 cells.  FACS analysis of aphidicolin synchronized MCF-7 cells in the 
presence (E2-positive) or absence (E2-negative) of 17β estradiol.  The data is collected from 
three independent experiments.  Comparsion of the profiles of G1, S and G2/M phases of 
experiment I has been shown in the left column (I), those of of experiment II have been 
shown in the middle column (II) and experiment III have been shown in the right column. 
The hatched vertical lines in each panel depict the start of the specific phase of the cell cycle. 
The data used for ploting the all cells cycle phases FACS data shown for experiment I in this 
figure has been also used to plot the E2-positive graph in figure 15.  
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        In contrast to the 18 hour peak of S phase in E2-positive conditions, under E2-negative 
conditions, the population of cells only entered the S phase of subsequent cell cycle at 18 
hours after release and never formed a sharp peak.  This suggests that cell cycle progression 
is delayed in the absence of E2.  
        The MCF-7 cells entered and exited the G2/M phase of the first cell cycle after release 
from arrest at the same time whether E2 was present or not.  The cells entered G2/M at 7 and 
exited G2/M at15 hours after being released from arrest.  Cells released under E2-positive 
conditions entered the second G2/M phase at 20 hours after release. The percentage of cells 
in G2/M phase peaked at 25 hours, which was the last harvested time point of this 
experiment. As expected after a delayed S phase, cells released from arrest did not show 
progression in to a second G2/M phase by 25 hours in E2-negative condition (Figure 16).  
The results from the second (II) and third (III) repeats of the experiment supported the results 
described for experiment I.  In order to calculate whether the changes between the S and 
G2/M phases upon E2-treatment is statistically significant compared to untreated cells, the 
percentage of the cells at the peak of each phase were used in order to measure the difference 
between the quantity of the cells present in each phase under E2-positive condition versus 
E2-negative condition. The numbers for each phase and condition were average of the three 
repeats of the experiment. Two-tailed t-test was used in order to measure the p-value. The 
results are depicted in table 4. 
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Table 4 -Analysis of the percentage of the aphidicolin synchronized MCF-7 cells present at 
the G1, S and G2/M phases (consequent cell cycle) in the presence versus absence of E2 as 
determined by FACS. Data shown is the average from three different experiments (Figure 
19).   
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        In summary, flow cytometric analysis of the aphidicolin synchronized MCF-7 cells 
clearly showed that liganded ERα modulates cell cycle progression by accelerating the 
progression of the cell cycle. The effect of liganded ERα on cell cycle progression is most 
pronounced in the S and G2/M phases. The major difference between the results generated 
from lovastatin mediated arrest compared to that of aphidicolin is that E2 modulated the first 
cell cyle after release from lovastatin arrest, but the second cell cycle was affected by E2 
after aphidicolin mediated arrest. The reason for the delayed effects of E2 in aphidicolin 
treated cells is because ERα expression did not increase until 8 hours after release from arrest 
and the MCF-7 cells treated with aphidicolin had already completed the first cell cycle.  
 
ERα  expression is regulated at the protein level and not at the transcriptional level. 
        The expression of ERα throughout the cell cycle has been examined by western blot 
analysis, providing insight in to the levels of expressed ERα protein. However, it is not 
known whether the expression of ERα mRNA is cell cycle regulated at the transcriptional 
level.  To determine the levels of ERα mRNA expression throughout the cell cycle, 
Quantitative Real Time Polymerase Chain Reaction (qRTPCR) analysis was performed on 
lovastatin synchronized MCF-7 cells. Synchronized MCF-7 cells were collected at 3 hours 
intervals between 0 hours (when the cells were released from arrest using mevalonate) and 40 
hours and RNA samples were extracted from each sample.  After reverse transcription, qRT-
PCR was performed using sense and antisense oligos for ERα.  Figure 17 (top panel) shows 
that lovastatin synchronization arrested 75% of the cells in G1 phase.  Upon release of the 
MCF-7 cells from arrest using mevalonate, they synchronously progressed through the cell 
cycle phases. FACS data shows that lovastatin synchronized MCF-7 cells exited G1 phase at 
15 hours post arrest and entered S phase, peaking in S phase at 20 hours after release.   The 
cells entered G2/M phase at 25 hours post release, reached a peak percentage of cells in 
G2/M phase at 30 hours and exited G2/M at 35 hours after being released (Figure 17). The 
middle panel shows the graph of values obtained from densitometry of western blot analysis 
of ERα protein expression (Figure 17).  
As observed previously (Figure 13), ERα protein showed a cell cycle regulated 
pattern. The densitometry results showed that ERα protein level increased from 15 to 28 
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hours after release and declined at 35 hours. Alignment of the western blot data and the 
FACS analysis shows that the increasing ERα protein expression coincided with the S phase 
and the highest ERα protein level coincides with the highest percentage (around 70%) of 
cells residing in S and G2/M pahses.  ERα protein expression declined at 35 hours, the same 
time that FACS analysis showed the cells had exited S and G2/M phases and had entered the 
G1 phase of the successive cell cycle (Figure 17).   
        In contrast to the western blot data that shows fluctuations in protein levels with the cell 
cycle, qRT-PCR results showed that mRNA levels of ERα did not change throughout the cell 
cycle (Figure 17).  Furthermore, the qRT-PCR analysis also showed that ERα mRNA levels 
are not affected by E2 as the values were equivalent for both groups of cells (presence and 
absence of E2 and repeated twice under both conditions).  The quantification of ERα mRNA 
via qRT-PCR revealed that the cell cycle dependent changes in ERα expression are not 
transcriptionally regulated. We deduced that the decreased ERα expression during the G1 
and early S phases are due to post-translational mechanisms. 
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Figure 17: ERα  is not regulated at the transcriptional level. Top panel shows the FACS 
analysis of the lovastatin synchronized MCF-7 cells. The middle panel shows the graphed 
values of densitometry from western blot analysis of ERα in lovastatin synchronized MCF-7 
cells.   The bottom panel shows the values obtained from qRT-PCR analysis of lovastatin 
synchronized MCF-7 cells from two separate experiments. The data used for ploting the all 
cells cycle phases FACS data in this figure has been also used to plot the experiment I in  
figure 14.  
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        ERα  expression is also cell cycle regulated in the ER-positive breast cancer cell line 
ZR75-1 
        To address whether ERα is cell cycle regulated in other ER-positive breast cancer cells, 
the ZR75-1 cell line was used to validate the generality of the ER cell cycle regulation in 
other cell lines. The ZR75-1 cell line has phenotypic characteristics similar to MCF-7 cells.  
For example, both ZR75-1 and MCF-7 cells are ER/PgR-positive and both cell lines have 
low invasive and metastatic potential 472.  
        ZR75-1 cells were maintained in E2-free media and then synchronized with lovastatin 
as described earlier for MCF-7 cells 463. Lovastatin synchronized 95 % of ZR75-1 cells in 
G0/G1 (Figure 18, bottom panel). Furthermore, the lovastatin synchronization was reversible 
with mevalonate, which means that upon release of the cells from lovastatin arrest ZR75-1 
cells progress through the cell cycle synchronously. ZR75-1 cells were harvested every four 
hours from zero hours (release from arrest) through 44 hours after addition of mevalonate.  
Lysates were collected for western blot analysis and cells were fixed and stained for flow 
cytometric analysis. 
        ZR75-1 cells exited G1 phase at 15 hours when the population of cells in S phase 
increased and reached a peak at 20 hours. As Figure 18 shows, there is not a sharp decline of 
the cells out of S phase, however at 25 hours, a fraction of the cells (<5%) exited S phase. 
The G2/M phase of lovastatin arrested ZR75-1 cells peaked at 25 hours after release and was 
prolonged until 38 hours after release (Figure 18).  
        ERα protein expression was up regulated in synchronized ZR75-1 cells at 24 hours after 
release from arrest and stayed high until 40 hours (Figure 18, upper panel). Cyclin B was also 
up regulated between the 20 and 40 hour time points. Based on FACS analysis of these cells, 
the percentage of cells in S and G2/M phases also peaked between 20 and 40 hours after 
release from arrest.  Cyclin B was used as a cell cycle marker for late S and G2/M phase and 
showed a similar pattern of cell cycle expression compared to ERα.   These data suggest that 
the endogenous ERα in ZR75-1 cells, like the MCF-7 cells, was subject to cell cycle 
regulation with expression levels peaking at the S and G2M phases of the cell cycle (Figure 
18).  From this series of experiments, we can conclude that cell cycle regulation of ERα is 
not a cell type specific phenomenon.  
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Figure 18: The cell cycle regulation of ERα protein is not cell type specific. 
Western blot analysis of ERα and cyclin B expression in lovastatin synchronized ZR75-1 
cells (top panel).  Actin is shown as a loading control.  FACS analysis of lovastatin 
synchronized ZR75-1 cells graphed as the percentage of cells in each cell cycle phase 
(bottom panel). 
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Radiation causes a dose dependent accumulation of MCF-7 cells in G2/M with 
concomitant ERα  expression 
        It is known that gamma-irradiation arrests cells in the G2/M phase of the cell cycle. We 
have shown that the timing of ERα peak expression correlates with the G2/M phases of the 
cell cycle. Therefore, we next investigated whether gamma-irradiated cells express a high 
level of ERα in G2/M phase.  ER-positive MCF-7 breast cancer cells were plated on day 
zero, and fresh medium was added the next day with either 10nM estradiol for the E2-
positive condition or without any estradiol for plates in the E2-negative conditon.  The cells 
were irradiated with a range of doses (from 0-7 grays). Cells were harvested and prepared for 
FACS and western blot analysis 24 hours after the exposure to radiation to assess ERα 
expression and cell cycle profile.  As the bar graph in Figure 19A shows, there is a radiation 
dose dependent accumulation of cells in G2/M phase of the cell cycle.  Cells also 
accumulated in S phase upon exposure to lower doses of radiation.  The percentage of cells 
in S, G2 and M phases combined was highest (40%) when cells were irradiated with 0.5, 1, 6 
or 7 grays. The western blot analysis of lysates from cells arrested through irradiation 
revealed that the level of ERα protein was also the highest in the cells irradiated with 0.5, 1, 
6 and 7 grays.  The FACS data of the control (0 gray) shows 40% of the cells reside in S and 
G2/M phases and that is why a high expression of ERα is observable in western blot. Cyclin 
B expression was used a marker to indicate when cells are late S and G2/M phases.  A 
western blot for cyclin B expression revealed the exact same pattern as for ERα, where the 
protein is up regulated after irradiation with 0.5, 1, 6 and 7 grays. 
        In summary, irradiation resulted in the accumulation of cells at S and G2/M phases and 
showed increased ERα protein expression in the samples enriched in S and G2/M (Figure 
19). These data support our previous findings that ERα is a cell cycle regulated protein with 
expression peaking at S and G2/M phases of the cell cycle.  
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Figure 19: Accumulation in S and G2/M phases due to irradiation correlates with 
increased ERα  expression. MCF-7 cells were exposed to increasing doses of radiation. (A) 
The percentage of cells in each phase of the cell cycle was determined by FACS analysis and 
is shown as a bar graph.  Western blot analyses of lysates collected from radiated cells were 
blotted for cyclin B, ERα and actin expression.  (B) The densitometric values of ERα and 
cyclin B expression were derived from the western blots perfomed on MCF-7 cell lysates 
after treatment with various doses of radiation.       
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ERα  depletion accelerates mitotic exit.  
The data to this point shows that cells arrested in G2/M phase of the cell cycle have increased 
expression of ERα.  The next step in understanding the role of ERα during the G2/M phase 
of the cell cycle was to determine whether the downregulation of ERα in MCF-7 cells would 
affect the cell cycle progression specifically during G2/M phase.  The method, which was 
employed to downregulate ERα expression, was use of shRNA. 
        First, an shRNA was generated using the U6 promoter based vector due to its ability to 
maintain the secondary structure of the short hairpin RNAs. This vector has been shown to 
effectively induce sequence specific gene silencing in mammalian cells and could be used to 
stably suppress target genes 368. To confirm the efficiency of ERα shRNA, western blot 
analyses were performed at 24, 36, and 48 hours after transfection of MCF-7 cells with ERα 
shRNA (Figure 20A). The vector containing shRNA-ERα did not have a selection marker; 
therefore, a plasmid with puromycin gene was cotransfected with the shRNA-ERα.  The 
selection of stable clones started 24 hours after the transfections and selectable, isolated 
colonies were observed 15 days after transfection. The stably expressed shRNA resulted in 
ERα expression that was silenced completely for the first two passages.  However the ERα 
expression came back after three to four passages, which made the system impractical for use 
during lovastatin synchronization.  For a successful synchronization experiment, MCF-7 cells 
need to be passaged 3-4 times to obtain enough cells needed for western blot and FACS 
analysis.  Due to the unsuccessful generation of stable ERα silenced pool we decided to 
deliver shRNA-ER transiently at the time of synchronization. In order to examine the 
efficiency of shRNA- ERα in silencing ERα after the transient transfection we transiently 
transfected MCF-7 cells with shRNA-ERα and harvested the cells in 24, 36 and 48 hours 
after the transfection. Western blot analysis showed that the decrease in the level of ERα 
protein occurred within 24 hours after the transfection of MCF-7 cells with shRNA to ERα 
(Figure 20A). Furthermore, the ERα level remained reduced at 36 and 48 hours after the 
transfection (Figure 20A).   
  ERα protein levels remained constant, as expected, in the cells transfected with 
scrambled RNA or empty vector. However, upon transfection of MCF-7 cells with shERα, 
the expression of ERα decreased (Figure 20B).   
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 ERα silenced MCF-7 cells were generated by transfecting the cells at the same time as 
plating the cells for lovastatin synchronization. Upon release of the cells from lovastatin 
arrest, cells were harvested at time intervals coinciding with S and G2/M phases (17-32 
hours) and were subjected to western blot analysis with ERα and FACS analysis. Western 
blot analysis of lovastatin synchorinzed parental (untransfected) cells showed that ERα 
protein levels increased at 21 hours, peaked at 26 hours then decreased by 33 hours after 
release from arrest (Figure 20C). The MCF-7 cells in which ERα has been silenced by 
transfection of shRNA to ERα did not show a detectable level of ERα protein for the 
duration of G2/M phase (Figure 20C). To determine the effects of ERα silencing on the 
progression of cells through G2/M phase of the cell cyle, FACS analysis of the parental and 
shRNA treated synchronized MCF-7 cells was performed.  The cells with down regulated 
ERα entered G2/M phase at 29 hours, peaked at 34 hours and then encountered a sharp 
decline with a complete exit from G2/M by 38 hours after release (Figure 20D).   In contrast, 
parental MCF-7 cells entered G2/M phase at 29 hours, had a peak percentage of cells in 
G2/M at 36 hours, but then underwent a slow exit from G2/M phase until 42 hours after 
release (Figure 20D). The arrows on the graph in Figure 20D indicate the estimated time of 
the cells exiting G2/M phase.  There was a six hours delay in exit from G2/M in the case of 
parental MCF-7 cells compared to the ERα-silenced MCF-7 cells (Figure 20D). 
        In summary, ERα down regulation results in a faster exit from G2/M phase, suggesting 
that ERα plays a role in delaying the exit of cells from G2/M phase. The ability of cells 
devoid of ERα expression to progress through the cell cycle more rapidly than those with 
ERα expression could explain why ER-negative breast cancer cells are more proliferative 
and aggressive than ER-positive breast cancer cells.  
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Figure 20: Downregulation of ERα  in MCF-7 cells increases passage through 
G2/M.MCF-7 cells were transfected with shRNA against ERα, a scrambled control shRNA 
or an empty vector and subjected to (A) western blot analysis and (B) immunoflouresent 
staining to assess the efficiency of ERα silencing. The ERα is fluorescently labeled red and 
the nucles was stained using DAPI in MCF-7 cells treated with shERα compared to the 
controls (scrambled RNA and empty vector).  MCF-7 cells were then synchronized, 
transfected with shRNA and again subjected to(C) western blot analysis and (D) FACS 
analysis to determine the effects of ERα downregulation on the cell cycle. 
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Exogenous ERα elongates the S and G2/M phases of MCF-7 cells. 
        ERα down regulation in MCF-7 cells resulted in a rapid exit from G2/M phase 
compared to parental MCF-7 cells.  To investigate wether this effect was mediated by ERα, 
HA-ERα was next over expressed in breast cancer cells and again, the progression of cells 
through the cell cycle phases was assessed.  The hypothesis was that unliganded ERα has an 
inhibitory effect on the progression of cell cycle compared to liganded ERα. To test this 
hypothesis, exogenous ERα was transfected in to lovastatin synchronized ER-positive MCF-
7 cells using an HA-ERα construct to generate ERα-overexpressing MCF-7 cells.   
        Upon overexpressing exogenous ERα in MCF-7 cells FACS analysis of the cell cycle 
profiles showed that 80% of MCF-7 cells arrested in G1 (time zero). Upon the release from 
arrest at time zero, cells entered the cell cycle synchronously (Figure 21, upper panel).   The 
experiment was repeated twice and is shown as experiments I and II.  Percentage of cells in 
each phase of the cell cycle was evaluated over a 24 hour period for the parental and HA-
ERα transfected MCF-7 cells to compare the duration of G1, S and G2/M phase. The FACS 
results for experiment I showed that in both conditions (untransfected and HA-ERα 
overexpressed) cells exited G1 phase at approximately 18 hours after release and entered S 
phase by 20 hours. However the parental MCF-7 cells had the highest peracentage of cells in 
S phase at 25 hours, while HA-ERα-cells formed a peak in S phase at 25 hours (Figure 21). 
In parental cell, S phase declined sharply starting at 25 hours post release with a complete 
exit out of S phase by 31 hours.  Meanwhile, the HA-ERα cells showed a prolonged exit 
from S phase. Additionally, parental MCF-7 cells entered the S phase of the subsequent cell 
cycle, but ERα-overexpressing MCF-7 cells showed no observable second S phase within the 
45 hour time frame studied (Figure 21).  The parental MCF- 7 cells then enter G2/M phase at 
25 hours, peaking at 28 and exiting completely from G2/M by 31 hours after release from 
arrest. After a slow exit from S phase, the ERα-overexpressing MCF-7 cells entered G2/M 
phase at 25 hours, peaked at 34 hours and exited the G2/M phase at 39 hours after release 
from arrest.  
        The outcome of the repeat of this experiment (II) was similar to experiment I (Figure 21, 
right column). Together, the data showed that ERα-overexpressing MCF-7 cells exhibit 
prolonged S and G2/M phases compared to parental MCF-7 cells, resulting in an 
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approximately six hours delay in the cell cycle (Figure 21). These results support our 
hypothesis that unliganded ERα has an inhibitory effect on the progression of the cell cycle. 
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Figure 21: Overexpression of ERα  elongates the S and G2/M phases. FACS analysis was 
performed on parental MCF-7 cells and HA-ERα-overexpressing MCF-7 cells to compare 
the effects of exogenous ERα on the phases of the cell cycle. Left column shows the results 
of experiment I, while the right column shows the duplicate experiment II.   
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        Exogenous ER is cell cycle regulated and expressed similarly to endogenous ERα  
        We next performed a similar experiment to HA-ER overexpression in MCF-7, by 
overexpressing ER in an otherwise ER negative cell line, MDA-MB231. To this end, we 
transfected MDA-MB231 with ERα cDNA and initially examined the timing of ER 
expression following transfection by harvesting cells every six hours for 36 hours following 
transfection.  ERα expression was first detected 12 hours after the transfection of ERα into 
the unsynchronized MDA-MB231 cells (Figure 22A).  MDA-MB231 cells were also 
synchronized using lovastatin and ERα was transfected in to the cells at time point zero 
(mevalonate mediated release from arrest) and cells were harvested every 4 hours to extract 
lysates for western blots (Figure 22B).  Exogenously transfected ERα resulted in low levels 
of expression at 12 hours, which had decreased by 16 hours and was completely undetectable 
by 20 hours after release. However, the expression of ERα was again observed at 24 hours 
and for the duration of the experiment (Figure 22B).  
   The data suggest that ERα expression observed at 12 and 16 hours is due to the 
transcription and translation of the transfected construct (as this is what we observed in the 
unynchronized cells (Figure 22A). However, in the synchronized cells, the exogenous 
expression was immediately down regulated in part since the majority of the cells reside in 
G1 phase at at 12 hours after release from arrest for synchronization. Based on the previous 
data, ERα is cell cycle regulated is expressed predominantly at the S and G2/M phases 
(Figure 15). Therefore the cell cycle regulatory mechanisms that are responsible for the 
expression of ERα in G2/M and/or the repression of ERα in G1 phase are down regulating 
ERα expression at the 12, 16 and 20 hour time points. ERα re-expression at the 24 hour time 
point correlates with the time point where the majority of cells are expected to reside in the 
late S and G2/M phases.  Hence, the transfection of both synchronized and unsynchronized 
MDA-MB231 cells with ERα showed that ERα is under tight cell cycle regulation that 
results in expression during G2/M phases whether the protein is exogenously  or 
endogenously expressed.  Furthermore, by monitoring the timing of expression of the 
transfected ERα, it was determined that cells required 12 hours to process the transfected 
DNA into expressed protein; therefore, for future experiments that require transient 
transfection, the cells will be transfected 12 hours prior to their release from arrest so that by 
the zero time point the transfected ERα is expressed. 
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Figure 22: The timing of ERα  expression in unsynchronized and synchronized 
MDA­MB231 cells after transfection with ERα . Western blot analyses of (A) 
unsychronized MDA-MB231 cells and (B) synchronized MDA-MB231 cells, which have 
been transfected with ERα and harvested every four to six hours to extract lysates. 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  ERα  expression is cell cycle regulated in an ER-negative cell line  
        Both exogenous and endogenous ERα are cell cycle regulated in ER positive cell lines 
MCF-7 and ZR75-1 cells (Figures 22, 15 and 18). The next objective was to determine 
whether ER-negative cells could regulate exogenous ERα expression similar to that of 
endogenous ERα in ER-positive cells.  A pcDNA3.1 vector containing the human ERα gene 
was generated for these experiments.   
        MDA-MB231 cells were synchronized in the same manner as MCF-7 cells previously, 
with lovastatin. As shown in Figure12 MDA-MB231 are synchronized very effectively with 
lovastatin with 80 to 85% of the cells arresting in G1 and released synchronously once 
lovastatin is removed.  ERα was transfected into the MDA-MB231 cells 12 hours prior to the 
release of the cells from lovastatin arrest (as determined in Figure 22). Following 
synchronization, cells were harvested at four hour time intervals and subjected to flow 
cytometry to determine the cell cycle distribution and western blot analysis with ERα and 
key cell cycle regulators (cyclin E, cyclin A and cyclin B) to ascertain the cell cycle 
expression pattern of ERα. 
        Cyclins E, A and B demonstrated a sequential expression pattern of cell cycle 
expression, which coincided with the cell cycle phase that they are known to regulate (Figure 
23A). For example, cyclin E expression was observed between 12 and 24 hours, which 
corresponded with G1 phase from the FACS data (compare G1 phase with cyclin E 
expression).  Cyclin A was induced at 20 hours post lovastatin release, and the FACS data 
showed that this time point corresponded to early S phase or the time point in which the 
percentage of cells entering S phase is increasing (Figure 23B).  Lastly, cyclin B expression 
was up-regulated at 27 hours, which corresponded to the entrance of the cells to G2/M phase 
based on the the FACS data. The percentage of cells in G1 phase had declined sharply by 24 
hours after entering the cell cycle (Figure 23B) and expression of exogenous ERα protein 
levels were also upregulated at 24 hours, after which it remained high. Therefore, the timing 
of ERα expression coincides with the entrance of cells in to S and G2/M phases (Figure 
23B), which is also consistent with the expression of cyclin A and cyclin B (Figure 23A).  In 
summary, the ER negative cell line MDA-MB231 has the ability to regulate the expression of 
ERα in a cell cycle dependent manner similar to that of ER positive cells, with expression 
coinciding with the S and G2/M phases of the cell cycle. 
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Figure 23: Exogenous ERα  is cell cycle regulated in the ER negative, MDA-MB231 
cells.  MDA-MB231 cells were synchronized with lovastatin and lysates were subjected to 
(A) western blots to assess ERα, cyclin A, cyclin B and cyclin E expression.  (B) FACS 
analysis was also performed on the cells to determine the percentage of cells in each cell 
cycle phase. The data used here has also been used to plot the experiment I (MDA-MB231 
cells) figure 12.  
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ERα  shortens the S and G2/M phases of ER-negative, MDA-MB231 cells. 
        In MCF-7 cells, liganded ERα has been shown to significantly decrease the time that 
cells spend in S and G2/M phases compared to unliganded ERα which delayed cell cycle 
progression (Figure 14).  Therefore, the effect of exogenous ERα on the cell cycle phases in 
otherwise ER-negative cells was also examined.  Lovastatin synchronized MDA-MB231 
cells were transfected with ERα twelve hours prior to the release of the cells from arrest, at 
which point the E2-positive group received E2. Samples were then harvested and prepared 
for flow cytometry.  
        Figure 24 shows duplicate experiments of lovastatin synchronization of MDA-MB231 
cells. In experiment I, lovastatin arrested 80% of the cells at G1 phase. Upon release of the 
cells from lovastatin arrest, the cells entered into and progressed through the cell cycle 
synchronously (Figure 24-expeiment I). The comparison of G1 phases between the E2-
positive and E2-negative conditions showed that the cells began to exit G1 phase at the same 
time (17 hours) under both conditions. However, cells in the presence of E2 exited G1 faster 
(they have a sharper drop-off in the percentage of cells in G1 phase) than those in the 
absence of E2.  
        Under E2-positive conditions, cells exited G1 at 25 hours, whereas under E2-negative 
conditions, cells exited G1 phase at 31 hours following release.  In both condtions, the cells 
progressed through the remainder of the cell cycle until they again entered into the G1 phase 
of the subsequent cell cycle. The population of cells entered S phase at 18 hours, had the 
greatest percentage of cells in S phase occurred at 22 hours and then underwent a sharp 
decline, showing cells exiting S phase by 28 hours in the E2-positive condition.  However in 
E2-negative conditions, cells entered S phase at 20 hours, peaked at 30, and exited S phase at 
35 hours after release. Lastly in the comparison of the G2/M phases, it is apparent that MDA-
MB231 cells treated with E2 exhibited a premature G2/M phase compared to those in the 
absence of E2.  Specifically, cells in the presence of E2 entered G2/M phase at 21 hours, 
formed a peak at 26 hours and exited G2/M at 34 hours after release. The cells kept in E2-
negative conditions entered G2/M phase at 25 hours, formed apeak at 36 hours, and finally 
exited G2/M at 42 hours. The combined S and G2/M phases demonstrated 6-8 hours of delay 
in cell cycle progression in the absence compared to the presence of E2 (Figure 24-
experiment I). The next column on the right shows a second repeat (experiment II) of 
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lovastatin synchronization on MDA-MB231 cells to compare the G1, S and G2/M phases of 
liganded exogenous ERα (E2-positive condition) and the unliganded exogenous ERα (E2-
negative condition). The results from the repeated experiment also confirmed the results from 
experiment I. Table 5 summarizes the results and quantifies the change in duration of S and 
G2/M phases in MDA-MB231 cells with ERα in the presence or absence of ligand. The total 
time spent by MDA-MB231 cells under E2-free conditions in a cell cycle was 37.5 hours, 
while the MDA-MB231 cells in the presence of E2 spent 35.75 hours in one round of the cell 
cycle. Treatment of the MDA-MB231 cells with estradiol resulted in a faster progression of 
cells through S phase and G2/M phase. Due to faster progression of the cells through cell 
cycle phases in E2 teated conditions (specifically through S and G2/M phases) cells form S 
phase peak 6.25 hours earlier and G2/M phase peak 3.25 hours earlier in the E2-treated 
condition (Table 5).  
  118 
 
       
 
 
 
 
 
 
 
Table 5 – Analysis of G1, S and G2/M phases of MDA-MB231 cells upon transfection of 
ERα in the presence versus absence of E2.  The change in the time for completion of one cell 
cycle in the presence or absence of E2 is shown along with statistical analysis.  
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Figure 24: Exogenous ERα  hastens the passage through S and G2/M in the presence of 
E2 in MDA-MB231 cells. FACS analysis data of two experiments (I and II) in which MDA-
MB231 cells expressing exogenous ERα were synchronized by lovastatin in the presence or 
absence of E2. The percentage of cells in each phase of the cell cycle is shown for the time 
following release from arrest.  The filled circle show liganded ERα compared to open circles 
showing the E2-negative condition. The time differential in each phase of the cell cycle 
between E2-positive and E2-negative conditions are noted on the figure and again in table 
format in table 5 
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Unliganded, exogenous ERα  prolongs the S and G2/M phases of the ER-negative cell 
line MDA-MB231 
        In MCF-7 cells, liganded ERα has been shown to significantly decrease the time that 
cells spend in S and G2/M phases compared to unliganded ERα (Figure 14).  However, 
overexpression of ERα in MCF-7 cells had an inhibitory effect on cell cycle progression 
compared to parental cells with only endogenous levels of ERα (Figure 21). To further 
examine the effect of the receptor (unliganded ERα) on the cell cycle, exogenous ERα was 
introduced in to otherwise ER-negative MDA-MB231 cells that had been synchronized using 
lovastatin. 
        The length of the cell cycle phases was examined by FACS analysis to examine the 
effects of ERα expression on MDA-MB231 cells. The parental MDA-MB231 cells exited G1 
phase at 20 hours after entering the cell cycle after arrest, while the ERα-overexpressing 
MDA-MB231 cells exited G1 phase at 23 hours (Figure 25-experiment I). Parental cells then 
entered S phase at 18 hours and peaked in S phase at 28 hours, while the ERα-
overexpressing MDA-MB231 cells entered S phase 20 hours and peaked at 32 hours after 
release (Figure 25-experiment I). Parental cells entered G2/M phase at 25 hours Peaking at 
33 hours compared to the ERα-overexpressing MDA-MB231 cells that entered G2/M phase 
at 33 hours, peaking at 37 hours after release (Figure 25-experiment I). 
        The middle column shows a repeat (experiment II) of lovastatin synchronization on 
MDA-MB231 cells and the right column shows the third replicate (experiment III) to 
compare the duration of G1, S and G2/M phases in ERα-overexpressing MDA-MB231 cells 
and parental MDA-MB231 cells. The results from experiments II and III supported those of 
experiment I. In summary, the introduction of exogenous ERα to MDA-MB231cells resulted 
in prolonged S and G2/M phases compared to parental MDA-MB231 cells, which did not 
express any ERα (Figure 25). These observations suggest that overexpressed ERα, in the 
absence of E2, has an inhibitory effect on the progression of the cell cyle that is similar to 
that of endogenous ERα in MCF-7 cells (Figure 21). 
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Figure 25: Exogenous ERα  inhibits the cell cycle of MDA-MB231 cells, similarto the 
effect of endogenous ERα  on the cell cycle in MCF-7 cells. FACS analysis of lovastatin 
synchronized MDA-MB231 cells is shown as the percentage of cells in each cell cycle phase 
over a 50 hours period. Three replicate experiments are shown (experiments I, II and III).   
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Differential effects of Tamoxifen and fulvestrant on cell cycle progression could be due 
to their unique interactions with ERα  
        Tamoxifen and fulvestrant are both antiestrogens used extensively in the clinic that exert 
their inhibitory effect on tumor proliferation by blocking the estrogenic activity through ER.   
Upon binding to ERα, both fulvestrant and tamoxifen inhibit the transcription of estrogen 
sensitive genes. However the binding of fulvestrant to ERα increases the rate of ER 
degradation and subsequently reduces the amount of ER protein in the cell, whereas 
tamoxifen has no effect on the stability of ERα. 
        The results presented thus far show that 1) unliganded ERα has an inhibitory effect on 
the cell cycle compared to liganded ERα and 2) down regulation of ERα increases 
progression through the cell cycle. The fact that fulvestrant degrades ERα while tamoxifen 
maintains the integrity of ERα protein, provided the experimental tools and the rationale to 
compare the effect of tamoxifen (intact ERα) versus fulvestrant (degraded ERα) on the 
progression of cells through the cell cycle. The hypothesis we tested here is that fulvestrant 
would hasten the passage of cells through the cell cycle due to the degradation of ERα, 
however treatment of cells with tamoxifen would not cause changes in cell cycle regulation 
due to its inability to downregulate or degrade ERα. To address this hypothesis, MCF-7 cells 
were treated with various concentrations of fulvestrant and tamoxifen and the time for 
progression through the cell cycle phases was determined (Figures 26A and 27A).  
        All concentrations of fulvestrant tested (2.5nm, 5nM, 10nM, 20nM, 40nM and 80nM) 
resulted in ERα degradation in MCF-7 cells (Figure 26A). In contrast, none of the doses of 
tamoxifen tested (2µM, 4µM, 6µM, 8µM and 10µM) affected the ERα protein stability in 
MCF-7 cells significantly (Figures 27A).  The treatments with 8µM and 10µM tamoxifen 
degraded ERα slightly. As a result of the downregulationo of ERα at high concentrations of 
tamoxifen, 5µM tamoxifen was used for comparison against 5nM fulvestrant in the lovastatin 
synchronization experiments. 
   To compare the effects of tamoxifen with fulvestrant on the transition of cells from 
the phases of the cell cycle, MCF-7 cells were synchronized with lovastatin and then treated 
with either tamoxifen (5µM) or fulvestrant (5nM) in parallel experiments. The results 
depicted in Figure 26B show that MCF-7 cells in the presence of fulvestrant entered S phase 
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at 8 hours, while the untreated MCF-7 cells entered S phase at 12 hours.  The percentage of 
cells in S phase then formed a peak 15 hours in fulvestrant compared to 20 hours in untreated 
cells. Cells exited S phase at 22 hours after treatment with fulvestrant, which was 6 hours 
earlier than the exit at 28 hours by untreated cells (Figure 26B). Cells entered G2/M phase of 
the cell cycle at 17 hours and reached a maximum at 25 hours regardless of whether they 
have been treated with fulvestrant or not. The fulvestrant treated MCF-7 cells, however, 
declined sharply and exited G2/M phase by 28 hours, while the untreated cells did not exit 
G2/M phase until 32 hours after release.  Therefore, fulvestrant affected the S and G2/M 
phases of the cell cycle by promoting the progression of the cells through S and G2/M 
phases. These results support the previous finding that down regulation of ERα in ER-
positive cells causes progression of the MCF-7 cells through G2/M phase (Figure 20).   
        In contrast to the increased progression through the cell cycle observed with fulvestrant 
treatment, tamoxifen treatment slowed down the progression of lovastatin synchronized 
MCF-7 cells through S and G2/M phases compared to untreated cells (Figure 27B). 
Untreated MCF-7 cells entered S phase at 8 hours and peaked at 15 hours, while the 
tamoxifen treated cells entered S phase at 12 hours and peaked at 20 hours after release from 
arrest (Figure 27B). Similar results were observed for the progression of treated versus 
untreated cells through G2/M phase. Untreated cells entered G2/M phase at 17 hours, while 
tamoxifen treated cells entered G2/M phase at 20 hours. The tamoxifen treated cells showed  
an overall slower progression through G2/M phase and a delay of 5 hours entering the G2/M 
phase of the subsequent cell cycle compared to untreated cells (Figure 27B). 
        In summary, fulvestrant treatment of synchronized MCF-7 cells resulted in a shorter S 
and G2/M phases compared to tamoxifen treatment (Figure 28). These differences in cell 
cycle progression could be accounted for by the effects of tamoxifen and fulvestrant on the 
stability of the ERα protein as the results with fulvestrant treatment, which mirror those from 
the shERα experiments in which ERα was silenced in MCF-7 cells (Figure 20).   The MCF-7 
cells treated with tamoxifen have a cell cycle profile similar to that of MCF-7 cells and 
MDA-MB231 cells with over expressed ERα (Figures 21 and 25). Tamoxifen treatment 
leaves the ERα protein intact, therefore the changes in transcription downstream of ER play a 
role in stalling the S and G2/M phases of the cell cycle upon treatment with tamoxifen. 
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Figure 26: Fulvestrant down regulates ERα  in MCF-7 cells, which results in 
progression through S and G2/M phases.  (A) MCF-7 cells were treated with increasing 
concentrations of fulvestrant and lysates were subjected to western blot analysis of ERα 
expression.  (B) MCF-7 cells were synchronized and cultured in the presence or absence of 
5nM fulvestrant.  At the indicated intervals, samples were collected and subjected to FACS 
analysis to determine the percentage of cells in S phase (upper graph) or G2/M phase (lower 
graph). 
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Figure 27: Tamoxifen preserves ERα  protein resulting in an inhibitory effect on the 
progression through S and G2/M phases of the MCF-7 cell cycle.  (A) MCF-7 cells 
were treated with different concentrations (0 - 10µM) of tamoxifen (TAM) and lysates 
were run on a western blot and probed for ERα.  (B) MCF-7 cells were synchronized and 
cultured in the presence or absence of 5µM tamoxifen. At the indicated intervals, samples 
were collected and subjected to FACS analysis to determine the percentage of cells in S 
phase (upper graph) or G2/M phase (lower graph). 
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Figure 28: Fulvestrant treatment of MCF-7 cells results in premature progression 
through S and G2/M phases of the cell cycle compared to tamoxifen treatment. 
Lovastatin synchronized MCF-7 cells were treated with tamoxifen or fulvestrant and 
subjected to FACS analysis.  The percentage of cells in (A) S phase and (B) G2/M are shown 
over the 50 hour period after release from arrest are compared between the two different 
treatment groups. 
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DISCUSSION 
        ERα is an important regulator of growth and differentiation in normal breast tissues 473.  
Normal mammary cells do not express ERα, except when needed for proliferation during 
puberty and pregnancy 302.  However, there is considerable evidence that ERα also plays an 
important role in the development and progression of breast cancer 5.  For example, clinical 
experience has established that ER-positive breast tumors have a more favorable prognosis 
compared to tumors that have little or no expression of ERα 292. Therefore, the functional 
role of ERα expression in breast cancer etiology is paradoxical; the expression of ERα is 
associated with good prognosis, but ERα is low in normal mammary cells and absent in 
triple negative tumors, which have an extremely poor prognosis.  Because it is not clear 
whether the presence or absence of ERα provides a mechanism for cancer cell growth, one 
should not categorize it as an oncogenic factor. Unlike ER, a typical protein with oncogeneic 
function, is the, Low Molecular Weight forms of cyclinE (LMW-E) which is associated both 
with poor prognosis and increased deregulated proliferation in  tumor cells and tissues 474.  
        The question that I set out to address in this chapter was whether the presence or 
absence of ERα provides the means that could cause progression of breast cancer.  Previous 
reports suggest that the presence of ERα could have an inhibitory effect on the proliferation 
of breast cancer cells 475, 476. However, the effects of ERα on the machinery of proliferation 
(the cell cycle) have not been shown. 
        The experiments described in this chapter are the first (to my knowledge) to address the 
effects of ERα on different phases of the cell cycle. The model system consisted primarily of 
MCF-7 cells, an ER-positive cell line, cultured in media supplemented in the presence or 
absence of the ER ligand E2.  However, to show that the results are not cell type specific, 
ZR75-1 cells, which are also ER-positive, were used to validate the generality of the results 
obtained with MCF-7.  Lovastatin was used to arrest the cells at G1 phase of the cell cycle 
and then the cells were released synchronously into the cell cycle by addition of mevalonate, 
which allowed for evaluation of cell cycle expression of ERα.  To study the effects of ligand 
on ERα, synchronization experiments were performed in duplicate arms, the arm that 
received E2 is considered liganded and the second arm is considered unliganded ERα as no 
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E2 was added to culture medium.  To compare effects of the presence versus absence of ERα 
on the cell cycle, MCF-7 cells with endogenous ERα expression or silenced ERα were 
utilized. Silencing ERα in MCF-7 cells provided a good model to compare the presence of 
versus absence of ERα in the same cell line. MDA-MB231 cells, which is an ER-negative 
cell line, was also used to examine whether exogenous ERα could mirror the cell cycle 
effects that were observed in MCF-7 cells with endogenous ERα.  
The data clearly shows that ERα is a cell cycle regulated protein (Figure 13).  
Western blot analysis of the samples harvested at time points taken through the different 
phases of the cell cycle revealed that ERα protein expression is low at G1 and is induced to 
its maximum level during S and G2/M phases of the cell cycle (Figure 13).  . To confirm the 
cell cycle regulation of ERα, ZR75-1 cells were also synchronized using lovastatin and cells 
were then released through the cell cycle phases. ERα showed the same pattern of cell cycle 
regulation in ZR75-1 as in MCF-7 cells (Figure 18).  Furthermore, the cell cycle regulation 
of ERα is independent of the ligand, 17-βestradiol (E2) as both liganded ERα and 
unliganded ERα are expressed during S and G2/M phases.  Eventhough the presence versus 
absence of 17β estradiol had no effect on the expression of ERα during S and G2/M phases, 
the presense of ligand resulted in a sharp rise and fall of the protein expression for ERα, 
which coincided with cyclin A and cyclin B expression during S and G2/M phases of the cell 
cycle (Figure 13).  On the other hand, in the absence of the ligand, the S and G2/M phases 
are prolonged (Figure 13 & 14).   FACS analysis confirmed the prolonged duration of S and 
G2/M phases in cells in the presence of unliganded ERα compared to the presence of 
liganded ERα (Figure 14). Interestingly, despite seeing consisnent shortening of G2/M phase 
of the cell cycle of MCF-7 cells in the presence of estradiol, we did not observe a change in 
the proliferation of MCF-7 cells over a 10 day period (Supplemental Figure 1).   
Next, we asked if ERα cell cycle regulation is at the level of transcription.  To answer 
this question, we harvested RNA at different time intervals following synchronization of 
MCF-7 by lovastatin, followed by qRT-PCR for ER. The results show that the level of ERα 
RNA expression remians constant and does not change during the cell cycle and is therefore 
not regulated at the level of transcription. 
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        ER negative cells also have the machinery necessary to regulate ER expression.  
Exogenous ERα was introduced into the ER-negative cell line MDA-MB231 and was 
expressed during S and G2/M phases similar to the endogenous ERα of MCF-7 cells (Figure 
22).  These experiments raise the question of whether ectopic expression of ER result in a 
different timing of expression compared to the cell cycle regulated expression of endogenous 
ERα.  So initially we transfected ERα into asynchronous MDA-MB231 cells  and examined 
when ER protein can be detected upon transfection (Figure 22A). The results clearly reveal 
that ERα is expressed within 12 hours of the transfection. However in synchronized cells 
ERα is predominantly expressed at 24 hours following transfection, which coincides with the 
exit of cells from S phase and entrance into G2/M phase of the cell cycle. It should be noted 
that in these synchronized cells, low levels of ERα are still detectable 12 hours following the 
transfection, which is diminished by 16 hours, most likely due to the cDNA expression time 
after the transfection.  The tight cell cycle periodicity in the transfected MDA-MB231 cells is 
very similar to that seen with endogenous ERα in MCF-7 cells and ZR75-1 cells, which also 
coincided with the expression of cyclins A and B. We also interrogated the role of 
unliganded versus liganded exogenous ERα in modulating the cell cycle in MDA-MB231 
cells.  Liganded ERα shortened the S and G2/M phases compared to non-transfected MDA-
MB231 cells in the presence of E2.   
        To ensure that cell cycle effects observed in MCF-7 cells were due to ERα, and 
not the method by which the cells were synchronized, we used a different method to 
synchronize cells by using aphidicholin as an arresting agent (Figure 15).  The ERα 
expression was again examined along with the cell cycle profile after arresting cells with 
aphidicolin. Aphidicholin arrests cells at the end of G1 phase, therefore after release from 
arrest cells enter S phase immediately.  As a result, two cell cycles could be follwed during a 
44 hour time span. Two peaks of ERα expression were observed, which corresponded with 
an increase in the S and G2/M population of the cells. The FACS data confirmed the results 
acheived with lovastatin.  In both cases, liganded ERα hastens the progression through S and 
G2/M phases of the cell cycle compared to unliganded ERα, which has a reverse effect and 
prolongs the S and G2/M phases duration compared to parental cell line (Figures 14 and 16). 
However the change was observed in the second cell cycle phase after treatment with 
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aphidicolin. It is possible that upon traetment with aphidicolin, the cells arrest slightly later in 
the cell cycle and the machinery regulating ERα expression are not active until the second S 
and G2/M phases. These data emphasize the notion that ERα is cell cycle regulated and that 
ERα, in turn, modulates the cell cycle. Other arresting agents can also be used to effectively 
synchronize MCF-7 cells, such as double thymidine block and using this third method of 
synchrony we also observed a difference in the way presence of ligand would affect the cell 
cycle progression.  The results of double thymidine synchronization of MCF-7 in the 
presence and absence of the ligant is shown in Supplemental Figures 2 and 3. 
        We next directly addressed the role of ERα in mediating the changes in cell cycle 
profile by ligand in MCF-7 by downregulating it and alternatively by overexpressing it in 
both MCF-7 and MDA-MB231 cells. The rational for these series of experiments came from 
the fact that increased ERα expression appears early in the pre-malignant to malignant 
progression of breast cancer 7 while the more aggressive form of breast cancer do not express 
ER477. At this point the question was solely the role of ERα on cell cycle progression. ERα 
was silenced in MCF-7 cells and also overexpressed in both MDA-MB231 and MCF-7 cells. 
ERα depletion showed acceleration of mitotic exit whereas ERα overexpression resulted in a 
prolonged S and G2/M phase. These data show that even without taking the ligand E2 in to 
account, the receptor has cell cycle effects.  The presence of unliganded ERα inhibits the cell 
cycle and the absence of ERα increases cell cycle progression.  The proliferative respsonse to 
a lack of ERα may partially explain the aggressive phenotype of the ER-negative tumors.  
        Tamoxifen and fulvestrant are anti-estrogens, which antagonize the ERα signal in 
different ways. Tamoxifen does not affect the integrity of ERα protein while fulvestrant 
results in the down regulation of ERα. These agents provided tools to modulate the 
expression of ERα in vitro as is done in the clinical setting.   ERα degradation after 
fulvestrant treatment caused a faster cell cycle progression through S and G2/M phases 
compared to the untreated cells.  There was a striking difference in the cell cycle profiles of 
cells treated with fulvestrant compared to tamoxifen because tamoxifen treatment which 
resulted in the elongation of S and G2/M phases compared to the fulvestrant treated cells. 
These data support the findings that shERα also shortened the duration of S and G2/M 
phases 
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        There are increasing numbers of reports showing that proteasome inhibitors are 
effective for certain types of cancer 478. The effectiveness of proteasome inhibitors for breast 
cancer is yet to be seen 479. However, our data suggest that the inhibition of proteasome 
mediated ERα degradation may be effective to restrain proliferation of breast cancer cells.  
There is some data showing that the proteasome inhibitor, PS-341, inhibits the growth of 
MCF7 cells 480.  The traditional antiestrogen, tamoxifen, not only binds to ERα to antagonize 
it, but also inhibits ERα’s degradation 481.  Therefore it would be interesting to be able to 
tease apart these two effects of tamoxifen to determine whether inhibition of ERα’s 
transactivation and/or inhibition of the degradation of ERα accounts for its antiproliferative 
role in ERα-positive cancer cells. 
        In summary the results described here show that ER is cell cycle regulated at the G2/M 
phase of the cell cycle.  Further, upon removal of ER from an ER-positive cell line, the 
length of G2/M is reduced, while overexpression of ER inhibits cell cycle progression during 
G2 and M phase in both ER-positive and ER-negative breast cancer cells. These data imply 
that ERα is an important factor in modulating the cell cycle, which could lead to inhibition or 
progression of the tumor cells. These data also provide the rationale for the hypothesis that 
ERα has opposing effects on the progression of cell cycle in G2/M phase, under non-
liganded and liganded conditions, suggesting that estradiol increases cell cycle progression. 
The next chapter of my dissertation will address the mechanisms responsible for changes in 
ERα expression throughout the cell cycle and the pathways downstream of ERα, which 
modulate cell cycle progression. 
 
 
 
 
 
 
 
 
 
 
  132 
Chapter III:    
The cell cycle dependent regulation of ERα and the resulting modulation of G2/M phase are 
due to an interaction of ERα with cyclin B. 
 
INTRODUCTION 
         In chapter II we showed that ERα is expressed in a cell cycle regulated manner in ER-
positive cell lines and when exogenously expressed in ER-negative cell lines (Figures 13 & 
22).   Furthermore our data also showed that the changes in the ERα expression throughout 
the cell cycle were not regulated at the level of transcription (Figure 17). We also showed 
that the addition of estradiol to the cells shortened the transition of cells from S into G2/M 
phase of the cell cycle. Lastly we showed that exogenously expressed ERα in ER-negative 
cells (MDA-MB231) slows down the cell cycle progression while silencing ERα in ER-
positive cell (MCF-7), speeds the cell cycle progression.  
        In this Chapter we set out to investigate if the turnover of ER is responsible for the 
progression of cells through the cell cycle. It is well established that turnover of ERα protein 
is mediated through the ubiquitin–proteasome pathway 482. Specifically, it has been shown in 
an in vitro setting that ER degradation depends on E1 (ubiquitin-activating enzyme) and E2 
(ubiquitin-conjugating enzymes) 483. The results from Chapter II suggested that the regulation 
of ERα during S and G2/M phases of the cell cycle is at the protein level (Figure 7).  These 
important and novel findings led to the hypothesis that this cell cycle turnover of ERα is also 
regulated by proteasomal degradation.   Chapter III addresses the question of whether ER 
protein is regulated at the level of proteasomal degradation in a cell cycle manner and if so, 
what cellular process targets ERα for degradation.  
        While analyzing the changes in cell cycle protein expression, it was observed that ERα 
is down regulated at the end of G2/M, which coincided with the timing of cyclin B down 
regulation leading to the hypothesis that ERα could share the E3 ligase, Anaphase Promoting 
Complex (APC), with cyclin B. The first question to address was whether ERα is 
ubiquitinated upon exposure to APC.  In collaboration with Dr. Weihua Zhang (University of 
Houston), it was observed that ERα became ubiquitinated at the end of M phase upon 
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exposure to APC along with E1 and E2 enzymes. To directly show that APC targets ERα to 
the proteasome, the next step was to determine whether ERα binds to the components of 
APC and determine if the inhibition of the proteasome by MG132 could lead to the down 
regulation of ERα at the end of M phase. The results showed that ERα and cyclin B both 
bind to cdc27, which is one of the components present in the APC complex. Based on this 
novel finding we hypothesized that ERα and cyclin B bind together directly. Through 
immunoprecipitation experiments cyclin B/Cdk1 was identified as an ERα interacting 
protein.  
        We have previously shown that liganded ERα causes increased progression through S 
and G2/M phasse of the cell cycle.  Therefore, the next question was how liganded ER 
confers the increased progression through S and G2/M phase of the cell cycle compared to 
unliganded ER. The results showed that ERE site is transcriptionally active during S and 
G2/M phases in the presence of liganded ERα compared to the unliganded ERα. The 
transcription of well established ERα targets genes such as PgR and pS2 484, 485 were also 
examined in collaboration with Dr. Powel Brown’s laboratory (UT-MDACC). The induction 
of PgR and pS2 transcription during S and G2/M phases were reported using qRT-PCR. In 
summary this chapter will further investigate the mechanisms behind the cell cycle regulation 
of ERα and how liganded ERα results in a fast progression of cells through S and G2/M 
phases of the cell cycle while unliganded ERα prolongs these phases.  
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MATERIALS & METHODS 
 
Immunoprecipitation Assays 
        MCF-7 cells were cultured in E2-free media and were synchronized with lovastatin as 
described in Chapter II. Cells were harvested using trypsin and were resuspended in ppi 
(protease/phosphatase inhibitor- components listed under western blot analysis in chapter II) 
for sonication. After performing a protein assay to determine protein concentration, lysates 
were kept in -80°C. For immunoprecipitation (IP), protein lysates were thawed on ice. 300-
500µg of protein lysate was aliquoted for each IP and the volume was adjusted to 50µL with 
1x PBS. 30µL of 0.1g/mL sepharose A beads (Amersham/GE Healthcare- Piscataway, NJ) 
were aliquotted for each sample. The beads were resuspended in an equal volume of 1x 
buffer [11.2ml of 5x lysis buffer (3mL of 1M Tris HCl, pH 7.5, 3mL of 5M NaCl, 300µL of 
20% NP-40 and 5.7 mL of ddH2O), 7mL of 10x ppi and 39.6mL of ddH2O).  The beads in 
buffer were left on ice for 15 minutes to swell. The swelled beads were centrifuged for 3 
minutes at 6000rpm at 4°C.  The buffer was aspirated and the process of adding fresh buffer 
followed by centrifugation was repeated 3 times to wash the beads.  36µL of 10x5x10 buffer 
(225µL of 10x ppi, 450µL of 5x lysis buffer, 22.5µL of 0.1M DDT and 202.5µL of ddH2O) 
was added to each tube and antibody was added to each tube of protein lysate samples. For 
IP, 3µL of polyclonal cyclin B (Santa cruz, H-20, SC594) or 5µL polyclonal ERα antibody 
(Santa cruz, HC-20, SC543) was used per sample. The samples (lysates and antibody) were 
incubated for an hour in the cold room (4°C) with rocking. At the end of the first hour 
incubation, 30µL of beads was added to each sample and were mixed thoroughly.  The beads 
with protein and antibody were then incubated in the cold room for 3-4 hours with rocking.  
After incubation, the samples were centrifuged for 3 minutes at 6500rpm at 4°C. The 
supernatant was carefully removed without disturbing the beads and 300µL of 1x lysis buffer 
was added to wash the samples by centrifuging at 6500rpm for 3 minutes at 4°C. The wash 
was repeated four times. After the last wash the samples were subjected to western blot 
analysis as described in materials and method section of chapter II. Blots probed with  anti-
ERα (Novocastra Laboratories-UK) or anti-cyclin B monoclonal (GNS-1) antibodies at 
1µg/mL in blotto and developed as described in chapter II.  
  135 
 
GST Pull-down Assay 
        The GST-ERα construct was provided to us by Dr. Kumar’s lab 486. The construct 
contained a gene for ampicillin (Amp) resistance. The GST-ERα construct was transformed 
into BL21 gold competent cells in order to amplify the plasmid and also to make bacterial 
stock. For transformation, the BL21cells were thawed on ice and 100µL of the competent 
cells were aliquotted into pre-chilled polypropylene tubes. 50ng of GST-ERα was added to 
each reaction tube containing cells, which was then swirled gently and incubated on ice for 
30 minutes. Meanwhile, SOC medium (Super Optimal Broth) [2% tryptone 0.5% yeast 
extract, 10mM sodium chloride, 2.5mM potassium chloride, 10mM magnesium chloride, 
10mM magnesium sulfate, 20mM glucose] was preheated in a 42°C water bath. In the final 
step of cell transformation, the use of S.O.C. Medium results in maximal transformation 
efficiency of E. coli 487.  Each transformation reaction was heat-pulsed by placing it in 42°C 
water bath for 20 seconds, followed by incubation on ice for 2 minutes. Next, 0.9mL of 
preheated SOC medium to 42°C was added to each reaction and then incubated at 37°C for 
an hour while shaking at 250rpm. The cells were centrifuged for 5 minutes before lawn 
streaking the entire transformation reaction onto a single LB agar plate containing 100µg/mL 
of ampicillin.  The plates were then incubated over night at 37°C. The next day, a single 
isolated colony was picked for amplification by inoculating 5mL of LB broth plus Amp and 
incubated over night again at 37°C. The following day, 50µL of the 5mL culture was 
transferred to 50mL of LB plus Amp and again incubated over night at 37°C. On day three 
following transformation, the 50mL culture was added to 500mL of LB broth with Amp and 
incubated at 30°C for 3-4 hours, while checking the optical density (OD) at 600nm every 30 
minutes. The desired OD, signifying the optimum amount of density of the bacteria for the 
purpose of GST-pull down, is 1.2-1.6. Once the OD was within the optimal range, the sample 
was spun down at 7000rpm for 15 minutes at 4°C.  The resulting pellet was resuspended in 
10mL of lysis buffer (20% Glucose, 10% Glycerol, 2mM MgCl2, 50mM Tris pH 8.0, ddH2O 
to final volume of 100mL, 1M DTT and 10mL fresh ppi).  The sample was sonicated for 2-3 
minutes, pulsing at the 40-50 setting using a portable hand sonicator.  The lysates were set on 
ice for 20-30 minutes before centrifugation at 10,000rpm for 10-15 minutes at 4°C. The 
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supernatant was removed and added to 0.5mL of pre-soaked GST-beads [Glutathione 
Sepharose 4B, Amersham Pharmacia Biotech (Piscataway, NJ)] in PBS or NP-40 (50mM 
Tris, 150mM NaCl, 0.5% NP-40, Glycerol, MgCl2, EDTA, ddH2O to final volume of 
500mL). The beads and sample were rotated at 4°C for three hours before washing them 
three times with 8-10mL of NP-40 buffer and spinning at 3500rpm. The beads and attached 
proteins (GST- ERα) were then transferred to a 1.5mL eppendorf tube and kept at -80°C. 
         To ensure that the ERα-GST fusion protein was not degraded during the process of 
purification, the integrity of the samples were analyzed on a coomasie blue stained SDS-
PAGE gel. For in vitro binding assays, cyclin B protein was generated using TNT® quick-
coupled transcription/translation system (Promega, Madison-WI) for in vitro analysis of ERα 
binding to cyclin B. To this end, cyclin B was cloned into a pGEM vector, which is a vector 
containing a multiple cloning region and also SP6 and T7 polymerase promoters. The pGEM 
vector containing an SP6 promoter in front of the cyclin B gene was used for translation 
using the TNT kit.  All samples and reagents were kept on ice at all times to prevent 
degradation of the translated protein.  
         TNT® SP6 quick master mix, [35S] Methionine (1000 ci/mmol at 10 mCi/mL) and 
PCR-generated DNA template (0.5µg) were combined together and incubated at 30°C for 60-
90 minutes. The integrity of the cyclin B translation was monitored by its mobility on SDS-
PAGE gel. To examine the in vitro binding of ERα and cyclin B, 10µL of translated cyclin B 
was added to 2µg of either full-length or truncated GST purified ERα protein.  The truncated 
forms of ER protein were GST-AB (AB domain/AF1,), GST-C (C domain/DBD,), GST-D 
(D domain/Hinge region), GST-F (F domain/AF2), all fused to GST] or GST beads alone and 
400µL of protein-binding buffer (1M Tris, pH 7.5, 1M NaCl, Glycerol, 1% NP-40 also 
20µL/mL of sodium vanadate and 40µL/mL of fresh protease inhibitor), in each tube.  The 
samples were incubated at 4°C for 4 hours followed by six washes with protein binding 
buffer.  After centrifugation, the supernatant was removed and 10µL of 4x SDS dye was 
added prior to loading the samples for SDS-PAGE analysis.  The proteins were then 
transferred, stained with ponceau stain and developed by phoshpho-imager.  Ponceau 
staining allows for visualization of total protein and phospho-imager shows the specific 
proteins of interest by radio-labeling. 
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RNA Extraction 
         Total RNA was extracted from synchronized MCF-7 cells by Cesium Chloride 
separation and centrifugation. This method provided a high yield of pure RNA. Cells were 
cultured for each condition as indicated in the results section and for each experimental 
condition using 150mm plates cells were homogenized by addition 3mL of GIT (93.53g 
Guanidine Isothiocyanate powder and 1.67mL of 3M sodium acetate (NaAc) solution 
brought up to 200mL with DEPC water, filtered and kept in a dark container).  Before 
addition of GIT to each plate, 37.5µL of fresh β-mercaptoethanol was added.  The cells 
detached from the plate and were scraped for transfer to a labeled 15mL conical tube. The 
harvested cells were vortexed vigorously and DNA was sheared by passing the solution 
through a 18 gauge needle several times at which point 2.7 ml of RNA containing GIT 
solution was layered on top of a 1.9mL of CsCl solution. The tubes were centrifuged at 
38,000rpm overnight (up to 16 hours) at room temperature. The next day the RNA was 
visible as a clear pellet at the bottom wall of the Beckman tube. The supernatant was 
removed gently, without disturbing the pellet, which was then washed from the wall of the 
tube with 170µL of 0.3M sodium acetate (NaAc) and incubated in 37°C for 10 minutes.    
        After the incubation, 500µL of a 1:1 mix of phenol/chlorophorm was added to each 
tube, vortexed and centrifuged at room temperature at 14,000rpm for 3 minutes. The 
supernatant was transferred to a second labeled tube and the process of washing with 
phenol/chlorophorm was repeated 3 more times. After the washes, RNA was precipitated by 
the addition of 1mL of 100% ethanol to each tube and placed in liquid nitrogen for an hour, 
followed by pelleting the now purified RNA via centrifugation and washing the pellet with 
80% ethanol to remove any residual salt. The pellet was left to dry for an hour in a laminar 
flow hood then the RNA was reconstituted with 0.1X TE in DEPC water. The quantity and 
quality of RNA samples were assessed by determining the OD at 260/280.  The RNA 
prepared by this methodology can be stored at -80C for years without any degradation. 
 
 
ERE-Luciferase Assay 
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        The transcriptional activity of ERα at the ERE site was measured in lovastatin 
synchronized MCF-7 cells to examine the ERα associated activity during S and G2/M 
phases.  To this end MCF-7 cells, which had been kept in E2-free media for three weeks 
were exposed to lovastatin for 36 hours. Twenty-four hours after the lovastatin treatment (12 
hours prior to mevalonate treatment) cells were transfected with the construct containing 
ERE-Luciferase. Transfection took place without changing media on the cells in order to 
keep lovastatin on the cells. The negative controls used for these experiments were MCF-7 
cells, which did not transfect with ERE-Luc and also MDA-MB231 cells, which had been 
transfected with ERE-Luc. Thirty-six hours post lovastatin treatment (twelve hours after the 
ERE-Luc transfection) cells received mevalonate. At the time of mevalonate addition the E2-
positive group received 10nM E2 while the E2-negative group did not receive any E2.  
        After harvesting the cells, samples were prepared for luciferase assay.  500µL of passive 
lysis buffer (Promega-  Madison, WI) was added to each well of the six well plate that MCF-
7 cells had been cultured in.  The contents of the plates were mixed by rocking for 15 
minutes at room temperature. Then the cells in each well were scraped (triplicates for each 
time point and condition) and collected in labeled centrifuge tubes. The tubes were frozen 
and thawed three times using liquid nitrogen and a 37°C H2O bath to ensure complete cell 
lysis. After centrifuging the tubes for 10 minutes at 14000rpm, 20µL of each sample was 
transferred into the specific tubes used (BD Monolight™ Luminometer Cuvettes, 12X75 mm, 
Sparks, MD) 80µL of Luciferase Assay Reagent II (LAR II) (Promega-  Madison, WI) was 
added to the 20µL of the sample in the tube. Using an illuminator machine the firefly-
luciferase activity in each sample was quantified.  
 
ImmunoFluorescent staining 
        5x104 cells were plated on sterilized cover slips that had been placed inside each well of 
a 6 well plate. At the time of harvest cells on the coverslips were fixed with 4% 
paraformaldehyde in PBS at room temperature (RT) for five minutes, then washed with PBS 
for 3x 5minutes, followed by blocking (3% BSA containing 0.1% NP-40 in PBS) for 1 hour 
at RT. Primary antibodies were added at a dilution of 1:200 in blocking solution and were 
incubated on the slides at 4°C overnight. The next day, the slides were washed for 3 X 10 
minutes with PBS and were incubated with fluorescent labeled secondary antibodies for three 
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hours at RT. Slides were washed again with PBS for 3 X10 minutes and covered with 4',6-
diamidino-2-phenylindole (DAPI) containing anti-fade solution (Vector, Burlingame, CA). 
At the very last step the coverslip were flipped on a microscope slide so the side with the 
fixed/stained cells has direct contact with the slide. The slides and coverslips were sealed 
with a clear nail polish. Slides were then stored in dark in 4°C, and analyzed microscopically 
within 2 weeks of storage. Slides were then analyzed using an Olympus DSU spinning disc 
confocal fluorescent microscope. All the pictures were taken using a 60X lens.  
 
In vitro ubiquitination assay 
       The main components of this assay were purified ER, APC, E1 and E2. 100 µg of 
recombinant human ERα  (Panvera, Madison, WI) was further purified by 
immunoprecipitation with 200µL protein G conjugated Sepharose beads prebound to 10µg of 
rabbit polyclonal ERα antibody (MC20- Santa Cruz, CA). ER-bound beads were eluted with 
0.1M glycine and neutralized with 5mM Tris buffer to pH 7.0. The eluted ERα was then 
subjected to dialysis with saline at 4°C for 2 hours. The purified protein concentration was 
measured spectrophotometrically (OD 260) following dialysis.  
       For APC, we used anti-cdc27 antibody (one of the components of this E3 ligase) to 
purify it from cell extracts.  To this end, 100µL protein G conjugated sepharose beads, pre-
bound with10µg of goat anti-cdc27 antibody (Santa Cruz, CA), was used for APC 
purification through immunoprecipitation on 1mg of cell extracts from synchronized MDA-
MB231 cells, which correspond to G2/M phase. E1 activating and E2 conjugating enzymes 
were purchased from Boston Biochem (Cambridge, MA). 
        The in vitro ubiquitination assays were conducted in 30µL of reaction buffer (10mM 
Tris-HCl, 10mM NaCl, 30mM MgCl2, 1mM dithiothreitol, 0.1mM ATP, and 1.0mM 
Ubiquitin, pH 7.5) at 37°C with gentle rocking for 1 hour. The samples used in this assay 
were: 1) ERα protein/cdc27 antibody pre-bound protein G beads, 2) ERα/ E1/cdc27 antibody 
pre-bound protein G beads, 3) ERα/ E1/ E2/cdc27 antibody pre-bound protein G beads and 
4) ERα/ E1/ E2/protein G beads with precipitates of APC from G2 phase of MDA-MB231 
cells.  The reactions were terminated with SDS sample buffer and subjected to western blot 
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to analyze the ability to form polyubiquitin chains on ERα using monoclonal anti-ERα 
antibody. 
 
Reverse-Phase Protein Array (RPPA) analysis 
        RPPA analysis was performed to examine an array of different protein expression in 
MCF-7 cells in the presence versus absence of E2.   To prepare for RPPA, MCF-7 cells were 
plated in 100mm plates and incubated in 37°C at 6.5% CO2 in E2-free medium. Twenty four 
hours after plating, cells were synchronized with lovastatin as described in chapter II and 
were harvested in four hour intervals upon release from lovastatin by addition of mevalonate. 
Cells were harvested using the same procedure as for western blot analysis (see Chapter II). 
Lysates were stored in -20°C until all samples had been acquired for RPPA.  
Lysates (?1 nL of protein lysate was used to print the sample on the nitrocellulose 
glass slide) were first printed on the slides.  Non-specific binding events were blocked using 
a blocking buffer and then the slides were probed with primary followed by secondary 
antibodies. In order to amplify the signal slides go through a series of incubations, which are 
first incubation with streptavidin-biotin-peroxidase complex and then this incubation follows 
by biotinyl-tyramide/hydrogen peroxide incubation and finally incubation with streptavidin-
peroxidase. Using hydrogen peroxide the slides develope and then scaned by using 
DakoCytomation catalyzed signal amplification (CSA) system. The values obtained were 
ploted as the graphs shown in Figures 40 and Supplemental Figure 4. 
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RESULTS 
 
ERα  induces transcriptional activity through an ERE site during S and G2/M phase in 
MCF-7 cells.  
        Previous western blot and FACS analyses showed that ERα protein is maximally 
expressed in G2/M phase and causes rapid exit from the cell cycle in the presence of E2 
(Figures 13 and 14).  These data provided the rationale to examine the transcriptional activity 
of ER by measuring the ERE activity in cells that express ERα, to determine whether 
maximal expression of ERα at G2/M phases can also modulate the transcriptional activation 
at ERE site during G2/M. To this end, we measured the transcriptional activity at ERE sites 
in lovastatin arrested MCF-7 cells in complete medium without starving for E2. A dual 
luciferase assay was used to investigate the transcriptional activity initiated by ERα at ERE 
sites during different phases of the cell cycle. A schematic diagram of the experimental 
design used to synchronize the cells and introduce the ERE sites to MCF-7 cells is shown in 
Figure 29. The cells were then processed for FACS and luciferase assay, which were 
performed twice each.   Luciferase activity revealed that ERE is activated at 20 hours after 
cells enter the cell cycle, which overlaps with the time that cells are entering S phase. The 
ERE activity reached peaked at 30 hours, then dropped quickly (Figure 30B) which 
coincided with the peak and then decline of the percentage of cells in G2/M phase of the cell 
cycle (Figure 30A).  The experiment was repeated twice and the results were similar for both 
experiment I and II. In summary, the ERE driven luciferase assay showed increased ERE 
mediated transcriptional activity during S and G2/M phases, which coincided with the timing 
of ERα expression during the cell cycle. The next question was whether the transcriptional 
activity of ERE initiated by ERα protein is affected by the presence or absence of E2.  
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Figure 29:  Experimental design used to test ERE activity.  MCF-7 cells were cultured in 
E2 free media and synchronized using lovastatin.  Twelve hours prior to release from arrest 
using mevalonate, the cells were transfected with ERE-Luc plasmid.  Cells were then 
harvested for analysis by FACS and luciferase assays. 
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Figure 30:  ERE activity is elevated during S and G2/M phases in MCF-7 cells.   
(A) The percentage of cells in each phase of the cell cycle was determined by FACS analysis 
of lovastatin synchronized MCF-7 used for the luciferase assay. (B) ERE activity was 
assessed using a luciferase assay. The results from two different experiments are provided. 
The data used here has also been used to plot the graphs in figure 17. 
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The Transcriptional activity of ERα  that is regulated by ERE sites is highest during S 
and G2/M phases coinciding with the expression of ERα  protein. 
         In chapter II we showed that in a synchronized population of MCF-7 cells, ERα 
expression is cell cycle dependent. The ERα expressed during S and G2/M phases modulates 
the exit from S and G2/M phases of the cell cycle.  Furthermore, the modulation of the cell 
cycle by ERα is different in the presence versus absence of E2. These findings led to the 
hypothesis that ER may modulate cell cycle progression from S to G2/M as a function of ER 
transcriptional activity at ERE site and that the genes activated by ERE are different in the 
presence versus absence of E2. To test the hypothesis the ER activity was examined using an 
ERE-Luciferase construct (ERE-Luc) under both E2-positive and E2-negative conditions in 
synchronized population of cells.  MCF-7 cells, which had been cultured in E2-free media for 
three weeks, were synchronized with lovastatin and transfected with ERE-Luc plasmid 
twelve hours before the release from arrest. At the time of release, E2 was added to one 
group of cells.  Samples were harvested every 4 hours and prepared for FACS analysis and 
luciferase assay to examine the transcriptional activity of ERα and cell cycle profile of the 
cells.  
         The results shown in Figure 31 are from biological replicate (3 times) assays using the 
lysates from cells transfected with ERE-Luc.  In E2 treated group of experiment I, the ERE 
activity increased 6 hours after the release, until it peaked at 16 hours and then decreased to a 
minimum at 28 hours after release. ERE-Luc activity in E2-negative group shows a similar 
trend to the E2-positive group. However the amount of ERE activity in this group is much 
lower. This low ERE activity in E2-nagative group could be due to the basal level of ERE 
activity in MCF-7 cells. The results of experiments II and III show the same trend and 
confirm the time frame for ERE activity. The time span in which ERE was active (hours 6-
28) corresponds with the S and G2/M phases of the cell cycle (Figure 31).  
         In summary, the results from three independent experiments, revealed an increase in 
luciferase driven by ERE at the end of S and throughout and G2/M phase of the cell cycle, 
which also correlates with the timing of the ERα expression in the cell cycle (Figure 13). 
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Figure 31:  ERE site is highly activated during S and G2/M phases in the presence of 
liganded ERα  compared to unliganded ERα . (A) FACS analysis of three synchronization 
experiments in the presence or absence of E2 is shown as the percentage of cells in each cell 
cycle phase. (B) Luciferase activity driven by ERE in the presence or absence of E2 is 
graphed over a 42 hours time frame.  
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qRT-PCR analysis of ERα  target genes shows increased expression during S and G2/M 
phase. 
        Since the systemic ERE activity modulated by ER is cell cycle regulated (Figure 31), we 
next set out to examine the cell cycle regulation of specific ER target genes.  To examine the 
role of ERα in gene regulation during G2/M phases of the cell cycle, the expression of ERα 
target genes PgR and pS2 was quantified by performing qRT-PCR.  PgR and pS2 have 
previously been shown to be cell cycle regulated 488. 
        Lovastatin synchronized MCF-7 cells, released either in the presence or absence of E2, 
were harvested at time points throughout the 40 hours after the release and processed for 
flow cytometric analysis to ensure the cell cycle status at each time point and also for qRT-
PCR by extracting RNA from cells at each time point. FACS analysis showed the sequential 
entrance and exit of the cells through the cell cycle phases starting at G1 phase. Two 
representative experiments show that ERα mRNA expression does not change during the cell 
cycle, confirming previous results (Figure 17) that ERα is not being regulated at the 
transcriptional level in either the presence or absence or E2 (Figure 32). The qRT-PCR 
analysis of PgR expression showed that in E2-positive conditions PgR expression began to 
increase at 12 hours, formed a peak at 25 hours and then decreased slowly through to 38 
hours after release from arrest (Experiment I, Figure 32). In experiment II, the RNA levels of 
PgR started to increase at 5 hours, peaked around 25 hours after release, but then a decrease 
in the RNA levels of PgR were not observed in the presence of E2. In both trials, the 
expression of PgR did not increase from baseline levels in the absence of E2. Under E2 
positive conditions, the RNA levels of pS2 also increased at 5 hours and kept increasing 
through the remainder of the cell cycle.  However, under E2-negative conditions, the RNA 
levels of pS2, like PgR remained at a basal level (Figure 32).  The time points at which PgR 
and pS2 transcripts were expressed coincided with the S and G2/M phases of the cell cycle 
based on the FACS data (Figure 32).   
        In summary, qRT-PCR results showed that the transcription of two targets of ERα, PgR 
and pS2, increase during S and G2/M phases in the presence of E2. These results corroborate 
the previous finding that ERE driven activity is highest at S and G2/M phases and further 
shows that gene expression is regulated by liganded ERα. 
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Figure 32:  PgR and pS2 transcripts are up regulated during S and G2/M phases in the 
presence of liganded ERα .  MCF-7 cells were synchronized and released in the presence or 
absence of E2 and samples were collected for (A) FACS analysis to assess cell cycle profile 
of the cells.  qRT-PCR was performed to measure the transcripts of (B) ERα, (C)  PgR, and 
(D) pS2.  Two representative experiments are shown. The data used here to show the ERα 
RNA level has also been used to plot the graphs in figure 17. 
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Localization of ERα  is cell cycle regulated  
        Although ERα is known as a nuclear protein there are recent studies that show both 
cytoplasmic and cell membranous localization of ERα 350.   Therefore, the next objective was 
to determine whether the cellular localization of ERα differs throughout the cell cycle.  To 
examine the localization of ER at each point in the cell cycle, MCF-7 cells were plated on 
cover slips, synchronized with lovastatin. After 36 hours of lovastatin treatment, mevalonate 
were added to the wells while the E2-positive group received 10nM E2 at the time of release 
with mevalonate and E2-negative group only received mevalonate. At the time of harvest 
first 4% paraformaldehyde were added into each well and the plate left in -20°C for 20 
minutes. Then after 3X washed with 1X PBS, coverslips were taken out of each well of six 
well plate using 18 gauge needle. For the purpose of blocking and then staining of the 
coverslips I made a very smooth platform and would place a drop of antibody and then flip 
the coverslip over and keep it in dark and room temperature for the staining process.     Cells 
were triple-stained with an ERα antibody, DAPI (for nuclear staining) and cyclin B (Figure 
33A). The slides were analyzed under the fluorescent microscope to examine the localization 
of ERα and cyclin B compared to the DAPI staining. Two hundred and thirty different 
pictures were taken of the cells under the fluorescent microscope. The data revealed that ERα 
resides both in the cytoplasm and in the nucleus (Figure 33A). In Figure 33A the red staining 
is for ERα while the green staining is for cyclin B and blue staining (DAPI) marks the DNA. 
Four representative pictures for each condition are depicted in Figure 33A. These images 
mainly showed a colocalization of ERα and cyclin B (Figure 33A-merge cyclin B/ERα). Our 
results also showed that the addition of E2 resulted in the nuclearization of ERα and cyclin B 
(Figure 33B). The co-localization of ER and cyclin B is most likely mediated by E2 
treatment, which as we have shown in Chapter II, can hasten the progression of cells into the 
G2/M phase of the cell cycle.  Since cyclin B is one the key regulators of G2/M entry and 
exit, its co-localization with ER is further conformation of the transport of ERα from 
cytoplasm to nucleus at G2/M mediated by E2.  The measured p value for the difference 
between the nuclear versus cytoplasmic cyclin B was 0.0001 and for ERα was 0.1 (Figure 
33B). 
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Figure 33:  ERα  and cyclin B have similar localization and their movement to the 
nucleus is E2-dependent. (A) The location of ERα and cyclin B in MCF-7 cells with or 
without E2 was compared to that of cyclin B and DAPI (nuclear) in 230 frames of 
photographs taken with the fluorescent microscope (magnification: 60X). (B) The results 
were graphed as the percentage of cells found either in the nucleus or cytoplasm for ERα or 
cyclin B, as indicated. Error bars represent the standard error from the mean. P value was 
measured using a two tailed t-test. 
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Cyclin B and ERα  proteins form a complex, which also contains Cdk1. 
        Our results thus far show that cell cycle progression (specifically through S and G2/M 
phases) is faster in MCF-7 cells with liganded ERα compared to unliganded ERα. Therefore, 
the next objective was to determine potential mechanisms employed by liganded ERα that 
are responsible for the progression through S and G2/M phases of the cell cycle. The Cdk1 
protein is present throughout the cell cycle, however its activity is tightly regulated by 
protein-protein interactions with cyclin B and changes in its phosphorylation status.  The two 
regulatory partners of Cdk1 are the cyclins involved in S and G2/M phases of the cell cycle, 
cyclins A and B. Cdk1, when partnered with either cyclin A or cyclin B positively regulates 
progression through mitosis. One regulatory function overseen by Cdk1 to allow cells to 
proceed through mitosis is the phosphorylation of Anaphase Promoting Complex that 
promotes binding to cdc20. Upon binding of phosphorylated APC to cdc20, cyclins A and B 
are targeted for degradation and cells exit mitosis in to anaphase 489. 
        Based on our findings that ER and cyclin B are both cell cycle regulated with similar 
patterns of cell cycle expression and also that they are co-localized and that both their co-
localization is modulated by E2, we hypothesized that liganded ERα could contribute to the 
proliferative phenotype of cells through its binding to the cyclin B-Cdk1 complex. To 
determine whether liganded ERα binds to cyclin B-Cdk1, MCF-7 were synchronized with 
lovastatin and released from the arrest in the presence or absence of E2. Samples were taken 
at 3 hours intervals and were prepared for immunoprecipitation   and FACS analysis. The 
samples, which coincided with the timing of S and G2/M phases were examined for binding 
of ERα with cyclin B by immunoprecipitation assay (Figure 34). First, cyclin B was 
immunoprecipitated from lysates of synchronized cells and the presence of ERα and Cdk1 
were examined for immune complex formation. Then, the reverse experiment was performed 
by immunorecipitating with ERα, followed by western blot with cyclin B and Cdk1 to 
determine if all three proteins are found in the same complex.   
        The results show that ERα protein was immunoprecipitated with cyclin B in a cell cycle 
dependent fashion with peak complex formation detected at 24-44 hours after release from 
synchronization.  The FACS data in the lower panel confirms that this complex is forming 
during the times that the cells are in S and G2/M phases of the cell cycle. In the reverse 
experiment (Figure 34, second panel from the top), cyclin B is again associated with the 
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immunoprecipitated ERα.  Cyclin B expression is evident as part of a complex with ERα 
between the 24 and 44 hour time points.  Likewise, Cdk1 protein is detected at 24 hours and 
remains to the 44 hour time point upon immunoprecipitation with ERα.   Together, these data 
show that ERα, Cdk1 and cyclin B are complexed during the S and G2/M phases of the cell 
cycle.  
        The bottom two panels of Figure 34 show the IP/western blot analysis to assess cyclin B 
and ERα protein levels that were IPed with monoclonal antibody and immunoblotted with 
polyclonal antibody to ensure that we have captured both proteins as they are expressed 
during the cell cycle. The cell cycle regulation of both ERα and cyclin B is evident, as the 
proteins are expressed beginning at 16 and 12 hours, respectively. The expression of both 
ERα and cyclin B peak between 24 and 28 hours and then decrease by 44 hours. These peaks 
of ERα and cyclin B levels overlap with the S and G2/M phases of the cell cycle as 
determined by FACS analysis (Figure 34). This is the first time that the presence of ERα in 
the same complex with cyclin B and Cdk1 is being reported. 
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Figure 34:  ERα , cyclin B and Cdk1 are found in the same complex during S and G2/M 
phases of the cell cycle. IP westerns using the indicated antibodies for immunoprecipitation 
followed by probing the western blot are shown. Controls for the efficiency of 
immunoprecipitation are shown by IP and probing with antibodies to the same protein (for 
both ERα and cyclin B). The bottom panel shows the percentage of cells in each phase of the 
cell cycle from FACS analysis of the lovastatin synchronized MCF-7 cells used for 
immunoprecipitation. 
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ERα  binds to cyclin B the F domain  
        Using MCF-7 cells we showed that ERα and cyclin B bind to each other, therefore we 
next set out to determine if this binding is direct or whether it requires other proteins for their 
complex formation.  To this end, we used GST pull down assay to show the binding of ERα 
and cyclin B in vitro.  A series of constructs encoding GST-fusion proteins with mutated AB, 
C, D and F domains of ERα were used to verify the binding of ERα and cyclin B and to 
determine the domains within ERα that mediate the binding.   A diagram of the domains 
within ERα is shown in Figure 35A. 
         Figure 35B shows the results of the phosphor imager detection of the cyclin B product 
from TNT kit, run on an SDS PAGE blot indicating that the in vitro translated cyclin B is the 
right size and was not degraded. However, Figure 35C shows the ponceau staining of 
purified GST-fusion proteins run on SDS-PAGE and indicates that the full length ERα has 
been degraded.  The degradation is likely due to the fact that the fusion between GST  
and full length ERα generates a large protein  (92 KDa) that is hard to synthesize stably in 
vitro and is easily degraded during the in vitro purification process. However the other ER 
constructs were not degraded and the size on the gels corresponded to the predicted size. 
        ERα GST fusion constructs were transfected in to bacteria and lysate was incubated 
with in vitro synthesized 35S labeled cyclin B (TNT) to analyze binding. Proteins isolated on 
glutathione-sepharose beads were eluted and subsequently processed for analysis by western 
blot and phosphor image detection. Ponceau staining shows the presence of purified intact 
fusion proteins; GST-truncared AB-ERα protein/ GST-truncated C- ERα protein/ GST-
truncated D- ERα protein and GST-truncated F- ERα protein in the same reaction with 
synthesized 35S labeled cyclin B (Figure 35D).  
        There was a direct interaction between ERα and cyclin B (Figure 35E) shown by the 35S 
labeling in the lysates from transfection with the AB, C, and D truncated forms of ERα.   
However, no 35S labeling was detected in the lysates containing ERα with a truncation in the 
F domain.  The results suggest that the F domain of the ERα protein is involved in binding of 
cyclin B to the C-terminus of ERα. Even though functional role for the F domain has not 
been fully characterized to date but there are some reports suggesting that F domain is 
involved in responsiveness to antiestrogens (11). Mutations in the F-domain can confer 
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agonist activity to tamoxifen 490. Based on our data here it is possible that F domain have 
more function in the regulation of cell cycle. Binding of cyclin B to the F domain may 
interrupt the normal F domain functions and interactions.  
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Figure 35:  In vitro analysis of ERα  and cyclin B binding. (A) A schematic representation 
of the ERα protein showing the domains that were mutated in the GST-fusion constructs.  
Western blots were run to confirm the expression of (B) 35S labled cyclin B protein generated 
by in vitro translation and (C) truncated forms of purified ERα protein (constructs of GST 
fusion truncated forms of ERα at AB, C, D, E and F domains) upon transformation.  After 
incubation of cyclin B with the ERα truncated proteins, a western blot was run and analyzed 
by (D) ponceau staining to ensure protein loading and (E) phosphor imager to detect 
radioactivity associated with protein products eluted from GST pull down of ERα. 
 
 
  157 
The E3 ligase APC targets ubiquitin to ERα . 
        Several studies have shown that ERα is ubiquitinated and degraded via the proteasome 
pathway 483. In our studies, the down regulation of ERα at the end of G2/M phases observed 
by western blot analysis suggest that ERα could be degraded at the end of G2/M phase of the 
cell cycle. Furthermore, the expression of ERα throughout the cell cycle expression is similar 
to that of cyclin B.  The turnover of cyclin B is mediated via the E3 ligase APC, therefore we 
hypothesized that the turnover of ERα may also be mediated by the APC. To address this 
hypothesis, the direct interaction between liganded versus unliganded ERα and the APC 
complex was examined. 
 To address whether there is ubiquitination of ERα upon APC exposure, an in vitro 
ubiquitination assay using purified ERα was performed in the presence and absence of 
ubiquitin-like activating enzyme 1 (E1) and ubiquitin-like conjugating enzyme (E2) and 
APC, an E3 ligase (Figure 36). The purified ERα showed background levels of 
ubiquitination, which was not affected by the addition of E1. However, the addition of both 
E1 and E2 increased the ubiquitination of ERα slightly. The most dramatic increase in 
ubiqutination of ERα occurred when APC, E1 and E2 were added together to purified ERα 
(Figure 36).  These results suggest that the E3 ligase APC could be responsible for 
unliganded ERα turnover during the cell cycle.  However, this experiment was done in an in 
vitro system and had to be interrogated using MCF-7 to investigate its physiological 
relevance. To determine if there is a direct interaction between ERα and the APC complex, 
lysates of S and G2/M phase enriched MCF-7 cells were examined for an interaction of ERα 
with cdc27 of the APC complex.  
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Figure 36:  Ex vivo ERα  ubiquitination assay. Western blot analysis of ERα expression 
upon incubation of purified ERα with or without E1, E2 and E3 ligase (APC). The upper 
bands show the ubiquitinated ERα (Ubq-ERα). 
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APC binding to ERα  and cyclin B during S-G2/M transition and also the E2-dependent 
degradation of ERα  and cyclin B at S-G2/M transition 
        The lovastatin synchronization of MCF-7 cells was performed as depicted in Figure 
37A. MCF-7 cells treated with lovastatin for 36 hours. Then cells treated with mevalonate in 
order to release the cells from arrest. However twelve hours prior to mevalonate release (24 
hours after the lovastatin treatment) cells co transfected with myc-Ub and HA-ER constructs. 
Cells were also treated with MG132 to inhibit the proteasome.  There are 4 arms to this 
experiment: Twelve hours post transfection and at the time of release, cells were treated with 
1) E2 and MG132; 2) E2 alone; 3) MG132 alone; or 4) PBS. The cells were then harvested 
and subjected to IP/western studies to address two different questions. First we asked if both 
ERα and cyclin B can bind to cdc27 (a component of APC) during S-G2/M transition, The 
binding of ERα and cyclin B to cdc27 (APC) will provide in situ evidence that APC is the E3 
ligase for not only cyclin B but also for ERα.  Secondly we asked if the turn over of ERα and 
cyclin B is dependent of proteasome (the MG132 arms of the study) (Figure 37B).   
        Upon addition of mevalonate (and E2 into the E2-positive group) cells were harvested 
every 3 hours and samples were prepared for FACS analysis to gauge their position in the 
cell cycle and for immunoprecipitation and western blot analysis. In the groups, which 
required MG132, 10µM of MG132 were added three hours prior to the harvest. The lysates 
from the cell samples harvested for IP were immunoreceipitated using rabbit polyclonal 
cdc27 and the presence of ERα was assessed in the same complex by western blotting with 
ERα.  
        Under E2 positive conditions, MG132 treatment showed an overall increase in 
expression of cdc27, ERα and cyclin B (Figure 38). When ERα or cyclin B were 
immunopreciptated from cells that were treated with E2, cdc27 could be found associated 
with the complex at all times except for the 36 hour time point which is the G2/M peak 
(Figure 38).  These data suggest that that upon binding to cdc27, ERα and cyclin B are 
degraded by the proteasome at G2/M.  
        Under E2-negative conditions, the increased protein expression resulting from MG132 
treatment is not as pronounced as in the presence of E2.  Densitometry was performed and 
quantitatively shows that proteasomal inhibition affects E2 treated cells to a greater extent 
than untreated cells (Figure 38).  Immunoprecipiation with both ERα and cyclin B shows 
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complex formation with cdc27 from 8 hours until 36 hours after release under E2-positive 
conditions. The decreasing presence of cdc27 bound to ERα and cyclin B coincided with the 
end of G2/M phases (Figure 38). Without MG132 treatment, there was not a detectable level 
of cdc27 for densitometry. These data suggest that ERα and cyclin B form a complex, and 
upon binding, are targeted with ubiquitin by cdc27 for degradation by the proteasome (Figure 
38).  
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Figure 37: A schematic diagram to show the (A) schedule of the transfection and 
treatments of the MCF-7 cells with myc-Ub, HA-ERE2 and E2 and or MG132. (B) Depicts 
the arms of this experiment including treatment steps. 
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Figure 38: Both ERα  and cyclin B bind to cdc27. Lysates of synchronized MCF-7 cells 
treated with or without E2 and MG132 were subjected to SDS-PAGE analysis followed by 
western blotting with the indicated antibodies followed by densitometry of the cdc27 bands. 
(A) Western blot analysis of ERα, cyclin B and cdc27 expression upon treatment of MCF-7 
cells with E2 and MG132 (the arms of this experiment have been shown in Figure 37. (B) IP 
westerns using the indicated antibodies for immunoprecipitation followed by probing the 
western blot are shown.  (C) cdc27 protein level upon IP with ERα on samples, which treated 
(left panel) or untreated (right panel) with MG132, (D) cdc27 protein level upon IP with 
cyclin B on samples, which treated (left panel) or untreated (right panel) with MG132.  
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Nocodazole treatment arrests ER positive cells in G2/M phase while ER-negative cells 
are capable of returning to the cell cycle. 
        Throughout this thesis we have shown reproducibly that ERα is expressed during the S 
and G2/M phases of the cell cycle.  Therefore, we predicted that if we were to treat the cells 
with nocodazole, which arrests cells in G2/M phase, would allow for the detection of ERα 
when it is first expressed. To perform nocodazole synchronization of cells, an optimal 
nocodazole concentration was identified by initially treating cells with increasing 
concentrations (0-0.4µM) of nocodazole for 24 hours (Figure 39).   The lowest concentration 
of nocodazloe that would give rise to a G2/M arrest would be used in the next series of 
experiments.  For these experiments we used both MCF-7 (ER-positive) and MDA-MB231 
(ER-negative).     
        Following 24 hours of nocodazole treatment, cells were harvested (zero time point), and 
again at six and twelve hours after the treatment for flow cytometryic analysis.  After 24 hours 
of nocodazole treatment, 50% to 60% of MCF-7 cells and 90% of MDA-MB231 cells were in 
G2/M phase.  The percentage of MDA-MB231 cells in G2/M phase had drastically decreased 
by 6 and 12 hours after treatment due to the synchronous exit of the cells from G2/M phase 
upon release from nocodazole arrest.   By 12 hours after release from arrest, only 25% of 
MDA-MB231 cells were in G2/M phase. This data shows that MDA-MB231 cells not only can 
be arrested in G2/M following nocodazole arrest, but that they are also released from arrest 
upon removal of this arresting agent.  With MCF-7 an entirely different profile was observed. 
Upon removal of nocodazole from MCF-7 cells, which were already 50-60% arrested in G1, 
the cells were not released to enter G1 and as a result, the percentage of cells in G2/M phase 
remained fairly constant, not allowing for the meaningful assessment of cell cycle dependent 
protein expression (Figure 39). 
         These results that were specific to nocodazole suggested that MCF-7 (ER-positive) cells 
could not recover from the nocodazole arrest to enter the cell cycle again, while MDA-MB231 
(ER-negative) cells could come out of the nocodazole induced arrest. Hence, we can predict 
from these results that ER has a very profound role in the G2/M exit and when cells that are ER 
positive are arrested in G2/M, the levels of ER reach its maximum and most likely mediate 
negative signaling pathway to inhibit proliferation (Figure 39).  
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Figure 39:  ER-positive cells could not exit nocodazole induced G2/M phase arrest, 
while ER-negative cells entered the cell cycle upon release from nocodazole arrest.  
FACS analysis of MDA-MB231 (green) and MCF-7 (red and black) cells synchronized using 
increasing concentrations of nocodazole. The percentage of cells in each phase of the cell 
cycle is shown.  
 
 
 
 
 
  167 
RPPA can be used to screen proteins activated by the ERα pathway. 
        Reverse-Phase Protein Array (RPPA) analysis is an ideal method to examine the 
expression of a series of proteins in parallel. RPPA is a method to measure the protein 
expression levels (just like western blot) in a large number of biological samples using high 
quality antibodies 491. RPPA is also subject to accurate quantification as serial dilutions of the 
test lysates are printed on each slide alongside with known amounts of protein as controls. 
RPPA was performed in collaboration with Dr. Gordon Mills’ laboratory.  The expression 
pattern of a series of proteins (the list of all proteins examined is in supplemental Figure 4) 
during the cell cycle was examined in relation to cell cycle phase and ERα expression.  
Lovastatin synchronized MCF-7 cells, which had been divided in to two groups of E2-treated 
versus the E2-untreated were harvested and diluted in ppi (protease/phosphatase inhibitor- 
components listed under western blot analysis in chapter II) and sample buffer to the final 
concentration of 1µg/µL and subjected to RPPA analysis in the Mills’ laboratory The 
samples were immobilized (printed) on individual spots on as many microarray slides as 
there are antibodies. Then each slide was incubated with a single specific antibody in order to 
detect the specific target protein expression on all the samples simultaneously. Detection was 
performed using a primary and a secondary labeled antibody. Chemiluminescence was used 
to detect the expression. The values resulting from intensity of antibody detection were 
plotted in graphs in (Figures 40 and supplemental Figure 4). Using this analysis we found 
that three of the proteins examined had a very different pattern of cell cycle expression 
depending on whether or not E2 was present. The proteins that are modulated by E2 include 
ERp118, MAPKp, and AKTp473 (Figure 40). ERp118 expression shows a very different 
pattern for E2-positive compared to E2-negative condition. In E2-positive condition ERp118 
expression increased approximately 8 fold the expression peaked at 12 hours and declined by 
18 hours after release from arrest. These time points coincide with the G1 phase of the cell 
cycle. There was no change in ERp118 under E2-negative conditions. MAPKp also showed a 
very different pattern between E2-positive and E2-negative conditions.  
        MAPKp is highly expressed in E2-negative conditions starting at 4 hours and continuing 
throughout the cell cycle while MAPKp expression in E2-positive conditions remains at 
baseline through the cell cycle phases. AKTp473 expression increased at 10 hours, peaked at 
20 hours and decreased very suddenly, reaching zero by 28 hours. There was another incline 
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in expression between 32 and 40 hours. The time points that showed AKTp473 expression 
corresponded to G1 and G2/M phases. Under E2-negative conditions, the expression of 
AKTp473 increased from baseline between 10 and 18 hours after release from arrest. Based 
on the differences in expression profiles of different signaling molecules as shown in the 
pathway in Figure 41, one can speculate that the cell cycle regulated ERp118 could be the 
reason for the observed changes in S and G2/M phases of the cell cycle under E2-positive 
condition since ERp118 shows an increase under E2-positive condition in a cell cycle 
regulated manner. There is no detectable change in ERp118 level in E2-negative condition 
compared to E2-positive condition. 
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Figure 40: RPPA detects differential protein expression in key signaling proteins when 
ERα is liganded to E2 in MCF-7 cells.  RPPA analysis was performed on lovastatin 
synchronized MCF-7 cells in the presence and absence of E2.  (A) FACS analysis shows the 
percentage of cells in each cell cycle phase after release from arrest.  (B) Lysates from each 
time point were subjected to RPPA to detect the expression of ERp118, MAPKp and 
AKTp473 in the presence of E2 (black) and absence of E2 (red). 
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DISCUSSION 
         In this study, we found that the expression of ERα is cell cycle regulated.   The peak of 
ERα expression level coincides with late S and G2/M phases in a ligand independent fashion 
and levels decrease at the end of G2/M phase in a ligand dependent fashion. The data 
reported in chapter III of this study also suggests that the down-regulation of ERα is 
mediated by the proteasome pathway, in which APC functions as the E3 ligase scaffold.  
        The correlation between the expression of ERα during late G2 phase and the G2 arrest 
of the ERα-expressed MDA-MB231 cells suggested that ERα may have yet unknown 
functions in regulating G2/M phase. These functions are likely to induce inhibition of 
proliferation. A role for ERα in regulating the cell cycle would be consistent with other’s 
reported data that the constitutive expression of ERα in ER-negative breast cancer cells 
(MDA-MB231) caused G2 arrest in the presence of estrogen 492. Additionally, our data 
shows that ER-negative cells that have been arrested and synchronized in G2/M by 
nocodazole can re-enter the cell cycle upon release from nocodazole arrest. However, ER-
positive cells remain arrested in G2/M phase upon nocodazole treatment, unable to re-enter 
the cell cycle following removal of nocadazole. These observations emphasize that ERα 
function is important for the G2 and M phase transition.     
        To understand the function of ERα in relation to the genes it regulates, we, as well as 
others, have assessed whether the target genes are downregulated or upregulated upon 
exposure to liganded versus unliganded ERα. Microarray (cDNA) studies revealed that 
liganded ERα is able to downregulate almost as many genes as it upregulates 345, 493, 494. One 
of the genes that is downregulated by liganded ERα is cyclin G2. Northern blot analysis 
revealed that cyclin G2 mRNA is tightly regulated and oscillates through the cell cycle with 
peak expression in late S phase 495, 496. The induction of cyclin G2 has an inhibitory effect on 
the cell cycle independent of p53 495. Horne et.al even suggests that cyclin G2 may be a key 
negative regulator of cell cycle progression 497. Stossi et.al have shown the mechanism 
underlying the downregulation and eventually inhibition of cyclin G2 activity is through the 
recruitment of liganded ERα to the promoter region of cyclin G2, which results in the 
dismissal of RNA polymerase II. Additionally, liganded ERα also recruits Nuclear Receptor 
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Corepressor (N-CoR) and histone deacetylases, leading to the downregulation of cyclin G2 
346. Therefore this data is one example as to how liganded ERα may downregulate cyclin G2, 
which leads to the uncontrolled cell cycle progression. Another cell cycle brake that is 
downregulated via the activity of liganded ERα is Reprimo (RPRM)327. Ohki et.al identified 
RPRM through its upregulation upon x-irradiation. They also showed that RPRM is a 
downstream mediator of p53 activity. The function of RPRM was revealed by 
overexpressing RPRM in HeLa cells, which resulted in G2 arrest of these cells. The RPRM 
mediated mechanism of G2 arrest is through inhibition of Cdk1 and also inhibition of the 
nuclear translocation of cyclin B-Cdk1 complex 484. These interactions of ERα with cyclin 
G2 and RPRM demonstrate the ability of liganded ERα to accelerate the progression of the 
cell cycle by inhibition of the built-in cell cycle brakes. Conversely, there are other examples 
of liganded ERα accelerating the progression through cell cycle by upregulating genes that 
are involved in facilitating cell cycle progression 488, 498-501. For example, Frasor et.al took 
advantage of having the human genome sequence along with microarray technology in order 
to study the gene expression profile of breast tumors. In this study, liganded ERα resulted in 
the upregulation of cyclin A2, which is cell cycle regulated with its peak expression during 
early S until M phase, can form an active complex with both cdk2 and cdk1 resulting in the 
regulated progression of cells through S and G/2 M phases 498, 502, 503. The  upregulation of 
cyclin A2 mediated by liganded ERα suggests that these two proteins work cooperatively to 
allow cells  progress  through S and G2/M phases..  Another example is survivin a cell cycle 
regulated protein, which is expressed during G2/M phase of the cell cycle and whose levels 
are induced by liganded ERα. Survivin regulates the function and dynamics of microtubules 
of the mitotic spindle and has an antiapoptotic effect 504, 505. The overexpression of survivin 
by liganded ERα may overcome an apoptotic checkpoint and favor aberrant progression of 
transformed cells through mitosis 504. 
        Reports from other groups suggest that ERα may have essential functions in the cell 
beyond the classical mechanisms of ligand binding and growth factor regulated transcription.  
For example, Fan et al. show that the degradation of ERα is not necessary for its 
transcriptional activity 427. To this end they show inhibition of ubiquitination and proteasome 
pathway prevents the degradation of ERα upon ligand binding, allowing ERα to induce 
transcriptional activity at the ER-responsive gene 427. Other groups suggest that ERα can be 
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activated in a ligand independent manner 498, 506. This group suggests that the basal level of 
ER protein can dictate the ability of cells to migrate.  They show that the ER protein levels 
in, MCF-7, ZR75-1 and T47D cells is inversely correlated with cell migration 498, 506. Another 
example of the role of unliganded ER is through the work of Maynadier et.al 507.who 
suggests that unliganded ERα binds to the Cdk inhibitor, p21, an interaction that is disrupted 
upon estradiol treatment resulting in the binding of p21 to the cyclin E/Cdk2 complex. This 
group has not done the FACS analysis to reveal the status of the cell cycle, but their data 
shows that unliganded ERα arrests the cells at the end of S phase. The data by Maynadier et 
al. is very similar to the data that we generated during this study, showing that unliganded 
ERα exerts its inhibitory effect on the cell cycle during S and G2/M phases.  This group also 
shows that the binding of unliganded ERα or the variant of ERα only containing the 
interaction region (amino acids 184-283) with p21 results in significant increases of p21 
expression while silencing of ERα reduces p21 levels. Additionally they show that silencing 
p21 in cells with unliganded ERα abrogates the inhibitory effect of uniganded ERα 508.  
Together, these studies could explain the better outcomes of ER-positive breast tumors 
compared to ER-negative tumor and suggest that the key players in the ER mediated cell 
cycle progression are unliganded ERα and p21 which could inhibit cell cycle progression at 
S phase 507. Our data is consistent with these findings since it provides new evidence as to 
how ERα is regulated in the cell cycle and what are the downstream events of ER expression 
in the presence and absence of E2 ligand.  
        Initially we examined the transcriptional activity of ER during the cell cycle in the 
presence and absence of ligand. This analysis showed a higher ERE activity during S and 
G2/M phases for liganded ERα compared to unliganded ERα. For example, the transcription 
of pS2 and PgR (two downstream effectors of ER) were increased during S and G2/M phases 
when ERα was bound to E2 (Figure 32). Li et.al, in one of their early studies, showed that 
there is a sequences on the pS2 protein, that contains several S/TPXX amino acid motifs, 
which are often found in DNA binding proteins and are potential target sites for regulatory 
kinases such as the Cdk1497, 509. When they examined the intranuclear trafficking of pS2 
protein, they found that it is associated with interphase kinetochores and centrosomes, which 
are involved in cell cycle regulation and mitosis 509. Additionally,  mutant pS2 causes 
chromosome missegregation during mitosis 483. These results suggest  that pS2 is involved in 
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cell cycle regulation specifically during M phase of the cell cycle through its effect on the 
chromosome segregation function. Our own analysis, qRT-PCR in Figure 32, shows that 
liganded ERα induces the expression of pS2 during S and G2/M phases, which probably 
facilitates the chromosomal segregation and a fast passage through G2 and M phases.  In 
addition to PS2, PgR has also been identified as a target of ERα target gene, which is also 
induced upon the binding of estradiol to ER 484, 499.. PgR contains multiple phosphorylation 
sites that are potential substrates for Cdks, suggesting that PgR activity might be regulated 
during the cell cycle. In fact, PgR is phosphorylated on these sites and becomes 
transcirptionall active in a cell cycle regulated fashion with its peak activity occurring during 
S phase. 488, 510.  Similar to our data with PS2, we have been able to show that  the PgR 
transcript is also cell cycle regulated increasing during S and G2/M phases upon estradiol 
treatment. In another study Narayanan et. al also showed that PgR activity is stimulated by 
cyclin A/Cdk2 500. Collectively both published work and our own results suggest that PgR, a 
target gene of ERα, is cell cycle regulated at S and G2/M phases, and that through this 
cyclical pattern of expression, estradiol can exert its mitogenic effects specifically at S and 
G2/M phases.  
Musgrove et al. have shown that PgR affects the cell cycle by accelerating the passage of 
cells through the first cell cycle and then induces an arrest at the G0/G1 phase of the 
subsequent cell cycle 501. In agreement with this data, we made the observation that ERα 
expression resulted in cell cycle modulation in the second subsequent cell cycle (rather than 
the first cell cycle) after aphidicolin treatment (Figure 15).  Since the activity of PgR is 
regulated not only by progesterone but also by modulators of various cell signaling pathways 
in the cytoplasm, more experiments are required in order to explain this cell cycle arresting 
phenomenon 511, 512.    
Additionally, the localization of ERα during different phases of the cell cycle was 
examined in this study to help to explain the functions of ERα. ERα showed a similar pattern 
of subcellular localization as cyclin B. The cytoplasmic versus nuclear localization of ERα 
and cyclin B was assessed by immunnofluorescent analysis (Figure 33) and colocalization 
could be seen both in the cytoplasm and nucleus of both these proteins, which were also 
altered coordinately by the addition of E2. The possibility that ERα and cyclin B form a 
complex was examined by IP/western analysis of the two proteins using synchronized MCF-
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7 cells.   The results showed that ERα was in the same complex not only with cyclin B, but 
also with Cdk1 (Figure 34).  Cyclins, which are expressed in a cell cycle-dependent manner, 
can regulate steroid receptor function and this function could be independent of the kinase 
partner. There are several studies that have shown cyclin regulation of steroid receptors. For 
example, cyclin D forms a complex with the androgen receptor and inhibits its 
transactivation ability 513. Another example is that cyclin A/Cdk2 acts as a PgR coactivator 
500. Neuman et.al have shown that cyclin D can stimulate ERα transcriptional activity 
independent of cdk4 514. Lastly, cyclin E associates with androgen receptor by binding 
directly to the C terminus portion of androgen receptor. Cyclin E then functions as a 
coactivator for androgen receptor and enhances androgen receptors transactivation activity 
515. In all these cases the involvement of cyclins with the different members of the nuclear 
receptor family provides a potential means for integrating the regulation of these nuclear 
receptor’s activity with cell cycle progression. In the cases that both cyclin and its Cdk are 
being involved in binding to the nuclear receptor (i.e cyclin A/Cdk2 recruitment to PgR), the 
elevated level of kinase activity in the complex containing the nuclear receptor may result in 
the phosphorylation of coactivators and therefore facilitate the promoter targeting and 
subsequent transcriptional activities.    
To confirm the data generated by IP that cyclin B,cdk1 and ERα form a complex, an 
in vitro GST-pull down assay was performed. 35S labeled cyclin B was incubated with wild-
type and truncated forms of ERα (AB, C, D and F deletion constructs). The results of GST-
pull down assay confirmed the IP data showing that ER and cyclin B can directly bind to 
each other. The GST-pull down assay was performed using various mutant forms of ERα, 
thus giving us the opportunity to examine the specific site of ERα binding to cyclin B. As 
Figure 35 shows, when expressing the F-domain mutant, no binding between cyclin B and 
ERα were detected while all the other mutants bound to cyclin B. From this data it is 
concluded that cyclin B specifically binds to the F domain of ERα (Figure 35). Peters et. al 
have shown that both E and F domains of ER have a role in dimerization and interaction with 
coactivator Receptor Interacting Protein (RIP-140) 516. It is possible that cyclin B can directly 
bind to the F domain or it could require the binding of another coactivator to the F domain. 
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        The degradation of ERα is known to be mediated by a proteasome through a 
ubiquitination pathway. It has been reported that E1 and E2 were able to ubiquitinate ERα in 
vitro 483.  Our data support the findings that ERα could be ubiquitinated by E1 and E2, 
however the addition of APC dramatically increased the ERα ubiquitination in vitro, 
suggesting that APC is an E3 ligase for ERα ubiquitination.  This is a new finding, but is not 
unusual as many of the substrates for APC are cell cycle related, such as securin and cyclin 
B1 517. Since we already showed that cyclin B and ER are co-localized and are found in the 
same complex, this led to the hypothesis that through its binding with cyclin B, ERα is also 
degraded by the same E3 ligase as that for cyclin B. When we addressed this hypothesis, our 
results show that ERα can interact with cdc27, which is one of the protein complexes in the 
APC. The timing of cdc27 bound to ERα was similar to the APC- cyclin B binding (Figure 
38).  These results suggest that as a result of the APC directed ubiquitination, ERα is 
ubiquitinated at the end of S and G2/M phases of the cell cycle and degraded through the 
proteasome (Figures 36 and 38). 
The cell cycle dependent degradation of ERα in the absence of ligand is similar to 
that of the cyclins and further supports a role for ERα in G2/M phase progression. Additional 
evidence for the role of ER in G2/M was presented in the RPPA analyses, which depicted 
cell cycle regulation of ERp118, which was induced by the addition of ligand.  These results 
suggest that liganded ERα results in its phosphorylation at serine 118 (ERp118), which in 
turn could down regulate cell cycle breaks such as RPRM. The other hypothesis based on the 
RPPA data could be that ERp118 interrupts the function of FOXO transcription factor family 
members, which have been shown to have regulatory effects during G2/M phase of the cell 
cycle 518, 519. Another protein, which the RPPA showed to be cell cycle regulated and its 
regulation is modulated by the addition of E2 is AKTp473, whose levels are high during G1 
and S phases in E2-positive condition. It has been shown that E2 induces phosphorylation of 
AKT at ser473 (AKTp473), which in turn results in the phosphorylation of FOXO1 and 
FOXO3a to inactivate them 510, 520. The FOXO transcription factors are important in 
regulating different aspects of cellular homeostasis and apoptosis 521 while AKTp473 plays 
an important role in cell survival 522.  The RPPA results show that under E2-positive 
conditions ERp118 expression is increased approximately 8 fold in G1 phase of the cell cycle 
compared to other time points corresponding to the S and G2/M phases. There was no change 
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in ERp118 under E2-negative conditions. Phosphorylation of ER? at serine-118 results in 
activation of ER? in regulation of genes containing an estrogen response element in their 
promoters 172. The well-known kinase involved in the phosphorylation of serine 118 is 
MAPK 172. MAPK is active during all phases of the cell cycle in E2-positive condition 
(MAPK does not show increases activity in E2-negative condition). The MAPK during G1 
could be involved in phosphorylation of ERp118. The resulting active ERp118 may be 
responsible for the rapid progression of the cell cycle specifically at S and G2/M phases, 
following the phosphorylation of ERα at G1.  One interaction that the RPPA suggests and 
that needs further investigation is the E2-dependent interaction of ERα (ERαp118) with 
MAPK and AKTp473 during the cell cycle. If ERα interacts directly with MAPK and/or 
AKTp473 then we can speculate that the ERp118, which is cell cycle regulated is being 
phosphorylated through these kinases and as the result the active ERp118 could accelerate 
the cell cycle progression.  The relationships of these processes are depicted in a model in 
Figure 41. 
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Figure 41: A schematic diagram showing the possible pathways that could cause ERα  
phosphorylation and progression through cell cycle (especially at S and G2/M phases).  
E2 stimulation could result in the activation of both MAPK and Pi3K pathways, which in 
turn can phosphorylate ERα at serine 118, which activates ERα. Additionally E2 can directly 
result in the phosphorylation of AKT at serine 473. The AKTp473 inhibits the activation of 
FOXO1 and FOXO3a, which both are involved in the regulation of cell cycle passage 
especially at S and G2/M phases. 
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        In conclusion, the experiments presented in this chapter shed light on the possible 
function and mechanism of unliganded versus liganded ERα in the cell. We have shown that 
ERα and its transcriptional targets with ERE sites are regulated during the cell cycle.  
Additionally, we have identified cyclin B and cdc27 as binding partners of ERα and showed 
localization and ubiquitination status of the resulting complex.  Very importantly we show 
that the E3 ligase that may be responsible for the degradation of ER is APC. This information 
not only adds to our knowledge of cell biology but also can impact future research in breast 
cancer therapeutics. 
 
Significance and Future Directions 
Patients with ER-positive breast tumors have a more favorable prognosis than those 
with ER-negative tumors. In fact, several reports have revealed that the overexpression of ER 
in ER-negative breast tumor cells could result in the inhibition of the proliferation of these 
tumor cells (38, 39). The reason for such inhibition of cell proliferation has remained unclear.  
  In this study we showed that ERα upregulation alone could prolong the duration of 
cell cycle specifically in S and G2/M phases compared to parental cell line or the ER silenced 
counterpart. Our findings also suggest that unliganded ERα has an inhibitory effect on the 
progression of the cell cycle, specifically the exit of cells from mitosis. Other groups have 
also reported the inhibitory effect of unliganded ERα on breast cancer cells. They have 
shown that unliganded ERα in cells could provide protection against tumor spreading and 
metastasis 507 and involved in the inhibition of breast cancer cell growth as well as tumor 
formation in nude mice523. However, the liganded ERα (bound to E2) causes a rapid 
progression of the cell through the cell cycle. Considering breast cancer cell proliferation 
needing the degradation of ERα through coupling of ERα to E2, it would be reasonable to 
speculate that the combination of a drug that lowers estrogen level (such as using aromatase 
inhibitors) and preserves ERα from degradation (inhibitors of ubiquitin-proteasome pathway) 
would provide better outcome for breast cancer treatment. Our finding that APC functions as 
the E3 ligase for ERα might help to design more specific inhibitor for ERα degradation. 
Similarly, since ERα protein is predominantly expressed during S and G2/M phases of the 
cell cycle, it suggests that combination of, taxol (which arrests cells at G2/M by inhibiting 
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the microtubule depolymerization and hence stabilizes microtubules) with tamoxifen and 
aromatase inhibitors to enrich for ERα and maintain its expression while eliminating its 
ability to bind ligand would be a potential treatment strategy for patients with ER positive 
breast cancer..     
To better understand the importance of this research and to put it in to perspective of 
the field of endocrine therapy, it is necessary to give a brief  history of endocrine therapy. 
The first person to suggest endocrine therapy was Dr. Beatson, who realized that the 
hormonal function of ovaries affect the function of mammary glands. His approach to 
endocrine therapy was oophorectomy, which resulted in a quick regression of the cancerous 
tissues in patients. The reason behind this observation is that by oophorectomy he was 
eliminating the source of estrogen, which the cancerous tissues in the breast were dependent 
on. In the following years other methods of treatment were being used such as 
hypophysectomy and adrenalectomy. In all these treatment strategies, the main purpose was 
elimination of the source of estrogen in the body. Hypophysis controls the estrogen secretion 
from both adrenal glands and ovaries and results in the shut down of these organs.  High 
doses of synthetic nonsteroidal estrogen (i.e. Diestibestrol) were also used to suppress 
pituitary gonadotropic secretion and endogenous estrogen.  
  By eliminating estrogen from the body, regression of the cancerous tissue was 
achieved. However, the use of diestibestrol was discontinued due to its extreme toxicity.  
At this point the endocrine therapy shifted from inhibition and elimination of estrogen to 
inhibition and elimination of ER. Scientists started using SERMs and SERDs in order to 
inhibit the estrogen signaling. Antiestrogens are still being used in the clinic but primarily in 
post menopausal women, which have much less estrogen production. What my research has 
shown is that estrogen elimination (block) could be a much better and promising method of 
treatment rather than elimination of ER activity by using antiestrogens. In this dissertation, 
we have shown that the presence of ERα can function to inhibit cell cycle progression.  In 
the absence of estrogen, ERα is essential as an inhibitory factor in tumor cells. Antiestrogens 
(SERDs) actually degrade ERα and thus provide the same conditions as an ER-negative 
tumor, in which ER is absent and is not able to function. It is important to keep the integrity 
of the ERα protein intact. In this dissertation I have shown that APC is the E3 ligase essential 
for the degradation of ERα. Therefore, an APC inhibitor could be used to inhibit the ERα 
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degradation, enriching ERα in the cell. Furthermore studies on mitotically arrested cells 
show that drugs being used in order to perturb the spindle assembly such as taxanes, vinca 
alkaloids, and epothilones are not the best options for ER positive tumors 524. The reason is 
that the mechanism of action of these drugs is to perturb the spindle assembly and as a result 
induce apoptosis. Cancer cells resist apoptosis by a premature exit from the M phase before 
the onset of apoptosis, thereby avoiding the effects of spindle targeting agents 525.  Spindle 
Assembly Checkpoint (SAC) inhibition is not a good option to arrest the cells at mitosis, 
however perturbation of the growth of cancer cells could be accomplished downstream of the 
M phase checkpoint 525.   
        It is exciting having discovered that APC targets ERα to the proteasome and it also has 
precedence in  literature as a therapeutic strategy.   Huang et. al introduced tert amyl methyl 
ether (TAME), which is a small molecule that inhibits APC activation directly by preventing 
Cdc20 binding. A cell-permeable prodrug (proTAME) induces mitotic arrest and cell death 
526. TAME is an alternative for the current inhibitors of M phase, as it arrests the cells at M 
phase downstream of SAC so does not require checkpoint activity. The bypass of SAC by 
using TAME makes it possible for tumor cells to go through intrinsic apoptosis or an 
alternative death pathway when Bcl2 was overexpressed.   The use of TAME is supported by 
our data since it directly inhibits APC (the E3 ligase of ERα) and could be an effective 
method for enriching ERα expressing cells. However TAME cannot be used in conjunction 
with taxol, as taxol requires the APC pathway to be intact for its activity  527, so use of these 
two drugs simultaneously is not an appropriate strategy. The mechanism of action of TAME 
makes it a good agent to consider as an effective method for mitotic arrest and inturn 
enrichment of ERα expressing cells. 
        Based on the data presented in this dissertation, ERα in its unliganded status has an 
inhibitory effect on the cell cycle progression.  Others have also shown that unliganded ERα 
has a protective role against tumor invasion 507, 523. This data also implies that in vivo, one 
would need to enrich the cells for ERα by using agents that arrest the cells at M phase, and 
TAME could serve this purpose. The next step would be to also eliminate estrogen. 
Elimination of systemic estrogens is a very difficult task but  necessary to inhibit cancer 
progression. In a tissue culture setting elimination of estradiol is easily done by culturing the 
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cells under estradiol free conditions. However in the whole organism it is hard to eliminate 
all sources of estradiol. It may be the reason that current anti-estrogen treatments are most 
effective in post-menopausal women due to the lower level of circulating estradiol 528. 
Additionally, the current aromatase inhibitors that are being used are essentially inhibiting 
the estradiol production by inhibiting the aromatase enzyme in adipose tissues 529. The largest 
trial ever completed to date to compare the effects of Tamoxifen alone or aromatase inhibitor 
alone or the combination of these two together is ATAC trial 528. In this study, 3000 ER-
positive patients were recruited in each arm with a median follow up of 33 months.  This trial 
showed that patients in the anastrozole treatment alone arm had significantly better outcome 
by reducing the risk of recurrence by a relative 22% (p=0·005) and the risk of developing a 
second primary cancer by a relative 58% (p=0·007) compared to the other two arms 528. 
Therefore, despite their very limited inhibition of estrogen production, aromatase inhibitors 
have superior effect in terms of disease-free survival (DFS), time to recurrence (TTR), and 
incidence of contralateral breast cancer (CLBC) compared to antiestrogens 528.  
        Aromatase inhibitors do not affect the main estradiol production in the body, which is 
through ovaries and adrenal glands. If there was a drug that could eliminate estrogen from 
these sources it could revolutionize the treatment of breast cancer and all hormone dependent 
cancers. In order to keep the estrogen low in the blood circulation of a premenopause patient, 
chemical oopheroctomy could be performed with GnRH antagonists. GnRH is the hormone, 
which its secretion is regulated via the hypothalamus. GnRH stimulates FSH and LH 
synthesis from pituitary glands, which then gives rise to estrogen through the ovaries. GnRH 
antagonists function by blocking this pathway at pituitary gland by binding to GnRH 
receptors in the pituitary gland, inhibiting the FSH and LH release, which are the initial step 
before estrogen production from ovarioes 530, 531. Currently approved GnRH antagonists 
include the following: Cetrorelix, Ganirelix, Abarelix, Degarelix 532, 533. GnRH antagonists 
have to be combined with either TAME or taxol to enrich for high levels of ERα .Based on 
the results presented in this dissertation and published work, the most promising treatment 
could be the combination of an APC inhibitor (TAME) to sustain mitotic arrest and 
enrichment of the cells for ERα with an aromatase inhibitor or GnRH antoagonists. 
Anastrozole has been used already in ATAC trial and could provide a good choice for 
aromatase inhibitor.  
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        A rational clinical trial would be one with three arms to delineate the effects of the 
combination of drugs that inhibit ER degradation and eliminate estradiol. One arm will have 
ER-positive patients treated with anastrozole (or GnRH antagonists) and TAME, while the 
second arm would have patients treated with TAME alone and in the third arm patients 
would receive anastrozole (or GnRH antagonists), TAME and antiestrogen (Needs to be a 
SERM rather than SERD). However before the design of this trials get to the clinic a 
thorough evaluation of these combinations are needed in an in vitro settings using cell lines 
and in preclinical in vivo model systems.  
To go back again to the research of Dr. Beatson which was mentioned earlier. He was 
very wise to treat the patients by eliminating the main source of estradiol and I believe that 
after more than 100 years, it is recognized again that a drug is needed which eliminates/lower 
the circulating estradiol in premenopausal women as the best means to treat ER positive 
breast cancer patients. 
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Chapter IV:   SUPPLEMENTAL DATA  
 
MCF-7 cell growth is not significantly affected within 10 days of E2 treatment. 
        Liganded ERα shortened the S and G2/M phases of the cell cycle in the MCF-7 and 
MDA-MB231cells (Figures 14 and 24).  To determine whether a change in the phases of the 
cell cycle resulted in a change in proliferation of cells, the doubling time of MCF-7 and 
MDA-MB231 cells was determined in the presence or absence of E2. Based on preliminary 
data, increased proliferation and a decreased doubling time was expected in MCF-7 cells in 
the presence of E2. MCF-7 and MDA-MB231 cells, which had been kept in E2-free media, 
were divided in to two groups:  one to receive E2 and the other group that would remain clear 
of E2 throughout the experiment. Additionally, a group of cells were cultured in complete 
alpha medium as a positive control.  MDA-MB231 cells are generally rapidly proliferating 
when cultured in alpha medium, however these cells are ER-negative and therefore were not 
expected to show a difference in the presence or absence of E2.  All cells were plated with 
the same numbers and under the same conditions in 6 well plates.  Cells were harvested and 
counted and the media was changed on the remaining wells every other day for 10 days. 
Table 6 shows the doubling time of MCF-7 and MDA-MB231 cells under different 
conditions. Doubling time was calculated using the cell counts from the exponential growth 
phase using the following formula:    
Doubling time =[(0.301 Δt)] : [Log10 (N/N0)] 
 
 
 
 
 
 
 
    Table 6 – Analysis of the doubling time of MCF-7 and MDA-MB231 cells 
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As supplemental Figure 1 shows, both MDA-MB231 cells and MCF-7 cells had almost the 
same rates of proliferation despite the presence or absence of E2 (Table 6). These results 
were unexpected for MCF-7 cells, but could be explained by the possibility that liganded 
ERα can change the length of S and G2/M phases without changing the overall proliferation 
of the cell. However, we have also shown that the length of the cell cycle is significantly 
reduced in MCF-7 cells in the presence of E2.  By 10 days, the MCF-7 cells grown under E2-
positive conditions did start to show slightly higher growth rates than those in E2-negative 
conditions.  Therefore, it is likely that following the growth of the cells for a longer period of 
time would show more significant results.   
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Supplemental Figure 1: Comparison of the proliferation of MCF-7 cells and MDA-
MB231 cells under E2-positive and E2-negative conditions. 
A cell count was taken and graphed of MCF-7 and MDA-MB231 cells every other day for 10 
days in the presence or absence of E2.  
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MCF-7 cells can be synchronized using treatment with double thymidine block. 
        As an alternative method of cell synchronization and to confirm data using lovastatin 
and aphidicolin as arresting agents, MCF-7 cells were subjected to treatment with double 
thymidine. Treatment of cells with excess arrests the cells at the border of G1/S transtion as 
such treatment blocks DNA synthesis.   
        Supplemental Figure 2 shows that double thymidine block is a suitable method to 
synchronize the MCF-7 cells at the border of G1 and S.  Approximately 75% of the cells 
arrested at the G1/S border then quickly and synchronously exited G1 and entered into S and 
G2/M phases of the cell cycle after release in the 24:12:24 schedule compared to about 55% 
with the 36:18:36 schedule. Therefore the 24:12:24 double thymidine treatment schedule was 
chosen to study the changes in cell cycle profile due to the presence or absence of E2.   
Supplemental Figure 3 shows that almost 70% of cells were in G1 phase and 25% in S phase 
and 5% in G2/M upon release from double thymidine induced arrest.  However, FACS 
analysis showed unremarkable changes in the cell cycle profiles of the cells released under 
E2-positive versus the E2-negative conditions.  
        Thymidine arrests cells at the end of G1 phase and as soon as the cells were released 
from the thymidine arrest they pass quickly through S and G2/M phases.  It had been 
observed previously, when using aphidicolin as an arresting agent, that cells do not express 
ERα until the second cycle after release (Figure 16). Therefore, it is likely that if a longer 
time from release would be examined, the expected differences would be observed. By 16 
hours after the release, the second S phase begins and a difference between E2-negative 
versus E2-positive conditions was clearly observed, with cells under E2- positive conditions 
entering S and G2/M phases earlier than under E2-negative conditions (Supplemental Figure 
3). If double thymidine were to be chosen as an arresting agent, cells would need to be 
collected at time points for an additional 8-10 hours.  
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Supplemental Figure 2:  Double thymidine treatment synchronizes MCF-7 cells at G1 
phase. Two different schedules for thymidine treatment were used (24:12:24 or 36:18:36) to 
arrest MCF-7 cells at G1 phase.  Cells were harvest every 4 hours after release and subjected 
to flow cytometry.  The percentage of cells in each cell cycle phase is shown.  
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Supplemental Figure 3: Effects of estradiol on cell cycle phases do not occur until 
second cell cycle after arrest with double thymidine. 
MCF-7 cells were synchronized by double thymidine using the 24:12:24 treatment schedule. 
Cells were released under E2-positive or E2-negative conditions and cells were collected for 
FACS analysis and presented as the percentage of cells in each cell cycle phase. 
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RPPA can be used to screen proteins activated by the ERα pathway. 
        Reverse-Phase Protein Array (RPPA) analysis is an ideal method to examine the 
expression of a series of proteins in parallel. RPPA is a method to measure the protein 
expression levels (just like western blot) in a large number of biological samples using high 
quality antibodies 491. RPPA is also subject to accurate quantitaton as serial dilutions of the 
test lysates are printed on each slide alongside with known amounts of protein as controls. 
RPPA was performed in collaboration with Dr. Gordon Mills’ laboratory.  The expression 
pattern of a series of proteins (the list of all proteins examined is in supplemental Figure 4) 
during the cell cycle was examined in relation to cell cycle phase and ERα expression.  
Lovastatin synchronized MCF-7 cells, which had been divided in to two groups of E2-treated 
versus the E2-untreated were harvested and diluted in ppi (protease/phosphatase inhibitor- 
components listed under western blot analysis in chapter II) and sample buffer to the final 
concentration of 1µg/µl and subjected to RPPA analysis in the Mills’ laboratory.        
        The samples were immobilized (printed) on individual spots on as many microarray 
slides as there are antibodies. Then each slide was incubated with a single specific antibody 
to detect expression of the target protein on all the samples simultaneously. Detection was 
performed using a primary and a secondary labeled antibody. Chemiluminescence was used 
to detect the expression. The values resulting from intensity of antibody detection were 
plotted in graphs in (Figures 40 and supplemental Figure 4).  
        Using this analysis we found that three proteins (ERp118, MAPKp, and AKTp473) had 
a very different pattern of cell cycle expression depending on whether or not E2 was present 
(Figure 40). However there was no detectable change in the rest of the examined proteins 
between E2-positive (black) versus E2-negative (red) (Supplemental Figure 4).  
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Supplemental Figure 4: RPPA detects differential protein expression in key signaling 
proteins when ERα is liganded to E2 in MCF-7 cells.  RPPA analysis was performed on 
lovastatin synchronized MCF-7 cells in the presence and absence of E2.  (A) FACS analysis 
shows the percentage of cells in each cell cycle phase after release from arrest.  (B) Lysates 
from each time point were subjected to RPPA to detect the expression of an array of protein 
as marked on top left of each graph in the presence of E2 (black) and absence of E2 (red).  
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Chapter V: Concluding Remarks & Future Directions 
        The data presented in this dissertation clearly show that the ligand status of ERα plays a 
direct and very important role in ERα driven cell cycle effects.  The results are supported by 
using several different assays including FACS and western blot analyses and using multiple 
cell lines to verify that this is a general effect.  Therefore, the conclusions derived from this 
data can be used to further our understanding of cell proliferation in ER positive compared to 
ER negative tumors in the presence and absence of estrogen.  The following conclusions can 
be made: 
 
-   Endogenous ERα protein in ER-positive cells and exogenous ERα protein in 
otherwise ER-negative cells regulation, is cell cycle dependent. 
        -     ERα is regulated at the level of protein and not at the transcriptional level. 
        -     Cell cycle regulation of ERα is ligand independent. 
        -     Liganded ERα results in a fast progression through the cell cycle, specifically     
              through S and G2/M phases compared to unliganded ERα.  
       -     Overexpression of ERα either in MCF-7 (ER-positive) and MDA-MB231 cells   
              (ER-negative) cells caused a prolonged S and G2/M phase. 
      -      ERα shows cell cycle specific localization, with ERα residing in the cytoplasm at   
             the end of S phase and moving to the nucleus during G2 and early M phase. 
-   ERα is in a complex with cyclin B, Cdk1 and Cdc27 during late S, G2 and M    
-   phase. ERα gets ubiquitinated during S and G2/M phase in order to prepare for its  
degradation by the proteasome at G2/M phase. 
- Liganded ERα increases transcriptional activity at ERE of genes including pS2 and    
    PgR compared to unliganded ERα.  
These results support the rationale to treat ER-positive breast cancer patients with a drug that 
keeps the integrity of the ERα protein intact, while inhibiting the ligand binding to ERα.  
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Future Directions: 
 
Determine the role of phosphorylated ERα  at each phase of the cell cycle. 
        Future directions include understanding the role of phosphorylation in ERα regulation  
and whether phosphorylation of ERα is also cell cycle regulated. We will examine whether 
phosphorylation of ERα results in activation or repression of downstream events and whether 
phosphorylation depends on ligand.  The cyclin A-Cdk2 complex phosphorylates ERα on 
Serine 104/106, within ER Activation Function-1 domain (AF-1)  (22).   Cyclin A-Cdk2 
kinase activity occurs in the S phase of the cell cycle.   Our data showed that S and G2/M 
phases were the phases of the cell cycle, which were either shortened or elongated by ER in 
the presence or absence of the ligand, respectively (Figures 14 and 16). Results from RPPA 
analysis show that ERα that is phosphoryated at amino acid 118 changes in a cell cycle 
dependent manner, therefore we will expand our focus beyond only cyclin A/Cdk2 as a ERα 
kinase.  
 
Determine the interaction of ERα  with the cytoplasmic pathway(s) 
        The experiments described throughout this dissertation elucidate the effects of liganded 
versus unliganded ERα on the cell cycle phases.  Initial examination of the proteins involved 
in the pathways that lead to the cell cycle effects was also performed.  For example, ERα co-
localized with cyclin B. However, a mechanism for translocation of ERα and cyclin B was 
not explored.   Furthermore, when ERα is cytoplasmic, it could interact with factors of many 
cytoplasmic pathways, which could ultimately control the proliferation of cells. To this end, a 
thorough examination of the ERα interactions with both cytoplasmic and nuclear proteins 
throughout the cell cycle phases should be performed. Mass spectrometry, which is a 
powerful technique to determine the amino acid sequences of proteins, which can also reveal 
the structure of the protein, would be a suitable method to pursue this goal. For these 
experiments, cells will be synchronized in order to enrich cells in different phases. 
Immunoprecipitation will be performed using anti-ERα and anti phosphorylated-ERα 
antibodies. A 2-D gel of the immunoprecipiates will be silver stained and subjected to Mass-
spectometry. Our expected results would be the identification of binding partners for 
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liganded versus unliganded ERα during cell cycle phases of the cell cycle that would 
associate liganded with unliganded ER to the observed biologic effects in these phases of the 
cell cycle mediated by ERα. Examination of the phosphorylation state of ERα would provide 
information on whether a kinase is upstream of ERα. For this purpose, we will perform the 
immunoprecipitation assay using antibodies against other known kinases of ERα such as 
extracellular signal-regulated kinases1/2 (24), p38 mitogen-activated protein kinase (MAPK), 
172, 183, Cdk7 (26), c-Src 168, 534, protein kinase A 405, pp90-rsk1 184, or AKT 226 to reveal 
whether these kinases are also involved in phosphorylation of ERα in S and G2/M phase or 
in the other phases of the cell cycle.  Preliminary data also suggested that Cdk1 is a binding 
partner for ERα.  If we reveal the phosphorylation of ERα by any of these kinases, 
subsequently we will examine the function of the phosphorylated form in the cell cycle. For 
these set of experiments first we will examine the pattern of phosphorylated ERα during cell 
cycle phases.  
 
Pursue in depth analysis and examination of the differential nocodazole arrest 
mechanisms in ER-positive cells compared to ER-negative cells. 
        As Figure 39 shows, ER-positive cells were unable to exit G2/M upon arrest with 
nocodazole while ER-negative cells would release from G2/M and enter the G1 phase of the 
next cell cycle.   This was a consistent observation and therefore nocodazole was not used as 
an agent in to verify the results shown by using lovastatin; instead, aphidicolin, was used as a 
confirming agent (Figure 16). However, the mechanisms for the differential ability of ER-
positive and ER-negative cells to exit from nocodazole arrest could provide more information 
about the role of ERα in cell cycle regulation.  One reason that ER-positive cells did not 
overcome arrest could be activity of p53. Most of the ER-positive cells have a functional p53 
while the ER-negative cells do not 535. Deregulation of ERα and/or p53 increases the risk of 
developing mammary preneoplasia 536. For example, increased ERα expression coupled with 
p53 heterozygosity is associated with increased levels of phosphorylated AKT and decreased 
p27 expression.  
        Aberrations in ERα and p53 also result in a relative increase in Src phosphorylation, 
leading to cell proliferation 537.  Src and ERα levels were shown to be inversely correlated in 
primary breast cancers, leading Chu et al. to observation that c-Src phosphorylation 
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stimulates ERα ubiquitynation and proteasome-dependent degradation 534. Suppression of 
Src-induced migration and invasion is one possible pathway that p53 utilizes to inhibit tumor 
progression and metastasis 538. Studies have also shown that p53 can directly regulate ERα 
expression and transcriptional activity 539.  
        All of these studies suggest an association between ERα and p53 and could help to 
explain the discrepancy observed in the release, and lack thereof, of ER-negative and ER-
positive cells from nocodazole arrest, respectively.  Based on the findings by Shirley et al. 
that p53 regulates ERα transcription 540, it is speculated that accumulation of ERα at G2/M 
phase due to nocodazole arrest up regulates p53.   This feedback mechanism between ERα 
and p53 and the potential contribution to inhibition of cell cycle progression could be the 
reason that ERα status is a strong prognostic factor in breast cancer. Hormone-receptor status 
is also a predictor of response to endocrine therapy in breast cancer.  The data presented in 
this dissertation suggest that ERα expression leads to a favorable outcome in breast cancer 
both because it provides a target for endocrine therapy and also because the presence of 
unliganded ERα showing and inhibitory effect on the cell cycle progression. 
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